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ABSTRACT
Ebola viruses cause sever disease in humans and non-human primates. The resulting dis-
ease, Ebola virus disease (EVD), can have hemorrhagic manifestations and has mortality
rates ranging from 20-90%. There is a strong need for better understanding of the disease
as well as improved diagnostics and prognostics. One approach to improving diagnostic
and prognostics for severe viral diseases such as EVD is to define how the host response
to infection develops and produces indicators of disease and outcome.
To create a better means to understand if a patient is likely to survive or succumb to
Ebola (EBOV) infection, I have sought to develop an understanding of the host response
to EBOV infection in humans from the recent outbreak. I analyzed RNA-Seq samples
from the 2013-2016 West Africa outbreak. I identified that the innate immune pathways
are in general over activated in EVD and is stronger in patients who succumbed to dis-
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ease. Furthermore, I developed a set of 10 genes that can perform as a prognostic indicator
of disease independent of the viral load. This is the first demonstration that the circulat-
ing transcriptional immune response to EBOV infection can be used to predict infection
outcome.
To work towards a diagnostic platform of disease, I analyzed multiple studies of time-
resolved datasets in animal models of disease. I analyzed RNA-Seq and NanoString data
coupled with telemetry data in EBOV-challenged macaques. The earliest and strongest
changes seen in the pre-symptomatic stage of disease is the up-regulation of many innate
immune genes. I used this information to develop a NanoString codeset that can act as a
pre-symptomatic indicator of disease that was tested in further animal studies as a diag-
nostic in pre-symptomatic stages of disease.
Together, this work has identified a sets of genes that can work as a diagnostic for
pre-symptomatic patients of EBOV and act as a prognostic indicators of disease. In future
outbreaks, this type of information will be important to help track primary contacts of
infected individuals and first responders, as well as better inform clinical management of
patients. This lays the groundwork for similar analysis to be performed on other severe
viral diseases such as Lassa Fever and Marburg Fever.
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1Chapter 1
INTRODUCTION
1.1 Ebolavirus and Ebola Virus Disease
Ebola virus is a member of the Filoviridae family of negative-sense single-stranded
RNA viruses. Ebola viruses are the causative agents of Ebola Virus Disease (EVD) which
is a serious illness that can cause up to 90% case fatalities in humans and non-human pri-
mates (NHPs) (Feldmann and Geisbert (2011)). Currently, there are no licensed vaccines
or treatments for EVD. There are five species of the genus Ebolavirus: Zaire (EBOV),
Sudan (SUDV), Bundibugyo (BDBV), Tai Forest (TAFV), and Reston (RESTV). Four of
the five Ebolavirus species are known to cause disease in humans (EBOV, SUDV, BDBV,
and TAFV) with three of them linked to sporadic outbreaks in Central and Western Africa
(EBOV, SUDV, and BDBV) (Laupland and Valiquette (2014)). The recent outbreak in
West Africa in 2013-2016, the largest outbreak to date, was caused by the Makona variant
of EBOV. This outbreak resulted in 28,600 cases and 11,000 deaths (Center for Disease
Control (CDC), 2017) emphasizing the need to better understand EBOV pathogenesis.
Ebolavirus infection can be initiated by virus entry into the body through mucosal
sites or by direct contact (through open wounds). Once inside the body, the primary target
cells for Ebolavirus are thought to be dendritic cells and macrophages which become ac-
tively infected (Geisbert et al., 2003; Lu¨dtke et al., 2017). These infected cells then carry
2the virus to the primary organs of viral replication, which include the liver, spleen, and
lymph nodes (Feldmann and Geisbert, 2011). Here, the virus undergoes significant repli-
cation and expansion. During this expansion an infected individual will begin to present
with early disease symptoms.
Symptoms of EVD usually start with a prodrome period of general malaise and fever.
This can initiate 2-21 days after initial exposure to the virus. As the disease progresses,
additional symptoms such as nausea and vomiting, loss of appetite, and severe diarrhea
leading to dehydration develop (Laupland and Valiquette, 2014). People infected with
Ebolavirus can progress to a hemorrhagic fever, eventually presenting with disseminated
intravascular coagulation (DIC), multi-system organ failure, and death. The presentation
of DIC is often coupled with increased liver enzymes such as alanine aminotransferase
(ALT) and aspartate aminotransferase (AST), signifying poor liver health and are associ-
ated with poor disease outcome (Vernet et al., 2017).
EVD pathogenesis is linked to the over-activation of innate inflammatory signaling
and the absence of dendritic cell activation. The mechanism in which this excessively
exuberant response is triggered is unknown. Macrophages, but not dendritic cells (Bo-
sio et al., 2003), are activated upon infection with Ebolavirus and human macrophages
have been shown to produce many innate immune signals such as interferons (Bray and
Geisbert, 2005). The lack of dendritic cell activation may hinder the ability of the host
to mount a productive adaptive immune response. Lack of dendritic cell activation cou-
pled with an increase in checkpoint markers such as cytotoxic T-lymphocyte-associated
3protein 4 (CTLA-4) and programed cell death protein 1 (PD-1) (Ruibal et al., 2016) on
the surface of T-cells during infection are thought to be contributing factors associated
with lymphocyte death during infection. Lymphocyte death has also been noted in both
mouse (Bradfute et al., 2007) and non-human primate (NHP) (Reed et al., 2004) models
of infection.
Significant focus has been put on understanding the innate immune response to EVD.
The innate immune response to EVD contains two main areas of study: the antagonism of
the interferon response and the cytokine response. Many pro-inflammatory cytokines have
been shown to be associated with EVD. IL-10 and IL-8 levels have been shown to increase
in human fatal infections of SUDV (McElroy et al., 2014a) and EBOV (Baize et al., 2002).
IL-6 (another pro-inflammatory cytokine) has conflicting reports as one study found it to
be high in EBOV survivors (Baize et al., 2002) and another study found IL-6 to be higher
in fatal EBOV cases (McElroy et al., 2014a). A characteristic feature of EVD in humans
is a drastic increase in inflammatory cytokines that occurs during the symptomatic phase
of infection. This has been observed in many NHP models of infection (Bixler and Goff,
2015; Wauquier et al., 2010) and has been suggested to be similar to the response seen in
patients experiencing sepsis and severe viral diseases such as Marburg Fever (Rougeron
et al., 2015) or severe influenza infections (Liu et al., 2016).
Another aspect of the innate immune response that is of focus with regards to
Ebolavirus infections is the antagonism of the type I interferon (IFN) response. IFN antag-
onism is achieved through the inhibition of intracellular recognition of pathogen associated
4molecular patterns (PAMPs) by the Ebolavirus protein viral protein 35 (VP35) (Edwards
et al., 2016; Basler et al., 2000). However, recent findings suggest that VP35 inhibition of
PAMPS may be cell type specific (Leung et al., 2011). Another Ebolavirus protein, viral
protein 24 (VP24), has also been implicated in antagonizing the IFN response. Interferon
antagonism by VP24 occurs by inhibiting phosphorylation of signal transducer and acti-
vator of transcription 1 and 2 (STAT1/2) into pSTAT1/2 and thus preventing its nuclear
translocation (Reid et al., 2007). The antagonist actions of the virus against the interferon
response is thought to contribute to pathogenesis.
Many aspects of virus-host interaction can lead to different responses in infected cells
and therefore lead to the initiation of different extracellular signaling events. How innate
(IFN and cytokine) responses are influenced by virus infection is a challenging question
to answer using a few selected genes of interest. Therefore, multiplexed technologies such
as transcriptomics are attractive way to interrogate the host response to EBOV infection.
Over the past decade, this approach has been used with increasing sophistication to study
how EBOV infection alters the host transcriptome at the cellular and organismal level. In
this chapter I cover what has been done previousally to study EVD using transcriptomic
approaches.
1.2 Transcriptional Response to Ebola Virus Disease in vitro
Understanding the impact of EBOV infection on the host transcriptional response
can be carried out with multiple approaches. The most direct is the use of immortalized
cells or purified populations of primary cells that are infected in vitro. Infection of these
5cells can be done under tightly controlled conditions and the virus titer can be accurately
determined.
1.2.1 Studying the Transcriptional Response in immortalized cell lines
The use of immortalized cell lines to study the host response to EBOV infections
provides ease of access to cells and allows for large number of replicates to be analyzed
with minimal increase to cost. The transcriptional response to EBOV infection has often
been studied in immortalized human liver carcinoma cell lines (HepG2 and Huh7 cells).
The liver is an initial organ of EBOV replication. Thus, the liver likely plays an important
role in EBOV pathogenesis making the host liver response a key question in understanding
viral dysregulation of host signaling (Martines et al., 2015). Following initial studies in
liver cells, other studies have examined the host transcriptional response in cell lines that
are representative of other sites of EBOV infection such as kidney, lung, and immortalized
monocytes.
The earliest transcriptomic studies supported an existing hypothesis of the EBOV-
host interaction, namely that EBOV is a strong suppressor of the innate immune responses
(Basler et al., 2000, 2003; Ca´rdenas et al., 2006). Infections performed in Huh7 cells (Kash
et al., 2006) showed that EBOV infection resulted in only small changes in host gene ex-
pression compared to controls. Importantly, this study analyzed infection of an additional
related ebolavirus, RESTV, that has yet to be associated with severe disease in humans. In
RESTV infected cells, the authors observed an induction of host antiviral genes such as in-
terferon stimulated genes (ISGs) and inflammatory cytokines. These results are consistent
6with the conclusion that EBOV dominantly suppresses host signaling through the action of
antiviral proteins VP35 and VP24, while non-pathogenic viruses fail to suppress these an-
tiviral responses. This negative correlation of pathogenicity versus induction of ISGs has
also been observed in other viral infections, particularly influenza (Morrison et al., 2014;
Geiss et al., 2002).
The lack of a strong innate immune response following EBOV infection was also
seen following infection of HepG2 cells. Transcriptional profiles of cells infected with
EBOV show little induction of an innate immune responses (Holzer et al., 2016; Kuzmin
et al., 2017; Hartman et al., 2008). Importantly, this lack of induction of innate immune
response appears to be through active suppression of antiviral signaling in these cells by
EBOV. This can be demonstrated by adding a mutation in the VP35 protein in EBOV
that inhibits VP35s ability to suppresses interferon responsive factor 3 (IRF3) signaling
(Hartman et al., 2006). Cells infected with only the VP35 mutant EBOV were no longer
transcriptionally silent and upregulated both ISGs and cytokines compared to cells infected
with wild type EBOV. This suggests that EBOV infection would normally trigger a robust
innate immune response in liver cells, but that the deployment of viral proteins such as
VP35 suppressed these host responses.
The suppression of innate immune signaling following EBOV infection is outlined in
Figure 1.1 and is a common feature in immortalized cells. Analysis of the transcriptional
response of THP-1 monocytes (Edwards et al., 2016), immortalized lung cells (A549)
(Bosworth et al., 2017), and immortalized kidney cells (293T) (Kuzmin et al., 2017) fol-
7lowing EBOV infection, all found transcriptionally silent ISGs and showed very little evi-
dence of an innate immune response. Infection in the lung and kidney are secondary sites
and EBOV infection which should be considered when interpreting their results. It was
also shown again that this inhibition is likely from a strong contribution of VP35 with
little involvement of VP24 (Edwards et al., 2016) . The suppression of innate immune
responses is found across different variants of EBOV, including the Ecran (Mayinga) vari-
ant isolated in 1976 during the first EBOV outbreak to the recent Makona variant which
was the causative agent of the West Africa outbreak (Bosworth et al., 2017). Interestingly,
this inhibition of the IFN response is not universal across all cell types. When a different
kidney cell line (769p) was infected with EBOV, there was variable inhibition of the IFN
response and induction of some ISGs (Kuzmin et al., 2017). Similarly, when determining
if retinal pigment epithelial cells, a possible location for viral persistence after recovery,
could sustain EBOV infection using ARPE-19 cells, a large induction of the IFN response
was evident (Smith et al., 2017). This suggests that the ability of the virus to inhibit the
interferon response likely displays cell type specific activity.
Another finding that has been validated across multiple transcriptomic analyses is
the decrease in the transcription of genes associated with coagulation and acute phase re-
sponse in cell line infections with EBOV (Bosworth et al., 2017; Holzer et al., 2016; Kash
et al., 2006). This observation is opposite to the response seen in vivo. In vivo, EBOV
is known to cause coagulation dysfunction leading to symptoms of DIC. Many pathways
associated with the acute phase response are activated following EBOV infection in vivo
8Figure 1.1: Suppression of the transcriptional response to EBOV infection in immor-
talized cell lines. Illustration depicts the currently understood mechanism of virus-host an-
tagonism following EBOV entry into the cell. Upon viral uncoating, the virus releases two
important viral proteins, VP35 and VP24 (represented in red). VP35 is capable of blocking
activation of and signaling through the RIG-I pattern receptor, maintaining IKKE/TBK1
in an inactive state (host proteins are illustrated in green, with activating phosphorylation
events depicted in yellow). This prevents the phosphorylation and activation of IRF3 and
thereby the transcription of IFN beta and IRF3-responsive ISGs. VP24 acts downstream
of STAT protein phosphorylation by JAK to inhibit the translocation of STATs to the nu-
cleus, thereby inhibiting interferon signaling. Mutations in VP35 or VP24 compromise
the host antagonism of each protein and result in the activation of ISG transcription fol-
lowing EBOV infection. Depicted in blue is the inhibition of coagulation genes that is
seen following EBOV infection. Question marks signify that the mechanism by which this
suppression occurs is unknown.
9(Geisbert et al., 2003; McElroy et al., 2014a). This is accompanied by a large increase
in coagulation-associated mRNAs (Geisbert et al., 2003). While some cell lines show de-
crease in coagulation and acute phase response genes this is not uniformly observed across
all cell lines and EBOV variants. Infection of A549 cells with EBOV variant Makona in-
creased the acute phase response when compared to uninfected controls (Bosworth et al.,
2017). Further investigation of the transcriptional response to host protein production
would further help understand these differences and their relation to EVD.
1.2.2 Transcriptional analysis of a potential reservoir
Bats are a hypothesized reservoir for EBOV, based both on serosurveillance stud-
ies that identified anti-EBOV antibodies in adult bats (Hayman et al., 2012) and on the
isolation of a closely related virus, Marburg virus (MARV), from bats (Towner et al.,
2009). However, to date no infectious EBOV has been isolated from bats. To investigate
if bats have a different transcriptional response to EBOV infections, two studies carried
out RNA-Sequencing (RNA-Seq) analysis on immortalized bat cell lines (Holzer et al.,
2016; Kuzmin et al., 2017). Upon infection with wild-type EBOV (wtEBOV), there was
some evidence of an interferon response in one study (Holzer et al., 2016) whereas there
was no detectable interferon response in the other (Kuzmin et al., 2017). Infection of dif-
ferent immortalized bat cell lines with only VP35 mutant EBOVs which cannot block the
interferon response, found an increase in the expression of many ISGs. It was also found
that wtEBOV triggered a large down-regulation of many genes that was reversed when bat
cells were infected with only the mutant EBOV with a VP24 that was unable to inhibit the
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IFN response (Kuzmin et al., 2017). Together these studies show that the ability of EBOV
to inhibit the innate immune response is not specific to human immortalized cells.
1.2.3 Studying the Transcriptoinal Response in primary cells
The transcriptional response following EBOV-infection has also been studied in pri-
mary cells. Studies with primary cells are somewhat limited, as the isolation of primary
cells from primary tissue targets such as the spleen and liver is challenging. This has led
to a focus on cells that can be present in the circulating immune system, and on dendritic
cells and macrophages, which are thought to be the initial targets of productive EBOV
infection (Bray and Geisbert, 2005) and have been shown to have variable activation upon
infection with EBOV (Leung et al., 2011; Bosio et al., 2003). To investigate the activation
status of human dendritic cells, one study analyzed the global response of EBOV infec-
tion in human monocyte derived dendritic cells (mdDC) (Figure 1.2) (Ilinykh et al., 2015).
Consistent with what was observed in immortalized cell lines (Kash et al., 2006; Hartman
et al., 2008), EBOV infection of mdDCs did not induce the transcription of innate immune
response genes. This lack of an innate immune response again appears to be due to a
suppression of antiviral signaling pathways by viral proteins, mostly through the effects
of VP35 with minimal involvement by VP24. The same was seen with cytokine expres-
sion. This suggests that EBOV infection would induce the maturation and expression of
cytokines and ISGs in human dendritic cells if it were not for the suppressive actions of
VP35 and VP24. More work looking at the host response in other types of dendritic cells
(DCs) such as primary DCs, tissue specific DCs, and immature DCs would help determine
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if this response is mirrored in DCs or is primarily observed in mdDCs. Also, further work
is needed to determine the effects of these suppressed DCs on bystander cells.
In contrast, primary macrophages show a robust host response following EBOV
infection (Figure 1.2). Studies of early events in macrophage responses to EBOV
showed that attachment of EBOV or EBOV virus-like particles (EBOV-VLPs) to pri-
mary macrophages induced changes in gene expression as early as one hour post-infection
(Wahl-Jensen et al., 2005). Gene expression changes persisted through to 6 hours post-
infection. These changes in expression were generally associated with the inflammatory
response. In monocyte derived macrophages (MDMs), EBOV infection in vitro followed
over a longer timeframe resulted in dramatic changes in viral gene expression (Olejnik
et al., 2017). EBOV infection was followed by large changes in expression of genes asso-
ciated with IFN signaling, interferon stimulated genes, cytokines, and antigen presentation
(Olejnik et al., 2017). These data support the hypothesis that macrophages, unlike den-
dritic cells, are activated following EBOV infection. Of note, RESTV infection did not
induce changes in gene expression in MDMs (Olejnik et al., 2017). This is the opposite of
what was observed in immortalized liver cells suggesting a complex interplay of different
viruses with immune response induction and raising the question of how different host
responses in different infected cells contribute to the overall host response seen in vivo.
1.3 Transcriptional Response to Ebola Virus Disease in vivo
Studying the transcriptional response to Ebolavirus in vivo provides an opportunity
to better understand how the multitude of cell types and organ systems are interacting and
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Figure 1.2: Virus-host antagonism following EBOV infection of macrophages or
dendritic cells. Left panel illustrates the response to EBOV entry and attachment in
macrophages. Upon attachment, activation of TLR-4 and NF-κB by the entry process lead
to the induction of inflammatory transcripts. IRF3/IFN-induced genes are also induced in
macrophage-infected cells, suggesting that the function of VP24 and VP35 as viral antag-
onists of these signaling pathways is compromised or that other signaling pathways are
activated. Right hand panel illustrates the interaction of EBOV and the host-response in
dendritic cells. Similar to what is seen in many immortalized cell lines, VP35 will act as a
strong inhibitor of IRF-3 phosphorylation blocking interferon and ISG transcription. Also,
VP24 will act as an inhibitor of translocation of pSTAT1/2 to the nucleus further blocking
interferon transcription.
responding to the virus as a whole. The main animal models that are used for studying the
transcriptional host response to EBOV to date have been rodents and non-human primates
(NHPs).
1.3.1 Rodent Models and transcriptoinal response
Mice have been used to study EVD pathogenesis for more than two decades. Be-
cause standard inbred mouse strains are not susceptible to Ebolavirus infection (Bray et al.,
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1998), three distinct virus or host modification approaches have been used to facilitate this
work, each of which has its own advantages and limitations. EBOV that has been serially
passaged such that it has mutated in a manner that it is pathogenic in mice (mouse-adapted
EBOV (MA-EBOV)) has been used to study infection in inbred mice with an intact im-
mune response (Bray et al., 1998). Studies of non-adapted virus can be carried out in mice
deficient for innate immune responses (Dutta et al., 2017; Brannan et al., 2015). A more
recently adopted approach uses mice with a transplanted human immune system, which
allows the use of an immunocompetent system and a non-adapted EBOV (Lu¨dtke et al.,
2015; Bird et al., 2016). Of these approaches, the MA-EBOV model has been used most
extensively to study the host response to EBOV infection. The pathogenesis of the MA-
EBOV model does not recapitulate some clinical signs seen in human disease as there are
no signs of overt hemorrhage or coagulopathy through the mice do experience excessive
weight loss, elevated temperature, and loss of appetite (Nakayama and Saijo, 2013). The
later clinical signs are general to pathogenic infections in mice that are susceptible to in-
fection. Yet, the ability to easily alter the genetics of mice makes them an attractive model
to study the mechanisms of disease.
Infection of mice with both pathogenic and non-pathogenic EBOV has indicated that
there are strong transcriptional responses to EBOV infection in tissues and blood. Studies
of the transcriptional response in the spleen of EBOV infected mice have most effectively
demonstrated that there are two distinct responses to infection based on pathogenicity. One
study compared five different virus infections: EBOV-MA and EBOV-NPma/VP24ma,
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which are pathogenic in mice to wtEBOV, EBOV-NPma, or EBOV-VP24ma which are
non-pathogenic in mice (Ebihara et al., 2006). Following either pathogenic or non-
pathogenic challenge, all mice showed an up-regulation of transcripts involved in the in-
nate immune response and inflammation by 72 hours post-infection, including a strong up-
regulation of ISGs (Caballero et al., 2016). Following this conserved host response to all
forms of EBOV challenge, there were stark differences observed as infection progressed.
In animals that succumbed to infection, there were a greater number of differentially reg-
ulated genes seen at the 72 hour time-point compared to animals that survived challenge
(Figure 1.3) (Ebihara et al., 2006). Upregulated genes were mostly associated with leuko-
cyte infiltration and degranulation suggesting an increase in neutrophils late in infection.
This is a logical finding, as neutrophilia has been previously described in humans (Sanchez
et al., 2004) and macaque models of infection at the late stages of disease (Fisher-Hoch
et al., 1983).
Similar results have been seen in experiments using genetically diverse strains of
mice derived from the collaborative cross (CC) (Rasmussen et al., 2014; Churchill et al.,
2004). Through infection of CC mice with MA-EBOV using this genetically diverse back-
ground, susceptible verses non susceptible mouse strains could be identified. Gene ex-
pression changes analyzed in the spleen found similar results to those described above
(Cilloniz et al., 2011; Panchal et al., 2009) where susceptible mice saw a large number of
differentially expressed genes at late stages of infection and non-susceptible mice had a
very low level of differentially expressed genes at this time. In the livers of these mice,
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Figure 1.3: The host transcriptional response to EBOV infection in mouse liver and
spleen. In the liver, all mice challenged with EBOV show transcriptional changes. An-
imals that succumb experience a peak timepoint of transcriptional activity at 48 hours
post-infection (HPI.). Genes are enriched for transcripts associated with loss of vascular
permeability. Surviving mice do not experience a peak of transcriptional activity until 72
HPI. and do not induce genes associated with the breakdown of the vascular layers. In the
spleen (right), all animals challenged with EBOV mount a transcriptional response to in-
fection. In animals that will succumb to disease, peak transcriptional activity is observed at
72 HPI. These transcripts are associated with a strong induction of ISGs, the inflammatory
response, and evidence of neutrophil infiltration. In animals that survive, there are lower
levels of transcriptional activity throughout infection. There is moderate up-regulation of
ISGs and a weak inflammatory response.
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both susceptible mice and non-susceptible mice experienced a large number of differen-
tially regulated genes (Figure 1.3). However, the timing of gene expression was offset,
with susceptible mice showing an earlier onset of differentially regulated genes. Func-
tional analysis of differentially expressed genes in animals that succumbed to MA-EBOV
challenge suggested that susceptibility was related to an increase in vascular permeability.
The existence of a robust antiviral host response centered on IFN is also supported
by experiments using wtEBOV infection in mice lacking an intact antiviral signaling
molecules (Bradfute et al., 2012; Dutta et al., 2017). Consistent with earlier studies (Cil-
loniz et al., 2011; Panchal et al., 2009; Rasmussen et al., 2014), these studies have found
that in spleens of wild-type mice, wtEBOV and MA-EBOV infection resulted in a marked
induction of genes associated with inflammation and the IFN response. When antiviral
signaling is impaired through the removal of the mitochondrial antiviral-signaling pro-
tein (MAVS), an important component of the IFN induction pathway, the IFN response
is blunted and there are very little transcriptional changes of IFN stimulated genes (Dutta
et al., 2017). Another key finding was the discovery natural killer (NK) cell transcriptional
signatures present in mice that survived infection. NK cells have been of interest because
of their association with survival to EBOV infections (Warfield et al., 2004; Cimini et al.,
2017) thus supporting the transcriptional signature.
Mouse models, such as humanized mice show promise to better parse out the dynam-
ics of the host response to infection, have not had transcriptional analysis performed as of
yet. Humanized mice display clinical signs that more closely relate to human disease (Bird
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et al., 2016; Lu¨dtke et al., 2015) and are useful for understanding mechanisms of disease
progression and pathogenesis (Lu¨dtke et al., 2017). This model could provide more insight
into detailed pathogenesis and host response during an EBOV infection transcriptionally.
1.3.2 Non-Human Primate models and transcriptional response
The most widely accepted animal model of EVD for study of countermeasures such
as vaccines and therapies is the non-human primate (NHP) model (Nakayama and Saijo,
2013). NHPs display almost all of the clinical signs of acute EVD, including DIC and
hemorrhage. Despite most NHP survivors needing experimental treatments to survive in-
fection, individuals who survive challenge or have an extended course of disease can show
neurologic or ophthalmologic complications (Larsen et al., 2007; Zeng et al., 2017) simi-
lar to human cases (Shantha et al., 2016; Billioux et al., 2016). Similar to studies in mice,
studies of EVD in NHPs allow the collection of samples multiple times over the course of
infection from each challenged subject, providing information on overall course of infec-
tion as well as variation between individuals. Currently, the host transcriptional response
to EVD has been studied in two NHP models, rhesus (Macaca mulatta) and cynomolgus
(Macaca fascicularis) monkeys, supported by the annotation of the rhesus and cynomol-
gus transcriptomes (Lee et al., 2014; Peng et al., 2015; Zimin et al., 2014). An advantage
of the NHP system is that the response of immune cells circulating in the blood following
EBOV exposure has been extensively characterized, allowing comparisons to human tran-
scriptome datasets which is not currently possible with other animal model comparisons
(see section 1.4). Because the response seen in both rhesus and cynomolgus NHPs is ex-
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tremely similar, I will discuss results from the two different models simultaneously. Also,
two main routes of infection have been used to study the host response to infection: intra-
muscular injection and aerosol exposure. Again, the differences in these two responses are
very similar and will be combined in the following description.
As a first-order approximation, the NHP circulating immune response to EBOV chal-
lenge can be separated into four separate transcriptional phases (Figure 1.4). Following
EBOV challenge, there is an initial “silent” phase where there is little to no reproducible
host response in immune cells circulating in the peripheral blood. It is likely that there is a
host response at the site of infection or at a point of initial trafficking, but these sites have
yet to be analyzed. Following this “silent phase” there is an early phase host response to
EVD infection. This early phase response can be detected prior to or at the time of other
markers of infection such as fever or viremia (Rubins et al., 2007; Caballero et al., 2016).
This early phase is in direct contrast to much of the datasets from cell lines and reviews
which suggested that there is a suppression or evasion of the host immune response by
EBOV. In a NHP model of infection, as early as 2-4 days post-infection (DPI), there is a
strong up-regulation of many type-I IFN stimulated genes (Rubins et al., 2007; Yen et al.,
2011; Caballero et al., 2016; Menicucci et al., 2017). This early innate immune response
occurs to a lesser extent or is not detected in animals that are asymptomatic for disease
indicating that IFN is a result of productive infection (Yen et al., 2011; Caballero et al.,
2016; Rubins et al., 2007). This IFN response in intramuscular infections peaks at around
4 DPI and is sustained to the end of disease (Caballero et al., 2016). This general and early
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IFN response is similar to what has been observed for many other viruses including human
influenza infections (Zaas et al., 2009; Woods et al., 2013), macaque influenza infections
(Kobasa et al., 2007), as well as Lassa virus (LASV) and MARV infections in macaques
(Caballero et al., 2014; Connor et al., 2015; Malhotra et al., 2013).
The early phase of infection is closely followed by the up-regulation of many cy-
tokine genes (Rubins et al., 2007; Caballero et al., 2016) . These cytokines (e.g. CCL8,
FAS, and IL-6) begin to see significant expression in fatal cases starting at 4-5 days post-
infection and are sustained through the end of infection. In animals that do not succumb
to infection, cytokine expression in peripheral blood mononuclear cells (PBMCs) is dras-
tically lower than what is observed in animals that succumb to disease (Yen et al., 2011;
Caballero et al., 2016). This is consistent with EBOV infections leading to an overac-
tivation of proinflammatory cytokines which contributes to disease pathogenesis (Bixler
and Goff, 2015). This up-regulation of many cytokines is concurrent with nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) and tumor necrosis factor alpha
(TNF-α) activation determined through network analysis of the cytokine response (Rubins
et al., 2007).
The later stage of infection (5-11 days post-infection) is characterized by extreme
changes in gene expression in NHPs exposed to EBOV. Around 2000-3000 genes are usu-
ally found to be differentially regulated during the late stage of disease, depending on
fold-change cutoffs used (Menicucci et al., 2017; Rubins et al., 2007; Garamszegi et al.,
2014; Yen et al., 2011). Gene ontology classification of genes showing altered regulation
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Figure 1.4: The host transcriptional response to EBOV challenge in NHPs. Illus-
tration shows three distinct stages of transcriptional activation seen in peripheral blood
mononuclear cells (PBMCs) following EBOV infection of NHPs. The top half (above the
grey line) shows the likely viral progression of EBOV from infection of initial target cells
(Green phase) to replication in the spleen and liver (Blue phase) and finally dissemination
into secondary organs (red phase). The bottom panels illustrate the transcriptional activity
of different gene families during this progression. The earliest phase of transcriptional ac-
tivity (0-2 days post-infection (DPI)), green box, is the silent phase where very little if any
transcriptional activity is present in the PBMCs. During the phase, the virus has initiated
infection in primary cell targets. As the virus moves to its primary organs of infection, a
robust early phase of transcriptional activity is observed (2-4 DPI). Most notable in this
phase is the increase in ISGs. This ISG induction is closely followed by the induction of
cytokine genes. Finally, as the virus begins to disseminate through the whole body through
the blood (viremia) and begins to infect secondary organ targets the transcriptional activ-
ity enters the late phase characterized by the induction of many pro-inflammatory genes,
pro-apoptotic markers, and neutrophil markers in PBMCs.
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at late stages of disease found many are associated with apoptosis (Rubins et al., 2007) and
immune dysfunction through increases in inflammatory pathways and decreases in T-cell
activation pathways (Rubins et al., 2007; Yen et al., 2011; Menicucci et al., 2017). There is
evidence of neutrophil marker genes appearing in PBMCs during the late time of disease
(Caballero et al., 2016; Garamszegi et al., 2014) which may suggest immature neutrophils
being present in high quantities in the blood since neutrophils are not regularly found in
PBMCs. In animals that are either asymptomatic for disease or survive disease due to
vaccination or experimental therapeutic treatments, this over-activation and suppression of
many transcripts is seen to a much lesser extent. Activation of T and B cell function genes
is observed coupled with markers for natural killer cells (Yen et al., 2011). In surviving
animals, the end stage of disease is also associated with an increase in IFN gamma signal-
ing (Yen et al., 2011). IFN gamma has been suggested to play an important role in viral
clearance and suggests a mechanism for reducing viral loads (Rhein et al., 2015; Gupta
et al., 2005).
Further work in NHPs has been done to fully understand the mechanism of the rVSV-
EBOV vaccine (Jones et al., 2005; Geisbert and Feldmann, 2011; Marzi et al., 2011).
This vaccine platform utilizes a recombinant form of the vesicular stomatitis virus (VSV)
that expresses the EBOV-GP on the surface (rVSV/ZEBOV-GP) (Geisbert and Feldmann,
2011) and showed approximately 100% effective in humans (Henao-Restrepo et al., 2017).
Transcriptomic analysis was performed on macaques with samples taken before adminis-
tration of the vaccine, after the vaccine was given, and throughout challenge with EBOV to
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determine transcriptionally what important components of the immune response contribute
to protection (Barrenas et al., 2015; Menicucci et al., 2017). Following exposure to the vac-
cine, around 100 transcripts are found to be differentially regulated. These transcripts are
mostly associated with toll-like receptor (TLR) signaling and some innate immune genes
(Barrenas et al., 2015). After challenge with EBOV, these animals experience low levels of
circulating virus that is quickly cleared. These challenged animals experience an increase
in some innate immune genes including many IFN simulated genes (Menicucci et al.,
2017; Barrenas et al., 2015) suggesting that despite being protected, these animals still had
a modest immune response to challenge. Importantly, animals that were not vaccinated
against EBOV saw a continued increase in expression of many innate immune gene.
There are fewer transcriptomic analyses of tissues response to EBOV in NHPs com-
pared to the mouse model. Albeit one study suggests that infected tissues have a robust
host response to EBOV infection. The host transcriptional response in tissues is similar
to the transcriptional response identified in PBMCs with early expression appearing in the
spleen, liver, and pancreas, concurrent expression in the adrenal gland, and delayed ex-
pression in the lymph nodes. Expression in the brain was barely detectable and was only
observed in late stages of disease (Caballero et al., 2016). Additional sequencing sets in
tissues would help to further understand the host transcriptional response in tissues and
how it relates to the peripheral blood response.
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1.4 Transcriptional response to Ebola Virus Disease in Humans in vivo
The analysis of the host transcriptional response to EBOV infection in NHPs has
served as an important bridge for comparing and understanding the host transcriptional
response of humans infected with EBOV in the 2013-2016 West African outbreak. Two
recent studies have analyzed the global transcriptional response in peripheral blood of
infected patients in Guinea (Liu et al., 2017) and a longitudinal study of the response over
time in a single patient treated at the National Institutes of Health (NIH) clinical center
(Kash et al., 2017).
The first of these two studies involved a patient cohort from Guinea during the out-
break that were taken at the European Mobile Lab (EMLab) (Liu et al., 2017). The details
of the study are further characterized in Chapter 2. The focus of this study was to an-
alyze transcriptional differences observed in surviving patients as compared to fatalities.
This analysis showed that patients that succumbed to EBOV infection have a stronger ac-
cumulation of different pathogen response pathways than those that survived infection,
independent of the number of viral genome copies in the blood. These included innate
immune genes such as ISGs and cytokines and genes associated with the acute phase re-
sponse and liver-specific mRNAs. These changes are largely in alignment with what has
been seen in the blood of NHPs infected with EBOV. The strongest signals are those in-
volved in innate immune response and particularly type-I IFN response (Caballero et al.,
2016; Yen et al., 2011; Garamszegi et al., 2014). Also consistent with the NHP data are
the high levels of cytokine genes detected which were stronger in fatal cases than sur-
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vivors (Caballero et al., 2016) consistent with what has been seen at the protein level in
patients treated in the United States (US) (McElroy et al., 2016). Digital cell quantification
(DCQ) analysis of the human data, using the transcriptional response to predict changes
in cell populations, highlighted natural killer (NK) cell density increases correlating with
survival (Dutta et al., 2017), a finding that was is supported in mouse DCQ analysis of
EBOV infection (Dutta et al., 2017). NK cells have been shown to be increased in human
survivors through flow fluorescence-activated cell sorting (FACS) analysis (Cimini et al.,
2017). Importantly, there was no increase in neutrophil markers in humans infected with
EBOV in a sharp contrast with data obtained in NHPs.
The findings of this large patient cohort study are in general agreement with a second
study of a single patient treated at the NIH Clinical Center (Kash et al., 2017) whose
transcriptome was followed almost daily over the post-admission disease course. This
dataset showed that the infected individual had an early response to EBOV infection that
was dominated by high levels of innate immune genes including type-I ISGs and cytokines,
similar to NHP data and the other human study. This innate immune response began to
subside after a significant treatment course, correlating with decreasing viral load and
an increase in adaptive immune gene signatures. The increase in adaptive immune gene
subsets is in line with FACS analysis showing an increase in B-cell subtypes in patients
treated in the US following EBOV infection (Ellebedy et al., 2016). Interestingly, this
patient had neutrophil markers present in the circulating blood long after viral clearance.
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In addition to studies focusing on the mRNA coding transcriptome, there have also
been studies that have focused the non-coding transcripts present in blood following EBOV
infection. A study looking at patient samples from Sierra Leone identified microRNAs
(miRNAs) whose regulation is altered in relation to viral load and selected a set of miRNA
that have potential to be used as a biomarker for survival (Duy et al., 2016). Many of
the miRNAs found in human clinical samples also correlated with miRNAs discovered in
NHPs, consistent with the idea that these are part of a response to EBOV infection in both
humans and NHPs. This work bears future additional studies to identify these and other
potentially useful noncoding RNAs.
1.5 Comparison of Various Platforms
Across the various platforms used to study EVD, there are gene sets that show agree-
ment in their general pattern of regulation across many different models of EVD (Table
1.1). Most notably, in almost all the different models of studying EVD, there is a large
upregulation of many IFN stimulated genes. ISGs are upregulated in all models with the
exception of some types if immortalized cell lines (liver cells, A549s, 293T, and THP-1)
(Basler et al., 2003, 2000; Reid et al., 2007; Kash et al., 2006; Holzer et al., 2016; Kuzmin
et al., 2017; Hartman et al., 2008; Edwards et al., 2016; Bosworth et al., 2017) and mono-
cyte derived dendritic cells (Ilinykh et al., 2015). Especially notable is the fact that ISGs
are strongly upregulated in response to EBOV infection in all of the animal models (Ebi-
hara et al., 2006; Caballero et al., 2016; Cilloniz et al., 2011; Panchal et al., 2009). The
increase in ISGs is also seen in humans (Liu et al., 2017; Kash et al., 2017) where there
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Gene
Group
Immortalized
Cells Primary Cells Mouse NHP
Human
ISGs Suppressed inmost cell lines
Upregulated in
Macrophages
Upregulated
in spleens
Early Re-
sponse Upreg-
ulated
Upregulated
Pro-
inflammatory
Cytokines
Mostly sup-
pressed
Upregulated in
Macrophages Upregulated
Mid Response
Upregulated
Upregulated
Coagulation Suppressed N/A N/A N/A Upregulated
Neutrophil
associated
Transcripts
N/A N/A Upregulatedin spleens
Upregulated in
PBMCs
No Signifi-
cant Change
Acute Phase
Response Suppressed N/A N/A Upregulated
Upregulated
Natural
Killer Cell
Transcripts
N/A N/A
Upregulated
in Surviving
Animals
No Significant
Change
Upregulated
in Survivors
Table 1.1: Comparison of General Gene Transcription Across the Various Platforms
is an association with a larger amount of ISG expression and a worse outcome. This is
especially notable since IFN-beta (IFNβ) treatment has been suggested as a possible ther-
apeutic for EVD based on data from immortalized cells. When this approach was tested
in animals, it was found to provide no strong protection against disease in NHPs (Smith
et al., 2013) and a small trail in West Africa showed no significant benefit of treatment on
patient outcome (Konde et al., 2017).
The limited data in human infections has identified important differences between the
human transcriptional response and transcriptional response seen in animal models. One
large difference is that the transcriptome from EBOV-infected patients in Guinea were
found to have very high levels of acute phase genes circulating in the peripheral blood
(Liu et al., 2017). The NHP PBMC data does not show this same signature (Garamszegi
et al., 2014; Caballero et al., 2016). Furthermore, data from cell lines suggested a decrease
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in the acute phase response mRNAs associated with coagulation when cells were infected
with pre-2014 strains (Bosworth et al., 2017; Kash et al., 2006) but was induced with the
West Africa Makona variant (Bosworth et al., 2017).
Analysis of survival factors in animal models can possibly help inform treatments in
humans. Though most NHP survivors have either been vaccinated for the virus or received
therapeutics, and the mouse model requires adaptation of the virus to create mouse adapted
forms, many factors found in either of these models agree with what was found in humans.
Most notable is the association of natural killer cells and survival in both mice (Dutta et al.,
2017) and humans (Liu et al., 2017). Natural killer cells have been previously shown to
be associated with protection against EBOV infections (Warfield et al., 2004) as well as
IFN-gamma (IFN-γ) (Rhein et al., 2015) which is a by product of natural killer cells and
CD8+ T-cells.
1.6 Expanding the Transcriptional Response in Whole Blood
Though a lot of work has been done to understand the host response to EVD, under-
standing the transcriptional response to a more complete extent in whole blood is of im-
portance. In Chapter 2, I expand the knowledge of the transcriptional response to EBOV
infection using an RNA dataset acquired in symptomatic human infections from the 2013-
2016 EBOV outbreak in West Africa. I show that following EBOV infection, the human
response is characterized by a large increase in transcripts associated with the acute phase
response, the interferon response, and the cytokine response. I further show that in general,
fatal cases of infection show a stronger increase in these groups of genes than do patients
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that will go on to survived infection. I then go on to show how the changes in gene ex-
pression may be related to changes in cell populations and highlight how natural killer
cells may be important in protection to EBOV infection. Finally, I use the host response to
infection to develop a prognostic indictor of disease.
In Chapter 3, I further characterized the response to EBOV infection using an ani-
mal model of disease. This chapter expands upon the discoveries in Chapter 2 using the
NHP animal model within a controlled environment and a known route and does of infec-
tion. This also allows for a time course of disease to be analyzed in contrast to Chapter
2 where there was only one sample taken per individual. To better analyze the transcrip-
tional response, I helped to develop and characterize a targeted NanoString codeset that
can be used to study infectious disease in NHPs. In this study, I show first that in the NHP
model of infection, EBOV Kikwit infections from an earlier outbreak show similar gene
expression to EBOV Makona which caused the West Africa outbreak. I then go on to show
that independent of the route of infection, either through mucosal exposures or intramus-
cular injections, the transcriptional response is highly similar. The work in this chapter
using RNA-seq data was validated on a new NanoSting codeset. Both methods show ca-
pability using a subset of genes to correctly identify infected samples form uninfected
samples. They also show ability to accurately predict changes in cell populations com-
pared to experimental data. This not only shows the full utility of transcriptional profiling
in understanding EVD in whole blood samples but characterizes a NanoString codeset in
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more easily studying high consequence viruses which has many benefits over traditional
RNA-Seq.
In Chapter 4 I further expand on the analysis of the host transcriptional response to
EBOV infections in non-human primates in a model of infection that did not have uniform
disease such as in Chapter 3. In this model of infection, through the use of an intranasal
exposure, the animals had variable incubation times and times to death which more accu-
rately relates to the expectation of human disease. In this chapter, I show that despite the
variable onsets of disease, the progression of EVD in NHPs is consistent. This consistency
is related back to the human infections from Chapter 2 to show a high degree of correla-
tion between gene expression values in the NHPs at the symptomatic time point and the
symptomatic humans. Importantly, I show that in relation to symptom onset, the different
times to death of the animals can be normalized and patterns of gene expression analyzed.
This analysis shows that there is a subset of genes that are up-regulated up to 4 days be-
fore the onset of symptoms determined by a sustained fever. This lays the groundwork for
development of a pre-symptomatic marker for infection.
In Chapter 5, I use the information learned in Chapters 2-4 to develop a pre-
symptomatic NanoString codeset that can identify infection before the onset of symptoms
and shows specificity to EBOV when compared to Marburg (MARV) infections. Though
this work, I develop a method that can classify a sample as being from pre-infection, early
in infection, or late in infection. Once infection is identified, this algorithm then looks for
the presence of the causative agent of infection. If this can’t be identified, I use the host
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response to infection to further identify if the causative agent is from an EBOV infected
animal or a MARV infected animal. This work lead to a finalized set of NanoString probes
that can be used in future studies of EBOV in NHPs and humans (as available) to further
characterize a pre-symptomatic marker of EBOV infection. This is especially important
for health-care workers during an outbreak and primary contacts to identify if they have
been exposed before the onset of symptoms to better control an outbreak and improve
prognosis.
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Chapter 2
TRANSCRIPTOMIC SIGNATURES DIFFERENTIATE SURVIVAL FROM
FATAL OUTCOME IN HUMANS INFECTED WITH EBOLA VIRUS
2.1 Preamble
In 2014 Western Africa experienced an unanticipated large outbreak of infections
with Ebola virus (EBOV). What distinguishes fatal from non-fatal outcomes remains
largely unknown, yet is key to optimizing personalized treatment strategies.
Here transcriptome data form peripheral blood taken from infected and convalescent,
recovering patients, was used to identify host factors that were associated with acutely
ill patients that ultimately either survived or succumbed to the disease. The data demon-
strated that individuals who succumbed showed stronger upregulation of interferon signal-
ing and acute phase responses compared to survivors during acute infection. Particularly
notable was the accumulation of albumin and fibrinogen mRNA, which suggested signif-
icant liver pathology. Cell subtype prediction using mRNA expression patterns indicated
that NK-cell populations increased in patients who survived infection. By selecting genes
whose expression properties discriminated between fatal cases and survivors, small pan-
els of responding genes were identified that acted as strong predictors of patient outcome
independent of viral load.
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This work suggests that transcriptomic analysis of the host response to pathogen in-
fection using blood samples taken during an outbreak situation can provide multiple levels
of information on both disease state and mechanisms of pathogenesis. Host biomarkers
were identified that provide high predictive value under conditions where other predictors,
such as viral load are poor prognostic indicators. The data suggested that rapid analysis of
the host response to infection in an outbreak situation can provide valuable information to
guide an understanding of disease outcome and mechanisms of disease.
The work presented in this chapter has been previous published by Liu X*, Speranza
E*, Muoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng
EG, Ldtke A, Xia D, Kerber R, Krumkamp R, Duraffour S, Sissoko D, Kenny J, Rockliffe
N, Williamson ED, Laws TR, N’Faly M, Matthews DA, Gnther S, Cossins AR, Sprecher
A, Connor JH, Carroll MW, and Hiscox JA in “Transcriptomic Signatures Differentiate
Survival from Fatal Outcomes in Humans Infected with Ebola Virus”, Genome Biology,
January 2017.
XL and ES made an equal contribution. MWC, SG, CM-F, JHC and JAH designed
the study. MWC, CM-F, ARC, JHC and JAH wrote the manuscript. XL, ES, SH, NYR,
IG-D, TRL, YF, ARC, AL, DX, DAM, JHC and JAH performed the experiments and/or
analyzed the data. All other authors were involved either in sample collection, processing
and analysis, and/or logistical support. My contribution was to perform data analysis. I
performed the differential gene expression analysis, determined changes in cell types, and
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worked to develop a set of 10 genes using an support vector machine (SVM). For the
figures that follow, 21 of the 25 panels directly represent my work.
2.2 Introduction
Ebola virus (EBOV) causes a devastating infection known as Ebola virus disease
(EVD) that in many patients leads to a fatal outcome. The 2014-2015 West African virus
was caused by a new strain of EBOV called Makona. In the Republic of Guinea, which was
at the epicentre of the 2014-2015 EBOV outbreak, the fatality rate was around 60%, and far
higher than in Sierra Leone and Liberia. The processes that lead either to survival or a fatal
infection are unknown although viral load (the amount of virus) can be a key determinant
(Carroll et al., 2015; Crowe et al., 2016). This is especially relevant at extremes where
patients with very high viral loads have a poor prognosis. Factors influencing outcome
in patients with EVD include hospitalization (i.e. access to palliative care) (Uyeki et al.,
2016), anti-viral treatment (Sissoko et al., 2016) and age (Shah et al., 2016).
The interplay between EVD and outcome is complex and involves a balance between
the host response and viral load. Analysis of four patients from the 2014-2015 EBOV out-
break that underwent intensive treatment and care at Emory University Hospital in the US,
indicated these patients had a robust immune response during the acute phase of EBOV
infection (McElroy et al., 2015), which challenged previous assumptions about the ability
of EBOV to suppress the immune system (Basler et al., 2000). Certainly in non-human
primate models of fatal EBOV infection, an extreme aberrant immunological status and
anti-inflammatory response was shown to contribute to the development of fatal hemor-
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rhagic fever (Ebihara et al., 2011), and this has also been observed together with lympho-
cyte apoptosis in fatal human infections with EBOV (Wauquier et al., 2010). Analysis
of samples from patients with EVD treated in Guinea from the 2014-2015 outbreak also
revealed an immune component influenced survival (McElroy et al., 2015; Ruibal et al.,
2016).
The study of patient samples taken from previous outbreaks suggests that host re-
sponses may delineate survival and fatal outcomes and potential biomarkers indicative
of these outcomes can be identified. In the 2000-2001 Sudan-associated EVD outbreak in
Uganda, the case fatality rate for pediatric patients was lower than for adults (Mupere et al.,
2001). Data indicated that pediatric patients who survived had differential abundance of
certain serum proteins from pediatric patients who died, and that in contrast, adults had
similar levels of these same molecules (McElroy et al., 2014a). Whereas fatality rates in
the 2014-2015 West African outbreak suggested that children younger than 5 years had a
poorer prognosis (Shah et al., 2016).
Apart from providing data on the underlying causes of EVD, being able to predict the
outcome of infection based on analyte abundances would provide guidance as to potential
treatment and also uncover new therapeutic strategies (McElroy et al., 2014a,b). Several
such immunological/biochemical biomarkers have been identified in a previous outbreak
of Sudan virus (SUDV) (McElroy et al., 2014a,b). However, currently, viral load measure-
ments by qRT-PCR (given as a Ct value) are considered the gold standard for predicting
EVD outcome. Viral load measured as Ct can give some indication for outcome (Fitz-
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patrick et al., 2015; Carroll et al., 2015), and has been particularly useful in the triage of
patients for experimental anti-viral trials for EBOV (Sissoko et al., 2016). Viral load for
predicting outcome works well, particularly at extremes of Ct, where for example a Ct
of 12 would be suggestive of a fatal infection and a Ct value of 30, would be indicative
of survival. However it works less well where Ct values are not able to distinguish out-
come, mainly between Ct 20 and Ct 22. Here the outcome is approximately equal between
survival and a fatal infection.
The 2014-2015 EVD outbreak was unprecedented in scale and has revealed previ-
ously unappreciated aspects of EBOV biology, such as persistence in semen (Deen et al.,
2017). The strain responsible for this outbreak, EBOV Makona, also appears to have dif-
ferent growth kinetics when compared to previous strains, having a delayed onset to dis-
ease progression in a non-human primate model of EVD (Marzi et al., 2015) and reduced
lethality in an immune-deficient mouse model (Smither et al., 2016). Given the potential
new strain variation of EBOV responsible for this outbreak and EVD is a disease of the
host response, I wanted to investigate this using a genomics approach to identify transcrip-
tome changes in peripheral blood from acute patients who either went on to survive of die
from EVD. This would allow me to investigate whether those patients that succumbed to
EBOV showed a hyperactive response to infection and also potentially identify host-based
response markers that can help predict survival in situations where viral load gives little
predictive value.
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Therefore to characterize the infection of EBOV Makona in the human population, I
first used deep sequencing to define the transcriptional profile of blood taken from acute
patients who either went on to survive or die from EVD. These samples were obtained
from patients located in Guinea through the European Mobile Lab (EMLab). During the
2014-2015 outbreak, Guinea recorded the highest death rate for EBOV. Thus EVD patients
in Guinea were optimal for correlating changes in the host response to outcome: either a
fatal or non-fatal infection. Their responses to EVD would not have been influenced by
intensive palliative and/or experimental care that was utilized in high-income countries to
treat repatriated health care workers, where 81.5% of patients that received supportive care
survived (Uyeki et al., 2016). In contrast, the survival rate in Guinea was approximately
40% throughout the outbreak. These transcriptional signatures from acutely ill patients
were compared to profiles obtained from former patients who had recovered from EVD
and were EBOV negative by qRT-PCR and also to data obtained from healthy volunteers
mined from historical datasets.
Using transcriptome data from acute-infected patients and from the control patients,
profiles were identified that highlighted differences in the host response to EBOV at the
time of acute infection. This data was obtained for patients who were either going to
survive or die from EVD. The profiles of acutely-infected individuals differed from the
survivor EBOV-negative group and the healthy controls. The profiles provide significant
insight into the global circulating immune response to EBOV in acutely infected patients
on a scale that has previously not been possible. Significantly, differences in immune cell
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populations predicted through analysis of gene expression patterns were validated on an
independent group of EVD patients using flow cytometry to directly measure the same
cell types in patient blood. Machine learning was used to identify a panel of genes whose
abundance could be used to predict the outcome of infection at the acute phase. This
panel was validated on a separate independent group of patients whose viral loads were
similar, and was found to accurately predict outcome. This would be particularly useful in
a clinical setting in cases where the viral load provides little to no predictive power.
2.3 Methods
2.3.1 RNA extractions, library preparation and sequencing
Samples from patients were sequenced on a HiSeq2500 and several criteria were ap-
plied to the selection of data post sequencing. A total of 38,554 genes were mapped to
the 64,253 genes in the annotated human genome database. The RNA was DNase treated
using Ambion Turbo DNase. RNA-seq libraries were prepared from the DNAse-treated
RNA using the Epicentre ScriptSeq v2 RNA-Seq Library Preparation Kit and following
10-15 cycles of amplification; libraries were purified using AMPure XP beads. Each li-
brary was quantified using Qubit and the size distribution assessed using the Agilent 2100
Bioanalyser and the final libraries were pooled in equimolar ratios. The quantity and
quality of each pool was assessed by Bioanalyzer and subsequently by qPCR using the
Illumina Library Quantification Kit from Kapa on a Roche Light Cycler LC480II accord-
ing to the manufacturer’s instructions. The template DNA was denatured according to
the protocol described in the Illumina User Guide and loaded at 12 pM concentration.
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To improve sequencing quality control, 1% PhiX was spiked-in. The sequencing was
undertaken on the Illumina HiSeq 2500 with version 4 chemistry generating 2x125 bp
paired-end reads. Base calling and de-multiplexing of indexed reads was performed by
CASAVA version 1.8.2 (Illumina) to produce all the sequence data in fastq format. The
raw fastq files were trimmed to remove Illumina adapter sequences using Cutadapt ver-
sion 1.2.1 (Martin, 2011). The option ‘−O 3’ was set, so the 3’ end of any reads which
matched the adapter sequence over at least 3 bp was trimmed off. The reads were further
trimmed to remove low-quality bases, using Sickle version 1.2 with a minimum window
quality score of 20. After trimming, reads shorter than 10 bp were removed. Trimmed
R1/R2 read pairs were mapped to the human reference genome assembly GRCh38 (ftp:
//ftp.ensembl.org/pub/release-77/fasta/homo_sapiens/dna/
Homo_sapiens.GRCh38.dna_sm.primary_assembly.fa.gz) using TopHat2
version 2.1.0 (Kim et al., 2013; Langmead and Salzberg, 2012), which calls the map-
per Bowtie2 version 2.0.10. Paired-end mapping was carried out using option ‘−g 1’,
‘−−library−type fr−secondstrand’, ‘−−mate−inner−dist 160’ and ‘−−mate−std−dev
60’, which instructs TopHat2 to allow a maximum of one alignment to the reference for
a given read, choosing the alignment with the best alignment scores if there is more than
one or discarding the read if there is more than one equally good alignment.
The alignments were used for calculating read counts per gene using HTSeq-
count (http://www-huber.embl.de/users/anders/HTSeq/doc/count.
html). The raw counts generated from HTSeq-count were imported into the R envi-
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Sample set Quality Survival Analysis
EBOV-positive RNA
(n=138)
poor N/A N/A
Good (n=112)
Survive (n=24) Transcriptomics
Fatal (n=88) Transcritpomics
EBOV-positive,
Malaria-negative
(n=37)
N/A
Fatal (n=20) Flow Analysis
Survive (n=17) Flow Analysis
Febril and EBOV-
negative(n=10)
N/A N/A Flow Analysis
Malaria Only (n=5) N/A N/A Flow Analysis
EBOV-positive, CT
same (n=20) Good (n=20)
Survive (n=10) Validation Set
Fatal (n=10) Validation Set
Convalescent
(n=16)
Good (n=16) Survived (n=16) Controls
Canadians (n=6) Good (n=6)
Never Exposed
(n=6)
Baseline
Table 2.1: Description of Different Datasets Used for Analysis
ronment to carry out differential expression analysis using edgeR (Robinson et al., 2010)
for contrasting acute when tested and survived (acute survivor), acute when tested and died
(acute fatal) and acute (either fatal or survived) compared to convalescent controls. Differ-
entially expressed genes with a false discovery rate (FDR)<5% and an absolute log2 fold
change>1 were finally reported. Details on the sample numbers are provided in the text
and in Table 2.1.
2.3.2 Informatic analysis
Three criteria were used to identify sample quality: (1) removal of low-quality sam-
ples from the dataset such that all samples eventually selected had over 10% of reads map-
ping to the human genome; (2) calculation of the correlation coefficient of each remaining
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sample against any other samples within each groups and the scatter plot of all correlation
coefficient values was plotted for the fatal and survivor groups; and (3) a cutoff of a mean
correlation coefficient of 0.8 was selected based on the distribution and any samples with
a mean correlation coefficient of less than 0.8 were eliminated (see Figure 2.1).
To identify gene expression signatures for predicting outcomes of Ebola patients,
a machine learning approach was applied using the SVM function in R package ‘e1071’
(Meyer et al., 2017). These were based on the ten genes either with the highest fold change
or most significant identification. The performance of predictions was assessed following
a leave-one-out cross-validation approach. The prediction performances were assessed
by using R package ‘ROCR’ (Sing et al., 2005) through ROC curves and Accuracy/FPR
(False Positive Rate) plots. Validation of the predictor was carried out on an independent
dataset of 20 individuals not included in the testing and training of the model.
To perform the expansion substitution method to identify an optimal classifier, first,
the total gene set was reduced to a search space containing only genes that were differ-
entially expressed from convalescent controls to acute-fatal or convalescent controls to
acute-survivors. Then, for each iteration, ten genes were selected at random to be the start-
ing profile set. Each gene in the search space was substituted for a profile gene and the
correlation within groups (acute-fatal to acute-fatal and acute-survivor to acute-survivor)
and between groups (acute-fatal to acute-survivor) was calculated. If the new gene substi-
tution improved the within-group correlation and decreased the between-group correlation,
the new profile set was selected. This was run until convergence was reached and a last
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profile gene set was generated. The whole process was run 50 times. The final profile
set included the genes that showed up the most in a last gene set. Finally, the accuracy
of the classifier was determined by leave-one-out cross-validation where a sample was
classified as acute-survivor or acute-fatal based on the correlation to the acute-fatal group
or the acute-survivor group. The bias estimations were performed using the boot func-
tion in R for 100 iterations. A cutoff value for the correlation was determined at each cv
step and if the sample fell below the cutoff line, it was classified as acute-fatal and above
acute-survivor. Training and testing of the model was performed in the original dataset of
112 samples. The trained model was then used in a validation dataset of 20 independent
samples.
2.3.3 Ingenuity Pathway Analysis
The p-value was calculated by Fisher’s exact test right-tailed, which indicated the
probability of association of molecules from the dataset with the canonical pathway by
random chance alone. The Z-score was used to mathematically compare the dataset with
the canonical pathway patterns, taking into account the activation state of one of more key
molecules when the pathway was activated and also the molecules’ causal relationships
with each other. This is a Quant-based test that determined if canonical pathways, includ-
ing functional endpoints, were increased or decreased based on differentially expressed
genes or proteins in the dataset.
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2.3.4 Digital cell quantification
To determine relative cell type quantities from count data, I used DCQ through the
R-package ComICS (Gat-Viks and Irit, 2016). The default parameters were used with 500
repeats and a split ratio of 50% on an input dataset of fold changes compared to controls
(acute-fatal to controls and acute-survivors to controls). All 207 cell types were analyzed.
The resulting data provided a predicted mean relative abundance as well as the standard
deviation of the mean. To determine cell types that were significantly different from zero,
a standard t-test was performed with a p value cutoff of 0.05. Definition of immune subsets
is based on ImmGen database information and thus represents previously validated mouse
equivalents to human immune cells (Villadangos and Shortman, 2010; Haniffa et al., 2012;
Auffray et al., 2009).
2.3.5 Non-human primate data
The NHP data were taken from GEO GSE64538. This dataset contained RNA-seq
in PBMCs from vaccinated and unvaccinated animals at various time points during viral
challenge. Data were read into R and using edgeR and normalized for library size. DE
data were calculated using the negative binomial. Fold changes were calculated by first
normalizing to the pre-infection control for vaccinated and unvaccinated animals and then
taking the unvaccinated 7 dpi animals over the vaccinated 7 dpi.
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2.3.6 RF method for phenotypic prediction applied to the Ebola dataset
The list of all genes was split into six strata and the R package ‘randomForest’ was
used on expression data for each strata, with patients’ status marked as either Survivor or
Fatal. Classification was undertaken separately for the six strata and the data were pooled
and genes were ranked to identify the top ten genes which were used as biomarker genes.
Finally, the patients’ outcome prediction based on the top ten genes was performed using
the ‘randomForest’ method.
2.3.7 Bootstrapping
Bootstrapping for both RF and PGP predictive models was deployed using the R
function ‘boot’ with 1000 re-samplings set to generate 1000 estimates of prediction accu-
racy. Bootstrapping was set in ‘non-parameter’ mode and patient outcome was presented
in the function argument ‘strata’.
2.4 Results
2.4.1 Analyzing patient groups with EVD
To identify changes in the host response following exposure to EBOV, the transcrip-
tome of blood samples from infected patients was analyzed. These samples were collected
by the European Mobile Laboratory in Guinea during 2014 and 2015. The samples were
taken with the foremost aim of diagnosing the presence of EBOV using qRT-PCR, which
was then used in patient management in the Ebola Treatment Centre (ETC). For this pur-
pose, RNA was extracted in the setting of the European Mobile Laboratory in Guinea.
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Discarded samples were then held in an archive and used in this study under the aus-
pices of the EVIDENT project (Ebola Virus Disease correlates of protection, determinants
of outcome and clinical management). These discarded samples were then analyzed by
RNA-sequencing (RNA-seq) to identify and quantify messenger RNA (mRNA) expres-
sion. Following sequencing of 138 individual samples from individual patients, sample
selection criteria were used to identify and remove samples from datasets that showed ev-
idence of having degraded mRNAs (expected from field sample collection) (Table 2.1).
These criteria included the removal of samples that showed poor mapping and low cor-
relation values (Figure 2.1 and Methods). Here, samples were selected that had a similar
within-sample transcriptional profile (with an average correlation co-efficient above 0.8),
thus reducing extreme variation within one patient group due to mRNA quality issues.
From an initial set of 138 individual sequenced samples from separate patients, applica-
tion of these selection criteria led us to discard 26 samples and analyze the data from 112
unique patients: acute-survivor (n=24) and acute-fatal (n=88). The outcome for these
patients was unknown at the time of sample collection and subsequently recorded as they
either succumbed to a fatal infection or survived EVD. These were from a mixture of
Plasmodium (the causative agent of malaria) negative and positive patients. Importantly,
there was no significant difference in the time between symptom onset (as reported by
the patient) and taking of the sample during acute illness. The mean time to the onset of
symptoms for the acute survivors was 6.4 days and for acute fatalities was 5.9 days with a
range of 2-19 and 2-22 days, respectively.
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Figure 2.1: Sample selection criteria based on correlation value to within group ex-
pression. A mean correlation within the acute fatal (A) and acute survivors (B) was used
to determine samples with evidence of unreliable sequencing. A cut-off value of 0.8 was
used (dashed line) and samples that fell below this within-group mean correlation were re-
moved from analysis. This led to selection of 88 acute fatal samples and 24 acute survivors
To provide a baseline for gene expression, a blood sample was taken from a sep-
arate group of 16 survivors that were EBOV-negative by PCR and convalescent for the
disease and recovered from infection (recovered control group) (Table 2.1). This control
group represented a critical comparison population. During the 2014-2015 outbreak, amid
the breakdown of the in-country healthcare system and the stigma of being seen asso-
ciated with ETCs, acquiring samples from non-infected patients was not possible. The
EBOV survivors represented a known EBOV-negative population that were also tested
and confirmed to be Plasmodium-negative with no other overt signs of a febrile illness
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(which could have impacted the results in a control group). I also made use of historical
datasets obtained from the RNA-seq analysis of peripheral blood taken from healthy vol-
unteers based in British Columbia (Canada) (n=6) and thus would not have been exposed
to EBOV or a range of other pathogens present in West Africa (Shin et al., 2014) (GEO
Number GSE53655) (Table 2.1).
2.4.2 Analysis of gene responses of patients that differentiate fate after EBOV in-
fection
I compared the transcriptomes from these different groups to identify mRNAs in sur-
vivors and in fatal cases that showed greater than two-fold changes (FDR<5%) in abun-
dance compared to the recovered control group. In the acute-survivor group, almost 1300
genes were increased in transcript abundance compared to the survivor control group. The
corresponding value for the acute-fatal group was 2200 of which half were redundant with
those in the acute-survivor group and approximately 1200 were unique to the acute-fatal
cases (Figure 2.2A). Most of the gene transcripts were common to both the acute-fatal ver-
sus acute-survivor group. Additionally, some gene transcripts that had abundance differ-
ences were restricted to the acute-survivor group. Thus, in the blood from individuals with
acute-EBOV infection, mRNAs of various pro-inflammatory factors such as CXCL10,
CCL2/MCP-1, CCL8/MCP2 and CXCL11 showed increased abundance when acute-fatal
cases were compared to acute-survivors. Similar changes in mRNA abundance were ob-
served in a publicly available dataset from non-human primates (NHPs) that survived the
challenge with EBOV (Figure 2.3).
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Figure 2.2: Host transcriptional responses in acute EBOV infection. A is a venn dia-
gram representing genes that are differentially upregulated from survivor control to acute-
fatal (blue) and survivor control to acute-survivor (red). Shared genes are shown in ma-
genta. B is a histogram illustrating genes increased in abundance in different functional
groups. Genes significantly increased in abundance in acute-fatal only (red), acute-survival
only (green) or in both (blue) are shown. C is a heatmap of pathway upregulation in-
tensity calculated by Ingenuity Pathway Analysis (IPA) for acute-fatal to survivor control
(F/C), acute-survivor to survivor control (S/C) and acute-fatal to acute-survivor (F/S). Stars
within boxes represent calculated p-value significance of increased abundance (*< 0.05,
**< 10−3, ***< 10−6). D is a spider plot of the z-scores from the IPA. Increased abun-
dance in fatal to control is in red, survival to control in green.
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Figure 2.3: Differential accumulation of Cytokines during EBOV infection. A) bar
plot illustrates the differential accumulation of CXCL11 mRNA in acute-fatal (dark red
bar) and acute-survivor (green bar) human samples. For comparison, the differential ac-
cumulation of CXCL11 in non-human primates that succumb to EBOV infection is shown
in the light red bar and the accumulation in individuals that survive EBOV infection is
shown in the light green bar. Analogous data for CXCL10 is shown in B) for CCL2 in C)
and for CCL8 in D). These plots indicate that mRNA changes seen in human infection are
mimicked in primate models of lethal/non-lethal infection with EBOV.
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2.4.3 Analysis of gene pathways differentiating fate after EBOV infection
Gene set enrichment analysis (GSEA) showed that in acute patients both surviving
and having a fatal infection were associated with a significant enrichment of genes from
within the same signaling pathways (Figure 2.2B). The most significantly represented
included gene sets associated with interferon signaling, complement, coagulation, hor-
mone receptor and acute phase signaling. Many interferon-stimulated genes (ISGs) were
strongly increased in abundance in all acute infection cases compared to the survivor con-
trol group. There was greater increased in abundance of these gene transcripts in acute-
fatal compared to acute-survivors.
In addition to GSEA, I also analyzed the patterns of differentially expressed genes
using Ingenuity Pathway Analysis (IPA) (Qiagen Bioinformatics) to identify signaling
pathways associated with infection. Pathways showing significant upregulation in acute
infection are shown in Figure 2.2C. This analysis identified many of the same pathways
identified in GSEA such as complement, acute phase signaling and coagulation factors,
but also identified signaling pathways not identified by GSEA, such as IL-6 and IL-8, in-
dicating strong activation of these cytokines in EVD. IL-6 signaling has previously been
shown to be associated with fatal EBOV infections in some studies (Wauquier et al., 2010;
Hutchinson and Rollin, 2007) but not others (McElroy et al., 2014a). Our data support the
conclusion that IL-6 signaling was upregulated in both the acute-survivor and acute-fatal
cases. Spider plot analysis (Figure 2.2D) showed that in almost all gene expression cate-
gories, acute patients that succumbed to infection showed a more robust immune response.
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There were also distinctive differences in gene expression patterns when the tran-
scriptomes from acute-fatal cases were compared to those from acute-survivors. A total
of 246 transcripts were identified as being differentially abundant (log2FC>1, FDR 5%),
of which 220 transcripts or more increased (higher in fatal cases) and 26 decreased. This
differential abundance was most strongly observed in genes associated with coagulation
and acute phase signaling. Figure 2.4 shows the five most strongly differentially expressed
genes, of which four were associated with the clotting cascade genes, including fibrinogen
(FG) alpha chain (FGA, +54-fold), beta chain (FGB, +28-fold) and gamma chain (FGG,
+19-fold). The increased abundance of these mRNAs is again consistent with deposited
transcriptomic data from EBOV-infected NHP studies (Barrenas et al., 2015).
The transcriptome profile of peripheral blood from the survivor control group may
have been influenced by any remaining EBOV antigens and/or other infections (although
the patients were Plasmodium-negative at the time the peripheral blood sample was taken
to confirm convalescence). This may therefore have skewed any transcriptome comparison
to the acute patients. To test this hypothesis, I made use of a historical dataset deposited
on GEO (GSE53655) that was an analysis of peripheral blood from healthy volunteers
(Shin et al., 2014) (n=6) (Table 2.1) and compared this to the transcriptome profile from
the survivor control group. Given the location of the study for the health volunteers was
the University of British Columbia in Canada (Shin et al., 2014), I assumed that these
individuals had not been exposed to EBOV, Plasmodium or other pathogens prevalent in
Guinea. Differential gene expression (DGE) and GSEA indicated no significant difference
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Figure 2.4: Coagulation associated mRNAs accumulate in the blood of EBOV-infected
patients. Box and whisker plots illustrate the expression of the top acute phase genes
that are differentially expressed between survivor controls (blue), acute-fatal (red), and
acute-survivors (green) based on log2 fold change. From left to right, the graphs illustrate
mRNA expression for albumin (ALB), fibrinogen alpha (FGA), fibrinogen beta (FGB),
fibrinogen gamma (FGG) and fibrinogen gamma-like 1 (FGL1). Black brackets indicate
significance between survivor controls and acute-survivor or acute-fatal and grey brackets
indicate significance level between acute-survivors and those who will succumb to disease.
All brackets represent a log2(fold change)>2 and FDR<5%.
in the transcriptome of peripheral blood between the healthy volunteers and the recovered
control group (Figure 2.5).
2.4.4 Changing immune cell types in the acute phase are related to patient outcome
Changes in mRNA abundance in the blood sample between the acute-survivor and
acute-fatal patient groups may have been due to changing gene regulation in the cell types
present or changing proportions of specific immune cell types. I used digital cell quan-
tification (DCQ) (Altboum et al., 2014) to identify which cell types may have been differ-
entially abundant in acute-survivors and acute-fatal relative to the survivor control group.
In both the acute-survivor and acute-fatal groups, DCQ predicted a decrease in CD4+
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Figure 2.5: Comparison of the convalescent survivors to healthy controls. The healthy
controls comprised a group of healthy volunteers in British Colombia and were found
in GEO under GSE53655. A) The top fold change differentially expressed genes when
comparing convalescence survivors (blue) to acute infections and when comparing acute
survivor (green) to acute fatal (red). Healthy controls are shown (purple). The healthy
controls show no significant expression of these genes similar to the survivor controls.
B) The comparison of the two control groups as a PCA plot of their overall expression
values after normalisation using edgeR. The healthy controls are indicated in blue and the
survivor controls in red. C) The results of the gene set enrichment analysis comparing the
survivor controls to the healthy controls. Genes significantly upregulated are in red and
downregulated in blue. Through a Fisher’s exact test, no group of genes had a significant
enrichment when comparing the two groups (p-value cutoff of 0.05).
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T cells (Reed et al., 2004) and a significant increase in CD8+ memory T cell signature
in acute-survivors that is consistent with flow cytometry analysis from patient samples
(Ruibal et al., 2016) (Figure 2.6A). This analysis also demonstrated a potential decrease in
the population of circulating monocytes during acute infection with EBOV (Figure 2.6B)
with a stronger predicted decrease in the acute-fatal compared to the acute-survivor group.
To investigate the DCQ-based predictions, flow cytometry analysis was used to com-
pare blood samples taken from an independent and geographically separate group of pa-
tients (in Guinea) classified as acute-fatal (n=20), acute-survivor (n=17), EBOV-negative
but with Plasmodium (n=5) and other febrile illness (but EBOV-negative) (n=10) (Table
2.1). The flow cytometry analysis indicated that in the patients with EVD, who went on to
have a fatal outcome, they displayed low frequencies of circulating CD14+ classic mono-
cytes in peripheral blood (Figure 2.6D) compared not only with surviving patients, but
also with patients with other acute infectious diseases including malaria (Figure 2.6D),
consistent with the predictions from the DCQ analysis. In addition, the frequency of blood
monocytes in patients positively correlated with viral load, which indicated a statistical as-
sociation between the loss of circulating monocytes and high viremia (Figure 2.6E). Natu-
ral killer (NK) cells were predicted to accumulate in acute-survivors when compared to the
acute-fatal group (Figure 2.6C). This is consistent with an increase in mRNA abundance
in the acute-survivor group of the NK markers interferon gamma (+4 fold over controls)
and perforin (+3 fold over controls).
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Figure 2.6: Differentially abundant cell types present in human blood samples. A)
Relative abundance of specific T cell types with acute-fatal on the left of the heatmap and
acute-survivor on the right as predicted by DCQ compared to survivor controls. Within the
heatmap, darker blue represents a decrease in the abundance of a given cell type and darker
red represents an increase in the abundance of a given cell type. The color bar on the left is
showing if the given cell type is significantly differentially abundant (greater than or less
than 0 with a p value<0.05) in acute-survivors only (green), acute-fatal only (red) or both
(blue). B) Similar heatmap for dendritic cell types and (C) is for natural killer cell types.
Loss of circulating monocytes characterizes fatal EVD. (Continued on next page)
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Figure 2.6: (Previous Page.) D) Box and whisker plots depicting frequencies of peripheral
blood monocytes in fatal EVD patients (black), EVD survivors (blue), malaria patients
(brown) and other febrile patients (green) as shown by FACS. Horizontal bars represent
median values and the edge of the boxes represent 10-90 percentiles. Statistical analysis
was performed via non-parametric Kruskal-Wallis test followed by Dunn’s post-test. ns
non-significant, *p≤ 0.05. E) Correlation analysis indicating positive correlation between
frequency of CD14+ monocytes and the Ct values. Non-parametric Spearman’s rank cor-
relation analysis was performed. The line indicates a linear regression.
2.4.5 Predictive models based on differentiated gene responses between patient
groups
Differential gene expression analysis might provide suitable biomarkers for predict-
ing the eventual outcome of infection in individual patients and thereby better direct their
treatment. I assessed if a subset of differentially expression (DE) genes could be corre-
lated with outcome using one of three independent machine learning-based methods. The
method I used was support vector machine (SVM) analysis. Predictive models based on
the top ten genes ranked by p-value (79% accuracy) did not preform better than using the
Ct value (Figure 2.7). Also, genes identified through this approach were not linked to
known components of the immune response and both models showed wide dispersions for
each gene, which contributed to overlaps between the acute-survival and acute-fatal groups
(Figure 2.7). Including samples from the recovered control group in the analysis improved
predictive performance slightly and included some of the invoked genes that showed DE
responses to EBOV exposure.
To investigate the predictive power of a host-response-based gene set, a substitution
method on groups of ten randomly selected genes was performed to define a better SVM
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Figure 2.7: Receiver operating characteristic (ROC) curves for p-value host classifier
genes. ROC curve for the CT value classifier (green) compared to the top 10 differentially
expressed genes based on p-value (blue). On the x-axis is the false positive rate and the
y-axis is the average true positive rate. The error bars represents the s.d. of the true
positive rate. The line y=x represents where the classifier would fall it if was no better
than randomly guessing. Overall, the p-value classifier did not perform better than the CT
value.
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classifier (Figure 2.8). The resulting group of ten genes improved the accuracy of outcome
predictions from 79% to 85% (97 of 112 case outcomes predicted correctly). Figure 2.8A
illustrates the resulting separation of acute-fatal cases from instances of acute-survival,
while Figure 2.8B shows a receiver operating characteristic (ROC) curve compared to Ct.
The optimistic bias for the area under the curve (AUC) prediction for this model for the
training and testing data was 0.11. Through learning curve analysis, it was determined the
the bias is likely coming from not having sufficient number of samples.
Two other methods were also used to identify gene sets that correlated with outcome.
The second method used random forest (RF) and this improved accuracy to 89%, again
with ten genes as classifiers of outcome. The third method was an entirely different ap-
proach and used an intensive optimization protocol to establish a panel of gene pairs for
which the consensus expression profile across the panel for acute-survivors were max-
imally differentiated from the acute-fatal group. This method was termed paired gene
profiling (PGP). Classification of a query patient was achieved by correlation of his/her
expression profile across the panel to one or other of the alternative classifier profiles. This
technique achieved 92% accuracy, using a select group of ten genes that overlapped with
the panel of classifier genes for the SVM model. Thus, the ability to predict outcome was
independent of the method used to achieve it.
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Figure 2.8: Identification and testing of a small set of host mRNAs whose expression
predicts survival during acute EBOV infection. A) Mean correlation plots where each
sample is represented. Survivors in green, fatal in red. Line indicates prediction inflection
point. Individuals above the line would be predicted to be survivors using these mRNAs,
while individuals below would be predicted to succumb to the disease. B) ROC compar-
ing prediction of survival using EBOV PCR Ct value (green) and host mRNA expression
classifier (blue). The error bars represent standard deviation of the average true positive
rate. C) Box and whisker plots illustrating expression changes in log2(CPM) for the ten
genes in the host classifier in control (blue), fatal (red) and survivors (green).
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2.4.6 Effects of viral load on predictive outcome and testing on a separate group of
patients with EVD
The DGE analysis and gene classifiers were generated from patients that had a diverse
range of viral load. I wanted to examine whether both were independent of viral load and
instead just reflected the host response to EBOV infection. To investigate this, I determined
the transcriptome of blood samples taken from an independent group of patients from that
used in the initial DGE analysis and for gene classifiers. I focused specifically on samples
from new patients whose viral loads were not significantly different (Ct=20-22) between
a fatal (n=10) or non-fatal outcome (n=10) (Table 2.1). This is a crucial range for viral
load as between these Ct values the outcome of EVD cannot be predicted as the case fa-
tality rate in this group of patients was approximately 50% from the outbreak in Guinea.
From a disease biological perspective, this allowed me to investigate whether the observed
differentially expressed genes between a fatal and survivor outcome were potentially re-
lated to viral load. For example, a lower viral load promoted survival or whether DGE
was potentially host-moderated. All of these selected patients were antigenically nega-
tive for Plasmodium and thus the outcome and the host response were not complicated
by malaria. DGE analysis between these two groups of patients identified the enrichment
of very similar transcript abundance to that described in the original DGE analysis on the
acute-fatal and acute-survivor patients groups, suggesting that the host response (at least
at the transcript level in the blood) was mainly independent of viral load. There was also
good correlation between the top five differentially abundant gene transcripts expressed
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Figure 2.9: Validation of classifier in an independent dataset. The ability of the host-
based classifier to predict outcome was tested in an independent dataset where the Ct
values all lay between 20 and 22. A) ROC showing the host-based classifier (blue) in the
independent dataset compared to the Ct value (green). The line represents the line y=x
which shows where the ROC falls if the predictions are equal to random selection. B)
pROC showing the comparison for the host classifier (blue) and Ct value (green) with a
false positive rate up to 0.2. In the validation dataset, the host classifier was able to predict
better than the Ct value.
in the n=20 study and the n=112 patient study. When the ten gene SVM classifier was
compared to the Ct value in this group, it greatly outperformed the Ct value in predicting
survival as seen in the ROC and partial ROC (pROC) in Figure 2.9. The ten gene RF clas-
sifier was also able to predict survival in this group of patients where the Ct value failed.
This shows that the ability of the biomarker to predict outcome was independent of Ct
value and is useful in predicting outcome in patients where the Ct value is uninformative.
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2.5 Discussion
Understanding the pathogenesis of rare outbreak diseases such as EBOV is both dif-
ficult and important. To date, the overwhelming majority of cases of this disease have
occurred in situations where high-quality healthcare and monitoring are challenging. This
has made it difficult to understand in detail many of the basic aspects of disease devel-
opment and pathogenesis; information on the disease has been gathered through animal
models (Marzi et al., 2015; Smither et al., 2016).
Here I show that transcriptomic sequencing of blood samples taken from humans dur-
ing the 2013-2016 West African outbreak and leftover from diagnostic tests can be an im-
portant means of acquiring multiple levels of information about the host response to virus
infection, ranging from understanding how immune cell populations in the blood change
over time during infection to helping define potential host biomarkers of infection. This
strongly argues that integrating transcriptomic analysis of host responses during outbreaks
can provide important insights into disease pathogenesis that affect clinical management.
The strong ISG response observed in the large cohort of EVD patients is notable. IFN-like
responses have been reported to be associated with moderate disease in a diverse set of US
EBOV patients (McElroy et al., 2016) and have been suggested to be protective for EBOV
infection (Smith et al., 2013). The existence of a strong innate immune response in acute
cases in Guinean patients, given their differing clinical outcome and treatment, suggests
that this response may not be offering significant protection to promote survival.
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A particularly interesting finding from this study was the effectiveness of using a re-
covered control group as a comparison population to investigate differential gene expres-
sion. Ideally, a control group from Guinea that was never infected with EBOV would have
been optimal; however, at the time (and still persisting), stigma associated with EBOV
and ETCs rendered such a group challenging to identify and ethically problematic to take
blood samples. Using recovered control group transcriptomes had the potential to identify
some responses that began during acute Ebola infection and had not been resolved when
samples were taken from the control group. However, comparison of the peripheral blood
transcriptomes from this group to historical datasets from a completely unrelated healthy
control group separated both geographically and temporally from the West African out-
break (Shin et al., 2014) indicated no significant differences in the transcriptome (Figure
2.5). This suggested that at least when the peripheral blood samples were taken the control
group had recovered from infection. I found that immune-cell populations predicted by
the comparison analysis (Figure 2.6) and biomarkers identified through comparison were
both verified in independent datasets (Figure 2.9). It is unlikely that the Ebola outbreak
will be the only one in which the ‘ideal’ control population is difficult to sample and our
results suggest that convalescent patients may serve as an important alternate control. By
necessity, datasets from samples that had poor-quality reads were excluded from the anal-
ysis presented in this work. This may have biased the identification and measurement
of differentially expressed genes as well as the downstream analysis of gene classifiers
that correlated outcome. However, the underlying biology of EVD identified in this study
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through the transcriptomic approach correlated with both data from non-human primate
studies and clinical information from patients.
The increased accumulation of mRNAs for genes involved in the clotting cascade
found during acute infection with EBOV is consistent with earlier findings that fibrin de-
position was closely associated with EBOV infection (Feldmann and Geisbert, 2011; Geis-
bert et al., 2003). The increased abundance of multiple FG gene isoforms as well as the in-
creased abundance of albumin mRNA is initially perplexing, as these genes are considered
liver-specific mRNAs and not mRNAs that are found in blood. One potential explanation
is that the accumulation of these genes is an indication of significant liver damage leading
to leakage of hepatic mRNAs into the blood (Okubo et al., 2013). It is important to note
that during this outbreak, overt hemorrhaging was rarely observed (Chertow et al., 2014),
but strong increases in the abundance of these genes was seen in both the acute-survivor
and acute-fatal patient groups, suggesting that significant liver damage was present. As
a measure of aberrant liver function, in patients with EVD, aspartate transaminase (AST)
values were found to be higher than alanine transaminase (ALT) (Schieffelin et al., 2014).
This finding is consistent with observations of liver damage in repatriated patients from
Liberia treated in the United States (Lyon et al., 2014).
An important finding of this study is the similarity of the transcriptomic data to pro-
tein expression data analyzing cytokine expression observed in this (Ruibal et al., 2016)
and earlier outbreaks (Wauquier et al., 2010). These data emphasize the similarity of
cytokine abundance information collected through this approach to that seen in previous
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EBOV outbreaks and also to NHP models of EVD in humans. The robust IFN response
seen in human infection was somewhat surprising based on earlier reports. However, this
was consistent with data from NHP models of lethal infection with EBOV (Rubins et al.,
2007) that also showed very strong increases in IFN-responsive genes in circulating im-
mune cells and suggests that more robust IFN signaling may decrease an individual’s abil-
ity to survive EBOV infection. Certainly, this study on patients treated in a low-income
setting and results from patients treated in a high-income setting (McElroy et al., 2015)
challenges the assumption that humans do not mount a productive immune response.
The changes in the immune response identified in this study in the acute phase of
EVD between acute-survivors and acute-fatal patients were potentially caused by the dif-
ferential activation of gene transcription and also potential infiltration/exfiltration of dif-
ferent cell types in the blood. A prediction that monocyte cell populations were higher in
the acute-survivors than the acute-fatal patients was validated on an independent group of
patients using a cell-based approach (Figure 2.6D)-completely different to that of RNA-
seq (Figure 2.6A). I also predicted that NK cell populations were higher in acute-survivors
compared to acute-fatal patients during the acute phase. NK cells have been previously
suggested to be important innate immune cells in fighting EBOV infection (Warfield et al.,
2004; Cimini et al., 2017), so the increased abundance of these cells could be providing a
crucial survival advantage to the acute-survivors group.
Independent machine learning approaches identified different panels of genes whose
abundance could accurately predict outcome over a range of Ct values. Using host gene
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profiles to predict outcome also worked for those Ct values (between 20 and 22) where the
outcome was not clear in the data from the European Mobile Laboratory, i.e. where the
case fatality rate was approximately 50%. Other studies have also shown that Ct values
can be used to predict outcome. For example, a study of EVD patients in Sierra Leone
showed that patients with a Ct≥24 had an 87% chance of survival, whereas patients with a
Ct value<24 had a 22% chance of survival (Crowe et al., 2016). Interestingly, the average
patient Ct value in samples processed by the European Mobile Laboratory was 21.4, im-
plying that for the average patient their outcome could not have been predicted based on
Ct value alone. I show that the identified gene classifiers were valid over a wide range of
viral loads which clearly indicated that the host response was unrelated to the amount of
viremia. The classifiers were tested on an independent group of 20 patients. This provided
strong preliminary information that the model was not highly over-fitted, though additional
samples would increase confidence.
Assessing viral load together with an evaluation of the host response at the time of
diagnostic sampling may give an accurate indication of the survival chance for the patient,
across a broad range of viral loads. Management of patients in the developed world re-
sulted in far better survival rates than the management of patients in West Africa, due to
extensive palliative intervention; therefore, the acute and fatal outcomes in this study may
be more reflective of the situation in untreated patients. The triage of large numbers of pa-
tients under very resource-poor situations may promote survival rates by focusing efforts
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on those most in need. Predictive models based on clinical data have also been proposed
to determine the outcome for patients with EVD (Colubri et al., 2016).
The ability to triage patients by disease severity and likely outcome can be of practical
benefit for patient care. In any outbreak setting, it is inefficient to have the resources for the
most intensive care scattered about the Ebola Treatment Unit (ETU). Developing tests that
allow the stratification of risk would allow an ETU to centralize intensive care resources
for maximum efficiency and efficacy.
These findings also have implications for the design of clinical trials. Recent studies
used Ct value as a proxy for the probability of survival (e.g. the Favipiravir trial), but as
demonstrated here, Ct-based prediction is not perfect. As my results provide improved
prediction of outcome, the potential to show an effect of a therapeutic through a clinical
trial is improved. During the last outbreak, there was much public disagreement over the
ethics of randomizing patients with EVD to control groups in clinical trials (Cox et al.,
2014; Joffe, 2014; Adebamowo et al., 2014). In my opinion (and that of others), a rea-
sonable compromise position would be to exclude from randomization those patients with
the lowest probability of survival and provide them with the study drug. The results of
my work would allow for a more accurate identification of those EVD patients with a low
probability of survival rather than simply rely on Ct values only at admission.
The mRNAs associated with the correct prediction of outcome include the transcrip-
tion factor eomesodermin (eomes), an important characteristic of CD8+ T cell memory
transition (Buggert et al., 2014), and is consistent with the prediction of increased CD8+
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memory cells in survivors (Figure 2.6). Consistent across the three gene sets identified
by SVM, RF and the PGP were TGFB1, VACM1 and HOPX. TGFB1 is an extracel-
lular matrix protein that inhibits cell adhesion and is seen to be downregulated in both
fatal patients and survivors. VCAM1 is a gene important for lymphocyte extravasation
to sites of infection. This gene has previously been shown to be upregulated in response
to EBOV infection (Wahl-Jensen et al., 2005), consistent with the prediction of increased
CD8+ memory cells in survivors (Figure 2.6). The decreased abundance of TGFB1 and
the increased abundance of VCAM1 is suggestive of an increase in cell adhesion with an
increased instance of leukocyte cell adhesion to the endothelial layer and movement out of
the blood into tissues.
2.6 Future Directions
These data demonstrate that a blood sample from a patient with EVD is a powerful
source of disease information, which is relevant to clinical treatment. Analyzing the popu-
lation of mRNAs present in the blood can provide information on the extent of the immune
response to infection, the immune cells engaged (and depleted) during infection, and also
the accumulation of mRNAs likely derived from damaged internal organs such as the liver.
The changes in mRNA abundance also proved to be a reliable means of predicting whether
an individual patient would survive or succumb to EVD.
In large-scale outbreaks, blood represents one of the most available and informative
of diagnostic samples. This study suggest that using collected blood to analyze how a
patient is responding to infection will allow better diagnosis and prediction of disease out-
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come for this highly fatal infection. Though the analysis of a patient’s response to infection
has not always been thought of as an important component of a diagnostic approach, this
report and others (Zaas et al., 2009; Garamszegi et al., 2014; Tsalik et al., 2016) show that
it has significant value and likely should be adopted into future diagnostic and treatment
approaches. Integration of this type of analysis in future outbreak responses could help
direct therapy and maximize a beneficial outcome of infection, particularly in the develop-
ment of diagnostic approaches that can accurately stratify patients for treatment based on
the likely outcome of infection.
This study was uniformly combining fatal cases and survivors into a groups. Yet,
variability with in the groups was present and further stratifying patients may help to fur-
ther inform the disease course and pathogenesis. One example of this is that not all patients
had evidence of accumulation of liver associated mRNA across both fatal and survivor
groups. Further characterizing the differences between fatal cases and survivors that had a
accumulation of these mRNA vs ones that are considered weak could help to understand
how liver health may contribute to outcome of disease. Furthermore, a more in depth anal-
ysis of neutrophil associated markers is of particular interest since in this dataset, there was
no evidence of an accumulation of neutrophil associated transcripts, though neutrophilia
has been previously associated with disease in NHP models and mouse models of infection
(Geisbert et al., 2003).
This study is the first time that a large scale patient cohort of EBOV infected individ-
uals has been analyzed through a multi-parametric approach. It provided many opportu-
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nities to not only better understand the general change in EVD, but also better understand
the animal models of disease. Animal models of disease are important for testing of drugs
and vaccines. Comparing this dataset to that of the NHP or mouse model of disease can
help future studies to more clearly understanding the strengths and weaknesses of the an-
imal models and provide a more comprehensive view of the animal model compared to
humans. Alternatively, animal models of disease with time resolved datasets can help to
better understand the different phase of the human disease and to parse it down further.
In the following chapters, I describe work to characterize NHP models of EBOV Makona
infections. Importantly, I use animal models of disease that are meant to more accurately
represent human disease with regards to dose, possible exposure routes, and timing of
response.
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Chapter 3
COMPARISON OF TRANSCRIPTOMIC PLATFORMS FOR ANALYSIS OF
WHOLE BLOOD FROM EBOLA-INFECTED CYNOMOLGUS MACAQUES
3.1 Preamble
In the previous chapter, I demonstrated many aspects of the host response to Ebola
Virus Disease (EVD) and their association with outcome. Further characterization of the
host response in human patients is difficult as the dataset described the Chapter 2 is a rare
collection of RNA samples, yet further understanding the the different phases of disease
progression is important to better inform clinicians treating the disease. One thing that
cannot be addressed with the human datasets is what does the disease look like over time.
This is because the human samples came from a single time point per person all at a similar
point in disease progression.
To create a more complete understanding of the host response to Ebola Virus (EBOV)
infection, utilization of in vivo animal models of disease is important. A large amount of
focus has been placed on the non-human primate (NHP) model of disease. To create a bet-
ter understanding of the dynamics of the host response to EBOV infection in a non-human
primate model of disease, I studied cynomolgus macaques exposed to EBOV Makona via
different routes with the intent of comparing RNA-Seq to a NanoString nCounter codeset
targeting 769 non-human primate (NHP) genes. RNA-Seq analysis of serial blood samples
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showed different routes led to the same overall transcriptional response seen in previously
reported EBOV-exposed NHP studies. Both platforms displayed a strong correlation in
gene expression patterns, including a strong induction of innate immune response genes at
early time post-exposure, and neutrophil-associated genes at later time points. A 41-gene
classifier was tested in both platforms for ability to cluster samples by infection status.
Both NanoString and RNA-Seq could be used to predict relative abundances of circulating
immune cell populations that matched traditional hematology. This demonstrates the com-
plementarity of RNA-Seq and NanoString. Moreover, the development of an NHP-specific
NanoString codeset can augment studies of filoviruses and other high containment infec-
tious diseases without the infrastructure requirements of RNA-Seq technology.
The work presented in this chapter has been previously published under Speranza
E*, Altamura LA*, Kulcsar K, Bixler SL, Rossi C, Schoepp R, Nagle E, Aguilar W, Dou-
glas CE, Delp KL, Minogue T, Palacios G, Goff AJ, and Connor JH, “Comparison of
Transcriptomic Platforms for Analysis of Whole Blood from Ebola-Infected Cynomolgus
Macaques”, Scientific Reports, 2017.
CR and RS acquired field samples, isolated, propagated, characterized, and supplied
EBOV/Mak isolate. LA and TM Conceived and designed NanoString NHP codeset. SB
and AG performed the NHP study. WA and CD performed EBOV-infected NHP sample
processing and NanoString experiments. KK, EN, and GP conceived and performed RNA-
Seq experiments. KD performed ex vivo stimulation of NHP blood samples and NanoS-
tring experiments. LA and ES performed NanoString data analysis. ES, LA, and JHC
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wrote the manuscript. KK, SB, GP, and AG provided critical review of the manuscript.
I contributed through complete analysis of all the RNA-Seq data as well as the NanoS-
tring data from EBOV-infected animals. Of the figures in the chapter, 33 of the 39 panels
directly represent my work.
3.2 Introduction
Ebola virus (EBOV) is a negative sense non-segmented RNA virus of the family
Filoviridae, genus Ebolavirus. EBOV is the causative agent of Ebola virus disease (EVD)
in humans and non-human primates (NHPs). EVD is a very serious illness resulting in
20-90% case fatalities in humans and NHPs (Feldmann and Geisbert, 2011). Disease
transmission typically occurs by direct contact with bodily fluids and excreta from infected
individuals. The 2014 Western Africa EBOV outbreak was the most widespread to date,
suggesting mucosal routes of exposure played a large part in transmission.
NHPs, primarily cynomolgus and rhesus macaques, infected with wild-type EBOV
develop a slightly accelerated, but clinically similar, presentation to human EVD, thus
making them useful for studying host responses (Nakayama and Saijo, 2013). Following
intramuscular injection (IM), the virus replicates to high levels in the liver and spleen. By
approximately 4-5 days post-exposure, the virus is detectable at high levels in the blood
and has widely disseminated to other tissues. Typically animals will succumb to disease by
6-8 days post-exposure (Nakayama and Saijo, 2013). Several recent studies have turned
to focus on EBOV infection via contact with mucosal membranes or aerosol inhalation
(Reed et al., 2011; Jaax et al., 1996). Indeed, modeling of different transmission routes
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suggests that mucosal infection is possible, but may require greater infectious dose than is
needed for IM injection (Mire et al., 2016). Previous studies have shown 100% lethality
following IM exposure to as little as 18 PFU (Sullivan et al., 2003) as compared to 100
PFU suggested as a 100% lethal dose for the oral and conjunctival routes (Mire et al.,
2016). Also, animal models have shown that the virus can cause productive infection upon
entry through the lungs (Johnson et al., 1995), although the relevance of such models to
natural transmission is controversial.
Transcriptomic analysis is a useful technique to study the host response to EVD.
Previous work in NHPs examined the host response to infection within the circulating
immune system (Yen et al., 2011; Garamszegi et al., 2014; Caballero et al., 2016; Rubins
et al., 2007). Most notable was the observation of an early and robust innate immune
response (Caballero et al., 2016). This is different from in vitro models of infection using
human immortalized liver cells in which the virus is able to evade the innate immune
response through interferon antagonism (Messaoudi et al., 2015; Edwards et al., 2016;
Kash et al., 2006). Other recent studies have used transcriptomics in whole blood samples
from patients taken from the 2013-2016 EVD outbreak to better understand the progression
of host responses and correlate them with survival outcomes (Liu et al., 2017; Kash et al.,
2017).
Transcriptomic data sets can also be leveraged for the development of diagnos-
tic biomarker assays that can classify infection status and/or predict clinical outcomes,
and have been demonstrated in NHPs using microarrays (Garamszegi et al., 2014) and
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miRNA (Duy et al., 2016) expression, respectively. There has also been work to develop a
biomarker for survival in human infections of EBOV through transcriptomic analysis (Liu
et al., 2017). Other work has been aimed at the development of virus-specific biomarkers
for two other hemorrhagic fever viruses, Marburg virus (MARV) and Lassa fever virus
(LASV), which showed distinct expression profiles at time points as early as day 1 or 3
post-exposure for LASV and MARV, respectively (Caballero et al., 2014). Host biomarker-
targeted diagnostics capable of identifying EBOV infection signatures would be advan-
tageous for patient care and outbreak control by complementing existing virus-specific
nucleic acid tests and immunoassays, and potentially offering prognostic information.
In this study, I used two techniques, whole transcriptome RNA-Seq and targeted
NanoString gene expression profiling, to quantify mRNA and analyze the host response to
EBOV/Makona (EBOV/Mak) infection in whole blood samples obtained from cynomol-
gus macaques exposed by different routes of infection. I compared these platforms for
mRNA quantification and demonstrated successful profiling of host gene expression, pre-
dictive classification of subjects according to infection status, and extrapolation of relative
abundances of circulating immune cell populations. Although the results do not indicate
that different routes of infection affect the host response to EBOV/Mak, I provide strong
evidence that both RNA-Seq and NanoString yield complementary data for interrogating
this response. Moreover, the significantly simplified NanoString experimental workflow
and data analysis provides a valuable addition to the experimental toolkit available for
monitoring correlates of infection in filovirus NHP infection models.
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3.3 Methods
3.3.1 Biocontainment
All activities using infectious EBOV specimens and cell culture materials, as well
as housing and manipulations of EBOV-exposed NHPs, was performed in BSL-4/ABSL-4
registered laboratory suites at USAMRIID.
3.3.2 Virus Stock
A working seed bank of the isolate Ebola virus/H.sapiens-wt/SLE/2014/Makona-
G3864.1 (EBOV/Mak) was produced from a master stock that was made from an isolate
from serum of a 2014 Sierra Leone fatal human case (SL 3864.1). The working stock was
produced by infecting Vero E6 cells at a multiplicity of infection (MOI) of 0.001 in T175
flasks. Virus was diluted and propagated in Eagle’s Minimum Essential Medium (EMEM)
supplemented with 2% [vol/vol] heat-inactivated fetal bovine serum (∆FBS; HyClone), 2
mM L-glutamine (HyClone), 100 IU penicillin (Cellgro), 1000µg/ml streptomycin (Cell-
gro), and 1.25µg/ml amphotericin B (ThermoFisher Scientific). On day 9 post-inoculation,
the media was harvested, an additional 8% ∆FBS added after clarified by centrifugation,
and aliquoted into 1-ml single-use cryovials. The preparation was a Vero E6 passage 2
stock and contained an average of 4.02x106 plaque-forming units per ml (PFU/ml) of
infectious virus. This stock was evaluated for sterility on trypticase soy broth and choco-
late agar plates and tested for mycoplasma and endotoxin levels using Lonza’s Endpoint
Chromogenic Limulus Amebocyte Lysate (LAL) test and MycoAlert biochemical assay.
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The stock was determined to have no detectable mycoplasma, endotoxin or adventitious
agents based on the assays and techniques used. Total RNA isolated from this stock was
sequenced and tested in a number of real-time reverse-transcription polymerase chain reac-
tion (RT-qPCR) assays to include those specific for each filovirus. No known contaminates
were detected when sequencing the stock, and identity was confirmed by real-time reverse
transcription quantitative real-time PCR (RT-qPCR). By electron microscopy, virions ex-
hibited morphological characteristics typical of filoviruses in that they appeared as either
long filamentous or rod forms, sewing needle shaped, or in shorter mace-shaped configu-
rations. Particles varied in length with a uniform diameter of approximately 80 nm.
3.3.3 Ethics Statement
Research was conducted under an Institutional Animal Care and Use Committee
(IACUC) approved protocol in compliance with the Animal Welfare Act, PHS Policy,
and other Federal statutes and regulations relating to animals and experiments involving
animals. The study was also sent to Animal Care and Use Review Office (ACURO) for
review and approval. The facility where this research was conducted is accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, International
and adheres to principles stated in the Guide for the Care and Use of Laboratory Ani-
mals, National Research Council, 2011. Humane endpoints were used during all studies,
and NHPs were humanely euthanized when moribund, according to predefined clinical
endpoints using a scoring system.
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3.3.4 Study animals, routes of exposure, and periodic monitoring
Seven Chinese-origin cynomolgus macaques (Macaca fascicularis) were used for
this study (age range: 3-9 years). Prior to initiation of the study, the animals were found
to be negative for herpes B virus, simian retrovirus types-1, -2, and -3, simian immunod-
eficiency virus, and simian T-cell leukemia virus type-1 and negative for EBOV-reactive
antibodies.
Two animals each were challenged with 1000 or 10 PFU of EBOV/Mak via intramus-
cular inoculation. Two animals were each challenged with 100 PFU via the ophthalmic and
oral routes. For the oral exposures, 500µl of liquid inoculum was placed in the mouth. For
the ophthalmic exposures, 250µl of inoculum was placed in each eye. All viruses were
diluted in media to achieve the desired concentrations. The animals were observed daily
and evaluated for clinical signs of disease. Additionally, physical examinations and phle-
botomy were performed longitudinally throughout the course of the study. Blood samples
were collected at various time points throughout the study for analysis of chemistry and
hematological parameters, detection of viral genomes by RT-qPCR, and assessment of
antibody responses.
3.3.5 Hematology
Whole blood collected in K3-EDTA tubes was obtained for assessment of various
hematological parameters. Total white blood cell (WBC) counts, WBC differentials, red
blood cell counts, platelet counts, hematocrit values, total hemoglobin, mean cell volume,
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mean corpuscular volume, and mean corpuscular hemoglobin concentration were deter-
mined using an ADVIA 120 Hematology System (Siemens).
3.3.6 Chemistry
Serum was isolated from whole blood samples and used to assess concentrations of
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALKP), gamma-glutamyltransferase (GGT), blood urea nitrogen (BUN), and creatinine
(CRE) using a Vitros 350 chemistry system (Ortho Clinical Diagnostics).
3.3.7 Inoculum quantification
The dose of virus delivered to each group of animals was quantified by plaque assay.
Vero E6 cells were plated in six-well cluster plates at 85-100% confluency prior to use.
Virus controls were thawed at room temperature. Both viral controls and inocula prepared
for animal challenges were serially diluted from 10-1 to 10-6 using Minimal Essential
Media (MEM) supplemented with 10% [vol/vol] ∆FBS, 100 IU penicillin (Corning), 1000
µg/ml streptomycin (Corning). Virus positive controls and the 1000 PFU dose were diluted
from 10-1 to 10-6, while the 10 PFU doses were diluted from 100 to 10-5. Each dilution
was plated in triplicate wells. The plates were incubated at 370C with 5% CO2 with gentle
rocking every 15 min for a total of 60 min. A primary overlay consisting of 0.5% [wt/vol]
agarose (Seakem ME, Lonza), Eagle’s Basal Medium with Earle’s Salts, 10% [vol/vol]
∆FBS, and 100 IU penicillin (Corning), 1000 µg/ml streptomycin (Corning) (collectively,
EBME Complete) was prepared and 2 ml was added to each well. The plates were incu-
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bated at 370C with 5% CO2 for 7 days. Next, 2 ml of a secondary overlay consisting of
0.5% [wt/vol] agarose, EBME Complete, and 4% neutral red (Gibco) was added to each
well and incubated at 370C with 5% CO2. Plaques were manually enumerated on day 9
using a light box.
3.3.8 Viral load analysis by RT-qPCR
Freshly collected plasma samples (100µl) were combined with 300µl TRIzol LS
(ThermoFisher Scientific). These samples (i.e., the vials) were surface decontaminated
with 5% [vol/vol] solution of MICRO-CHEM PLUS (National Chemical Laboratories)
and removed from BSL-4 to BSL-2 containment in accordance with USAMRIID stan-
dard operating procedures. RNA was subsequently extracted using the QIAamp Viral
RNA Mini Kit (Qiagen). Viral genome equivalents per ml (GE/ml) were quantified us-
ing an EBOV-specific RT-qPCR assay and a synthetic RNA standard curve as previously
described (Trombley et al., 2010).
3.3.9 RNA isolation from whole blood
Previously flash-frozen whole blood samples were thawed, and then two matched
250µl aliquots were each combined with 750µl TRIzol LS, and removed from BSL-4 con-
tainment as described previously. For RNA-Seq analyses, RNA was isolated from whole
blood in TRIzol LS using the PureLink RNA Mini Kit (ThermoFisher Scientific) and RNA
was evaluated for quality on the Agilent 2200 TapeStation. For NanoString analyses, total
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RNA was isolated using the miRNeasy Mini Kit (Qiagen) and then quantified using the
Qubit RNA HS Assay Kit (ThermoFisher Scientific).
3.3.10 RNA-Seq
Libraries were generated on the Sciclone G3 Liquid Handling Robot (PerkinElmer)
using the TruSeq Stranded Total RNA Library Prep Kit (Illumina). Library quality was
evaluated on the Agilent 2200 TapeStation 2200 and quantified by qPCR using the KAPA
Complete (Universal) qPCR kit (Kapa Biosystems) for Illumina libraries. Libraries were
diluted to 12 pM and cluster generation was performed on the Illumina cBot. Libraries
were sequenced on the HiSeq 2500 using the paired end 2x100 bp, dual-index format.
3.3.11 NanoString targeted gene expression
Total RNA samples were analyzed using a custom-designed NanoString nCounter
gene expression codeset targeting 769 NHP genes. For each gene, a single probeset was de-
signed with predicted cross-hybridization to homologous genes for cynomolgus macaque
and rhesus macaque (Macaca mulatta). Probeset-target RNA hybridization reactions were
performed according to the manufacturer’s protocol. For each hybridization reaction, 100
ng total RNA was used or any quantity that was present in a 5µl aliquot of purified RNA if
less than 100 ng (mean: 92.5 ng, range: 32.5-100 ng). Purified probeset-target RNA com-
plexes from each reaction were processed and immobilized on nCounter Cartridges using
an nCounter MAX Prep Station and transcripts were quantified on the Digital Analyzer
(GEN 2).
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3.3.12 NanoString codeset validation
For initial testing, a reference sample consisting of RNA isolated from lysates of
major organs (minimally brain, liver, pancreas, lung, and stomach) from adult male and
female cynomolgus and rhesus macaques was used (Primate Universal RNA Tissue Lysate,
Adult Normal; Novus Biologicals). Varying amounts of RNA (100, 75, 50 and 25 ng per
hybridization reaction) were analyzed in triplicate using the NanoString nCounter NHP
gene expression codeset as described.
To examine the performance of the NanoString codeset under simulated infection
conditions, whole blood from a single cynomolgus macaque was stimulated ex-vivo with
lipopolysaccharide (LPS) or polyinosinic:polycyticylic acid (poly I:C) to induce changes
in gene expression. Whole blood collected in K3-EDTA tubes was diluted 1:5 with RPMI
1640 with L-glutamine (Cellgro). For stimulations, LPS or poly I:C was added to a fi-
nal concentration of 1.0 or 5.0µg/ml, respectively. Samples were added to 12-well cluster
plates and incubated at 370C with 5% CO2. Untreated blood samples were included as
controls. Samples were collected at 4 and 24 hrs after stimulation by gently pipetting up
and down to resuspend adherent cells and transferred to a microcentrifuge tube. Following
centrifugation at 1200xg for 10 min, the supernatants were removed, and the pellets were
resuspended in 0.5 ml H2O. For each sample, 1.5 ml TRIzol LS was used to lyse any adher-
ent cells in its corresponding well and then combined with the resuspended pellet. Samples
were stored at -800C until total RNA was isolated using the miRNeasy Mini Kit (Qiagen)
and then quantified using the Qubit RNA HS Assay Kit (ThermoFisher Scientific). Total
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RNA samples were analyzed using the NanoString nCounter NHP gene expression code-
set. For each hybridization reaction, 100 ng total RNA was used, or any quantity that was
present in a 5µl aliquot of purified RNA if less than 100ng. This experiment was repeated
twice using blood from the same macaque collected approximately six weeks apart.
3.3.13 RNA-Seq data processing
The whole blood data was processed with the following. The raw FASTQ files were
trimmed to remove low quality bases using the FASTX-Toolkit version 0.0.14 (Hannon-
Lab, 2010). Parameters used were -l 40, -q 33 (trimming), -q 20 (filtering), -p 80. Reads
were then aligned to the Macaca fascicularis genome version 5.0 (Yan et al., 2011) using
Bowtie 2 version 2.2.6 (Langmead and Salzberg, 2012) and TopHat version 2.1.0 (Trap-
nell et al., 2009) using the default parameters for alignment. Finally, count tables were
generated using HTSeq version 0.5.4 (Anders et al., 2014) with –stranded set to no. The
PBMC data of EBOV/Kik was processed according to (Caballero et al., 2016).
Count tables were read into R version 3.2.2 (R Core team, 2015). Genes that had
fewer than 10 counts across all samples were removed to prevent zero count rows for
skewing the normalization. Data was normalized using the DESeq2 (Love et al., 2014)
rlog normalization. After initial normalization, samples were removed if their median
value was greater than 2 standard deviations of the mean of the median normalized counts.
The data was then normalized again. This was repeated until the standard deviation of the
median normalized counts across samples was less than 10% of the mean. This allowed
for the removal of samples that showed evidence of poor quality sequencing.
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3.3.14 NanoString data processing
Data for the ex vivo stimulation study and the EBOV/Mak infection studies were
processed and analyzed independently as follows: nCounter .RCC files for each sample
were imported into nSolver 2.5 for review of quality control metrics (all passed). The
spike-in positive control geometric mean normalization factor (without negative control
background subtraction) was determined using nSolver for each sample. Using Graph-
Pad Prism 7, the global background of raw negative control probe counts was determined
across all samples (mean+2 standard deviations). A normalized global background thresh-
old was then calculated by first multiplying each sample’s positive control geometric mean
normalization factor by the raw global background threshold, and then calculating the
mean+2 standard deviations.
To identify stable reference genes to normalize data for varying RNA input,
NormFinder (Andersen et al., 2004) was used. Positive control geometric mean normal-
ized data for all genes was exported to Microsoft Excel, and then filtered to include only
genes where all samples had counts above the normalized global background threshold.
This was done to remove data bias by undetected genes in some samples. This filtered
data set (136 genes), was analyzed with the NormFinder Excel add-in and the top five
most stable genes were selected in each study. Raw counts from these genes, along with
the spike-in positive controls, were then used to perform both positive control and refer-
ence gene normalization of the raw data in nSolver. These data were then exported in .CSV
format for gene expression analyses.
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3.3.15 Bioinformatics analysis
Count data was converted into counts per million mapped reads (CPM) through the
fpm function in DESeq2. A pseudo count of 1 was added to all counts (both NanoString
and RNA-Seq CPM) before the log2 value was calculated and the log2 fold change calcu-
lated. Differential expression analysis was done for the RNA-Seq data using the DESeq2
negative bionomial model to generate a Benjamini-Hochberg corrected p-value for signif-
icantly differentially expressed genes. Correlation values were calculated using the cor()
function in R and p-values generated using the cor.test() function.
A 41 gene biomarker set was determined previously as genes identified to be signif-
icantly up-regulated in multiple macaque infected EBOV PBMC transcriptomic datasets.
Some of the genes were identified as common to other two hemorrhagic fever viruses,
Lassa and Marburg. These genes were found to highly reproducible across multiple
datasets as up-regulated before the onset of viremia. To determine the clustering ability
of the 41 gene biomarker set, a cluster statistic was calculated using the points position-
ing from a principal component analysis using the built in R function. After calculating
the principal components that contributed to 95% of the explained variance when centered
and scaled, a mean center point for each cluster was calculated. Next, the squared mean
Euclidian distance of each point to its center was calculated to determine how far points
were from the center. Then, the squared distance of the centers was calculated. The final
statistic was the ratio of the squared mean distance to the center over the squared distance
between the centers. For the simulations, 41 genes were chosen at random to calculate the
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statistic. Significance was determined by the percentage of random simulations that fell
below the biomarker statistic with a cutoff of 5%.
To extrapolate out cell type changes from the RNA-Seq data, digital cell quantifi-
cation package ComICS (Gat-Viks and Irit, 2016) in R was used. An input of log2 fold
change compared to 0 DPI was used as an input, default parameters used, and a split ratio
of 0.5. For the NanoString data, the nCounter Advanced Analysis software was used to
determine animal cell type changes for each animal.
3.4 Results
3.4.1 NHP infection studies and sample collection
To confirm the virulence and characterize the host response in NHPs to a representa-
tive isolate of the 2013-2016 EVD outbreak, a well-characterized challenge stock of virus
isolated was generated from the serum of a 2014 fatal human case in Sierra Leone (Ebola
virus/H.sapiens-wt/SLE/2014/Makona-G3864.1). The sequence obtained from the clini-
cal specimen (GenBank accession KR013754.1) was identical to 17 other passage zero
sequences from the outbreak at the time of selection of the challenge stock, and eight of
these came from non-survivors. In short, the sequence of SL-3864 was identical to the
sequence of viruses associated with lethal disease.
In parallel efforts to develop a model of EBOV/Mak infection that would recapitulate
potential transmission modes noted during the outbreak, exploratory studies in cynomol-
gus macaques in which both exposure routes and infectivity of the inocula varied were
carried out. Here, I report analyses on a subset of six of these animals that developed
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disease following exposure to virus by three different routes: intramuscular (IM), oral,
and ophthalmic (Table 3.1). For IM exposures, animals each received 1000 or 10 PFU
EBOV/Mak inoculum, respectively, by injection. By the oral and ophthalmic routes, NHPs
received 100 PFU EBOV/Mak inocula dropwise. The intent of these latter exposure routes
was to more realistically simulate mucosal exposure conditions using a lesser inoculum
(Mire et al., 2016). The IM exposures were included to bridge these data to existing
data sets collected during various filovirus countermeasure development efforts. Follow-
ing EBOV/Mak exposures, NHPs were observed for clinical manifestations of EVD as
well as body temperature and weight changes. Whole blood was collected on days 0, 3, 6,
and 10 post-exposure for assessment of clinical chemistry, hematology profiling, viremia
determination, and also archived for downstream assays.
NHP Sex
Weight
kg
Route PFU
Rash Day
(severity):
Localiza-
tion
LAD Day
(severity):
Localization
Motor
Dysfunc-
tion Day
(severity)
TTD
4 M 5.3 IM 10
10 (2):lo-
catlized
3 (1): L man,
R man, L Ax,
R Ax; 10 (2):
L Ax, R Ax, R
Ing
11 (3) 10.74
3 M 4.7 IM 10
10 (2): lo-
calized
10 (3): L Ing 11 (1) 11.80
6 M 7.0 IM 1000
8 (2):
widespread
9 (2): L Ax, R
Ax, L Ing, R
Ing
9 (3) 9.26
2 F 7.1 IM 1000
8 (2): lim-
ited
— — 7.85
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5 M 5.8 OP 100
10 (4): lim-
ited
10 (4): L Ing 11 (1) 12.86
1 M 5.2 OR 100
10 (3): lo-
calized
10 (3): L Ax,
R Ax, R Ing
9 (1) 9.86
Table 3.1: Information on Exposure Routes: Symptom sever-
ity: 1, minimal; 2, mild; 3, moderate; 4, severe. Abbreviations:
PFU, plaque forming unit; L man, left mandibular; R man, right
mandibular; L ax, left axial; R ax, right axial; L ing, left inguinal;
R ing, right inguial.
Following EBOV/Mak exposure, the progression to EVD was consistent with previ-
ous observations in the EBOV/Kikwit (EBOV/Kik) IM exposure model (Table 3.1; Figure
3.1). No obvious differences were observed among the exposure routes, and I acknowledge
that sample numbers reported here make robust statistical comparisons impossible. Ani-
mals that developed symptoms of EVD had elevated temperatures and evidence of plasma
viremia on day 6 post-exposure (Figure 3.1A & C), showed evidence of an inflammatory
response by day 6 post-exposure through elevated C-reactive protein (CRP), and elevated
liver enzymes aspartate and alanine aminotransferase levels (AST, ALT; Figure 3.1D-F)
by day 10 post-exposure. All animals described here either succumbed to EVD or were
humanely euthanized upon reaching predefined endpoints.
3.4.2 Whole transcriptome sequencing analyses
To understand the host response in circulating immune cells following NHP expo-
sure to EBOV/Mak, total RNA isolated from previously frozen whole blood aliquots was
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Figure 3.1: Clinical observations in NHPs exposed to EBOV/Mak. Cynomolgus
macaques were exposed to EBOV/Mak according the conditions indicated in the legend.
Data from each animal are plotted separately. (A) Changes in core body temperatures and
(B) percent weight changes relative to pre-infection baselines for each animal are shown.
(C) Plasma viremia expressed as log10 genome equivalents/ml was measured by an EBOV-
specific RT-qPCR assay. Levels of (D) C-reactive protein, (E) aspartate aminotransferase,
and (F) alanine aminotransferase in whole blood are shown for each animal.
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Figure 3.2: Available NHP whole blood RNA samples and gene expression analyses
performed. This matrix illustrates the whole blood RNA samples analyzed by RNA-Seq
and the NanoString nCounter platforms for symptomatic NHPs. The x-axis represents the
day post-exposure (DPI) and each row represents a different subject. The shape and fill
of the dots indicates which analyses were performed. Samples that yielded poor quality
RNA-Seq were removed from analysis after quality control checks. Exposure routes are
noted both by color and labeling.
analyzed by RNA-Seq on an Illumina HiSeq 2500 using TruSeq library preparation tech-
nology. There was an average coverage of 23 million reads per sample used in the align-
ment with 90% average alignment to the Cynomolgus Macaque Genome (Yan et al., 2011).
However, poor RNA quality limited data collection from all samples of one animal (NHP
2; IM exposure), and from four of five animals on day 10 post-exposure (Figure 3.2).
These poor quality samples were not included in the RNA-Seq analysis.
For each exposure route, IM or mucosal, I identified differentially expressed genes
at each time point relative to the day 0 baselines. I then compared the various exposure
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routes to address whether mucosal and IM infections resulted in different gene expression
profiles. By day 3 post-exposure, there was little evidence of differential gene expression
in either route of infection by RNA-Seq (Figure 3.3A) with a total of 11 differentially
expressed genes. We next compared the transcriptional response at day 6 post-exposure
between the two groups. The data showed a positive correlation between the IM and
mucosal exposure routes (Figure 3.3B). However, the number of differentially expressed
genes that showed both a significant change between days 0 and 6, as well as a difference
between IM and mucosal exposure routes, was minimal (5 genes total). Based on these
data, I concluded that data from animals in all three exposure routes could be pooled for
further transcriptomic analysis and method development.
3.4.3 Signaling pathway changes in the NHP response to EBOV/Mak
I performed differential gene expression analysis on the RNA-Seq dataset combining
gene expression across the different exposure routes on day 3, 6, and 10 post-exposure. At
day 3 post-exposure, there were no genes that were significantly differentially expressed
in the EBOV/Mak challenge (Figure 3.4A) compared to day 0. On day 6 post-exposure,
there were approximately 2000 genes significantly up-regulated (adjusted p-value<0.05,
log2(fold change)>1) and 200 genes significantly down-regulated (adjusted p-value<0.05,
log2(fold change)<-1) (Figure 3.4B). Gene set enrichment analysis (Figure 3.4C) demon-
strated that mRNAs with the most significant accumulation following EBOV infection
were interferon stimulated genes (ISG) and cytokines. mRNAs associated with the acute
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Figure 3.3: Comparison of RNA-Seq data from intramuscular and mucosal infection
routes. For each gene and time point, the mean counts across all subjects in each exposure
group was used to determine the fold change in expression relative to matched pre-infected
data. Fold change data was log2-transformed and the mucosal and intramuscular exposures
were then plotted on the x and y axes, respectively. Correlation plots for (A) day 3 and (B)
day 6 post-exposure are shown with their corresponding correlation and p-value statistics.
The line y=x is plotted for reference to show an ideal positive correlation. * represent a
significant correlation.
phase response and apoptosis also showed significant accumulation but were not enriched
until day 10 post-exposure.
The general transcriptional response of NHPs exposed to EBOV/Mak was very sim-
ilar to the response seen in NHPs challenged with other EBOV variants. As an example,
I performed principal component analysis on NGS datasets from this study and a study
that analyzed the response of PBMCs from NHPs exposed to EBOV/Kikwit (Caballero
et al., 2016). In this analysis, the first principal component (Figure 3.5A), clearly separates
EBOV/Kik and EBOV/Mak samples from each other. This is likely due to a number of
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Figure 3.4: Transcriptional Response to EBOV/Mak. (Caption on Next page)
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Figure 3.4: (Previous Page.) Overview of the general transcriptional changes observed in
EBOV/Mak infection. (A) is an MA-plot of the RNA-Seq data at day 3 post infection. The
x-axis represents the log2(base mean) of the counts and the y-axis is the log2(fold change)
compared to day 0. Each point is a single gene. Black dots indicate that the gene is not dif-
ferentially expressed (Not DE) and red dots indicate differentially expressed genes (DE).
(B) is a similar plot for day 6 post infection. (C) Gene set enrichment for differentially-
expressed genes using annotated gene lists (x axis). The y-axis is the number of genes
that are up-regulated in that group at day 6 post infection (black) or day 10 post infection
(grey). (D) is a table outlining the major findings from various EBOV infections. The
Kikwit data is from 1,2 and the human data is from 3. The first 6 rows outline the datasets
to show organism (NHP vs. Human), exposure route, EBOV variant (Makona or Kikwit),
infectious dose, and sample type. Following this, different gene groups are listed in the
left column with their general trend of regulation in the rows across the different groups.
Up regulated signifies that the group saw a general trend of up regulation compared to
controls. No significant change means there was no strong change in expression compared
to controls for that set of genes.
caveats between the two datasets including blood vs. PBMC, different exposure routes
and different challenge doses. Importantly, by looking at the second and third principal
components (Figure 3.5B), the samples begin to cluster into response groups that correlate
with disease course more than they correlate with challenge virus or sample type. The first
cluster (green oval) contains all the pre-exposure time points for the EBOV/Kik dataset
and the pre-exposure and day 3 post-exposure points for the EBOV/Mak dataset, high-
lighting the similarity of pre-symptomatic animals across the different virus challenges.
The second cluster represents day 4 post-exposure for EBOV/Kik and day 6 post-exposure
for EBOV/Mak. This suggests that for the EBOV/Kik challenge vs. the EBOV/Mak chal-
lenge, they are most similar at day 4 post-exposure and day 6 post-exposure, respectively.
This is illustrated in Figure 3.5C.
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In support of the symptomatic stages of disease clustering together, ISG and cytokine
expression following EBOV/Mak and EBOV/Kik exposure clusters with disease severity
more effectively than it clusters with the specific virus. When selected ISGs (Figure 3.5D)
or cytokines (Figure 3.5E) were used to cluster 3 post-EBOV/Mak exposure time points
(days 3, 6, and 10, where 6 and 10 are symptomatic stages) and 2 post-EBOV/Kik chal-
lenge time points (days 4 and 7 post-exposure; both symptomatic time points), the early
symptomatic time points and late symptomatic time points cluster together. This shows
that the gene expression changes following challenge with EBOV are primarily influenced
by stage of disease and challenge variant has a minor impact.
An additional illustration of conservation of the transcriptional host response can also
be seen when comparing NHP responses to the human transcriptional response (Liu et al.,
2017) to EBOV infection as was outlined in Chapter 2. Though datasets documenting
the host response to EBOV in humans are much less comprehensive than those for NHPs,
a comparison of the major pathways that show gene expression changes across different
NHP and human datasets is shown in Figure 3.4E. This comparison highlights that NHPs
and humans both show a strong induction of interferon signaling and cytokines during
infection. Some notable differences are in acute phase response genes where this was
notably the strongest response in humans (Liu et al., 2017) and only moderate in the NHPs.
Also, in humans, there was very little evidence of neutrophil associated transcripts whereas
in both PBMC and whole blood samples from NHPs, there was a strong induction of
neutrophil associated transcripts at near terminal time points.
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Figure 3.5: Comparison of EBOV/Mak to EBOV/Kik infection. (Caption on next page)
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Figure 3.5: (Previous Page.) Overview of the comparison of whole blood EBOV/Mak
infection to PBMC EBOV/Kik infection. (A) is a PCA plot of the gene expression changes
with the first principal component on the x-axis and the second principal component on the
y-axis. Black points are from EBOV/Mak infections and red points are from EBOV/Kik
infection. The different shapes represent different days as indicated in the legend. (B) is a
similar plot for the second principal component (x-axis) and the third principal component
(y-axis). The green circle is highlighting the pre-infection cluster and relates to the green
box in the legend. The blue circle is day 4 and day 6 post infection for EBOV/Kik and
EBOV/Mak respectively and related to the blue box in the legend. (C) is a generalized
graph of the relative disease severity (y-axis) where the higher along the y-axis the more
sever the disease course. The x-axis (black) is the days post infection for EBOV/Mak
infections and the x-axis (red) is the days post infection for EBOV/Kik infections. The
red line (EBOV/Kik) and black line (EBOV/Mak) show the disease progression in the two
infections. The green and blue shaded areas represent the clustering seen in (B). (D) is
a heatmap of many interferon stimulated genes. The rows are genes and the columns are
different days post infection from EBOV/Kik (red) or EBOV/Mak (black). (E) is a similar
heatmap for cytokine genes.
3.4.4 Development of a targeted NanoString codeset to monitor NHP responses to
infection
Although RNA-Seq sets the bar for unbiased genome-wide transcriptomics, it carries
with it significant requirements for RNA quality, and for technical and bioinformatics skills
to generate and analyze data. In contrast, the NanoString nCounter gene expression plat-
form can enable profiling of up to 800 unique transcripts with a much simpler workflow,
and with the ability to accommodate low quality RNA samples. Thus, in colloboration
with USAMRIID, I helped to develop an nCounter codeset targeting 769 genes, primar-
ily those involved in host immunology, inflammatory processes, and oncology, and which
would have maximal cross-hybridization potential with homologous transcripts among the
two NHP species commonly used as filovirus animal models - cynomolgus and rhesus
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macaques. Out of the total gene set, twelve genes were only annotated for cynomolgus
macaque, and thirteen genes were only annotated in the rhesus macaque transcriptome.
To validate the codeset, varying amounts of a universal reference RNA sample repre-
senting select organs (brain, liver, pancreas, lung, and stomach) of healthy male and female
cynomolgus and rhesus macaques were analyzed. Following normalization to internal pos-
itive and negative controls, detection of 605 genes was possible (78.7%) with counts above
the background threshold when using 100 ng of total RNA (Figure 3.6A). Using as little
as 25 ng RNA resulted in fewer genes being detected, but data correlation among varying
amounts of input RNA was high (Figure 3.6B). The inability to detect some genes in the
codeset was not surprising given that blood cell-derived transcripts were largely absent
from this reference material and this nCounter codeset specifically targeted genes involved
in circulating immune responses.
As a second level of validation, changes in cynomolgus macaque whole blood gene
expression following ex vivo stimulation were examined. Whole blood samples were un-
treated or stimulated with LPS or poly(I:C), and incubated for 4 or 24 hrs at 370C. Total
RNA was isolated from these samples and then analyzed using our nCounter codeset. In
this context, detections of the majority of genes in the panel was possible, the union of
detectable genes being 659 and 645 at the 4 and 24 hr time points, respectively (Figure
3.7A-B). Across all conditions, 709 gene targets (92.1%) with counts above the back-
ground threshold were detected. Also, an analysis of variance (ANOVA) was preformed
to determine differential gene expression relative to untreated samples at each time point
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Figure 3.6: Validation of the NHP Infection Response codeset using a universal refer-
ence RNA. Varying amounts of a NHP universal reference RNA preparation derived from
major organs of male and female cynomolgus and rhesus macaques were analyzed using
a custom NanoString nCounter gene expression codeset targeting 769 genes. Each input
RNA amount was analyzed in triplicate samples. For each RNA input amount raw data
(including counts from nontargeting negative control probes) were normalized to internal
positive controls and then a background threshold was defined as two standard deviations
above the normalized mean of negative control probes. (A) Histogram of average counts
per gene at varying RNA input amounts. A vertical dotted line indicates the mean of back-
ground thresholds across the four input RNA amounts. The number of genes detected and
the percentage of the total 769-gene codeset is shown. (B) Correlation of nCounter data at
varying RNA input amounts. A dashed identity line is shown (y=x).
(Figure 3.7C), and observed both up- and downregulation of transcripts in the treatment
groups. Moreover, the total number of differentially expressed genes increased slightly be-
tween 4 and 24 hrs. Principal component analysis (Figure 3.7D) demonstrated segregation
of untreated and treated groups within and between each time point, indicating changes in
gene expression profiles both due to treatment and time.
Finally, the overlap of the previous two experiments was compared, and found that
only 24 genes were undetectable in both contexts, confirming that 745 probesets (96.9%)
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Figure 3.7: Validation of the NHP Infection Response codeset using ex vivo stimu-
lated whole blood. Whole blood collected from a cynomolgus macaque stimulated with
poly(I:C), LPS, or left untreated was assessed on the NanoString platform. Venn diagrams
representing genes detected above background under each condition are shown for (A) 4
and (B) 24 hrs of stimulation. The total numbers of genes detected for each treatment are
shown in gray text. The union of all unique detected genes under all conditions is also
shown for each time point. (C) Differential gene expression relative to untreated samples
at each time point. Normalized and log2-tranformed data were analyzed by ANOVA using
a±2-fold change cutoff and an false-discovery rate adjusted p<0.05. (D) Principal com-
ponents analysis scatterplot of normalized data. Each treatment group is colored according
to the legend. Points for each time point are bound by an ellipse.
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could detect transcripts from non-human primates. These data demonstrated the potential
utility of the nCounter NHP codeset, and so analysis on all available EBOV/Mak-infected
NHP whole blood samples was carried out. In contrast to RNA-Seq, nCounter gene ex-
pression profiling generated good quality data for all samples tested.
3.4.5 Correlation of RNA-Seq and NanoString data sets
To demonstrate that NanoString is a viable alternative to RNA-Seq in the context of
EBOV/Mak infection, I determined if there was a correlation between the two data sets
in the expression of the 769 genes on the NanoString panel. When examining the en-
tire gene set averaging gene expression across the different days post infection for each
gene and gene expression platform, the correlation of count data was strongest among
similar time points. As there were almost no changes in gene expression data in NanoS-
tring or RNA-Seq analysis on day 3 post-exposure, comparison of fold change relative to
day 0 resulted in a poor correlation between the two platforms (Figure 3.8A). However,
given significant differential gene expression observed on day 6 post-exposure, there was
a strong positive correlation between the two platforms (Figure 3.8B). On a more granular
level, there was good agreement between the two approaches among select genes that were
upregulated (e.g., ISG15, IFIT2, S100A2), downregulated (e.g., NR4A2, CD6, CD83), or
that remained unchanged (e.g., ACTB, CFH, IL1R2) (Figure 3.8C). These genes did not
show any significant expression or induction at day 3 post-exposure in either platform, but
significant changes observed on day 6 were similar in both platforms.
101
3 DPI
-2 0 2 4 6
-2
0
2
4
6
Log2(Fold Change) NanoString
Lo
g2
(F
ol
d 
C
ha
ng
e)
 R
N
A-
Se
q r = -0.21
p = 0.08
ISG
15
IFI
T2
S1
00
A8
NR
4A
2
CD
6
CD
83
AC
TB CF
H
IL1
R2
-2
0
2
4
6
Lo
g2
(F
ol
d 
C
ha
ng
e)
NanoString
RNA-Seq
6 DPI
Log2(Fold Change) NanoString
Lo
g2
(F
ol
d 
C
ha
ng
e)
 R
N
A-
Se
q
-2 0 2 4 6
-2
0
2
4
6 r = -0.84*
p < 10-6
Lo
g2
(F
ol
d 
C
ha
ng
e)
ISG15IFIT2S100A8NR4A2CD6CD83ACTBCFHIL1R2
-2
0
2
4
6
NanoString
RNA-Seq
IS
G
15
IF
IT
2
S1
00
A8
N
R
4A
2
C
D
6
C
D
83
AC
TB
C
FH
IL
1R
2
IS
G
15
IF
IT
2
S1
00
A8
N
R
4A
2
C
D
6
C
D
83
AC
TB
C
FH
IL
1R
2
A
DC
B
Figure 3.8: Comparison of RNA-Seq and NanoString data sets. For each gene and time
point, the mean counts across all subjects measured with each platform was used to de-
termine the fold change in expression relative to matched pre-infection data. Fold change
data was log2-transformed and the RNA-Seq and NanoString data were then plotted on the
x and y axes, respectively. Correlation plots for (A) day 3 and (B) day 6 post-exposure are
shown with their corresponding correlation and p-value statistics. The line y=x is plotted
for reference to show an ideal positive correlation. (C) Expression of representative up-
regulated (ISG15, IFIT2, S100A8), downregulated (NR4A2, CD6, CD83), and unchanged
(ACTB, CFH, IL1R2) genes are shown for (left panel) day 3 and (right panel) day 6 post-
exposure. NanoString and RNA-Seq data are shown by gray and black bars, respectively.
* represents a significant correlation.
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I examined the expression of a panel of interferon-stimulated genes (ISGs) in these
data sets (Figure 3.9). There was no significant induction of ISGs on day 3 post-exposure,
but many of the classical ISGs were strongly upregulated on day 6 concurrently with the
onset of viremia. Consistent with previous findings (Caballero et al., 2016), there was no
detection of type I interferon mRNA in blood by RNA-Seq. However, the NanoString
platform was able to detect an increase in interferon beta (IFNβ) by day 10 post-exposure
in all of the animals except NHP 2, which died at day 8 post-exposure (Figure 3.10). This
highlights the ability of the NanoString platform to successfully interrogate samples where
RNA quality is poor, either due to severe disease or less than ideal sample handling prior
to gene expression analysis.
3.4.6 Verification of a PBMC-derived signature of EBOV infection in whole blood
The targeted nature of gene expression profiling on the NanoString platform is well-
suited to verification of biomarkers identified by unbiased RNA-Seq or DNA microarrays.
Previously, a gene set of 41 genes was identified by RNA-Seq across multiple datasets that
were differentially expressed and consistently up-regulated in peripheral blood mononu-
clear cells (PBMCs) isolated from NHPs infected with different strains of EBOV, Lassa
Virus, or Marburg Virus when compared to uninfected controls. Using both RNA-Seq and
NanoString data sets, I sought to examine the ability of this gene signature to classify in-
fection status using whole blood isolated from EBOV/Mak-infected NHPs. I focused this
analysis at day 6 post-exposure, as animals were unresponsive to the infection on day 3
post-exposure both clinically and transcriptomically. This difference in disease kinetics
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Figure 3.9: ISG Response in Nanostring and RNA-Seq dataset. Heatmap showing the
progression of interferon-stimulated genes (ISG) in Nanostring and RNA-Seq. The color
represents the log 2 (fold change) with red being up-regulated and blue down-regulated.
Comparative data for both day 3 (3 DPI) and day 6 (6 DPI) post-exposure are shown.
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Figure 3.10: Upregulation of interferon beta in NHPs can only be detected using
NanoString. (A) IFNB1 expression in RNA-Seq data shown as log2(CPM) over day
post-infection (DPI). No animal had any significant counts (sum counts across time for
individual animal ¡ 4). (B) IFNB1 expression in NanoString as normalized counts over
DPI. Background for this platform was defined as 16 counts as determined by negative
control lanes.
relative to previous data sets may be due to the lower infectious dose used here or possibly
delayed disease onset for EBOV/Mak (Marzi et al., 2015).
To determine each platform’s ability to distinguish infected animals from uninfected
animals using the 41-gene classifier, I examined data collected on day 6 post-exposure in
comparison to pre-infection controls. I used principal component analysis (PCA) to define
the clusters (Figure 3.11), and then calculated the ratio of the distance of each point to
the center of its group cluster relative to the distance between the two clusters. This was
compared to 1000 iterations of randomly selecting 41 genes from the 769-gene NanoString
codeset or, in the case of the RNA-Seq dataset, from the entire set of detected genes. Using
data from both platforms, there was a significant improvement in the ability to cluster the
two groups from each other when using the 41 gene set as opposed to a random signature
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Figure 3.11: Clustering ability of the 41-gene set to distinguish infected from non-
infected. Principal components analysis (PCA) plots of 41-gene EBOV infection classifier
using (A) RNA-Seq and (B) NanoString expression data. Control (pre-infection baseline)
and infected (day 6 post-exposure) data are highlighted in black and blue, respectively.
Each table shows the clustering ability of the classifier relative to a random collection of
genes present in the total NanoString or RNA-Seq data sets. The decrease from the random
data was significant for both (p = 0.001 for NanoString genes and 0 total gene set). The
decrease in the cluster statistic was again significant (p = 0) compared to 1000 random
iterations.
(Figure 3.11). These data confirm the compatibility of this infection gene signature with
EBOV/Mak-infected whole blood samples and gene expression data from either platform
examined here. This also suggests that the 41-gene signature can be used as a corroborator
of EBOV infection since it was able to cluster better than the random iterations in almost
all cases.
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3.4.7 Using Gene Expression to Predict Cell Changes
One of the benefits that the NanoString software provides is the ability to predict
changes in cell types based on RNA expression to perform in silico cytometry analysis.
Since ample hematology data was collected on infected NHPs, I was able to compare the
changes predicted by in silico approaches to the actual data collected.
I first looked at the changes predicted by the RNA-Seq data. To this end, I used
Digital Cell Quantification (DCQ) (Altboum et al., 2014) which takes the fold changes of
various cell marker genes as an input and predicts the changes of up to 200 different cell
types using a generalized linear model. I then compared the predicted cell type changes
for neutrophils, monocytes, and lymphocytes (Figure 3.12, Figure 3.13). There was strong
positive correlation between DCQ and hematology profiles (r=0.86, p<0.001). The benefit
of the DCQ is that more cell types can be analyzed than any other platform.
To perform similar analysis on the NanoString data, I used the Advanced Analysis
Plugin for the nSolver software. This software uses a knowledge base specific gene expres-
sion profiles from isolated human immune cells and correlates expression of many genes
in isolated populations to relative cell type abundance in individual animals. A benefit of
this analysis over the DCQ is that cell type changes for individual animals can be predicted
and compared. Figure 3.12A shows the results comparing the changes in lymphocytes and
Figure 3.12B in neutrophils. For the lymphocytes, there was a positive correlation (r =
0.55, p = 0.01) and all animals but 1 (NHP 1) had a regression line with a slope greater
than 0. The neutrophils had a less apparent correlation (r = 0.46, p = 0.04) but still had
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Figure 3.12: Comparison of nSolver and DCQ to the CBC data. Comparison of the
nSolver prediction of changes in cell types for individual animals for (A) lymphocytes
and (B) neutrophils (x-axis) compared to the CBC data for those animals (y-axis). The
different animals are plotted with different colors and shapes. (C) A comparable plot for
the DCQ data. Since DCQ using mean expression across biological replicates, the x is the
DCQ relative abundance and the Y is the mean fold change from 0 DPI from the CBC
data. The cell types are shown as different shapes.
a significant correlation. In this case, two animals had regression slopes that were close
to zero (NHP 3 and NHP 4). The nSolver software was able to predict individual animals
changes but it correlated to the hematology data with less confidence.
3.5 Discussion
In this study, I demonstrate the utility of a NanoString codeset targeting NHP genes
to analyze the host response to EBOV/Mak infection as compared to the gold-standard
of RNA-Seq. This codeset was developed to study gene expression in cynomolgus and
rhesus macaques and targets 769 genes involved in host immunology and inflammatory
processes. Through use of universal macaque RNA samples and ex vivo stimulation of
macaque whole blood, 92.1% of targets were validated as detectable using the novel code-
set design. This codeset was used to profile the circulating immune response to EBOV
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Figure 3.13: Comparison of CBC data to DCQ predictions. (A) Comparison of the
CBC data to the predicted relative abundance using DCQ for neutrophil amount. Day post-
infection (DPI) is shown on the x-axis. The secondary (right) y-axis shows the DCQ pre-
dicted relative abundance (black line). This corresponds to the black line. The log2(fold)
of the CBC data relative to day 0 for each individual animal is seen on the primary (left)
y-axis (colored lines). This corresponds to the colored lines. Each animal has a different
line pattern to distinguish them.
infection in cynomolgus macaques and was compared to traditional RNA-Seq analysis to
determine usability for differential gene expression analysis, circulating cell type predic-
tions, and functionality as an infection classifier. The NanoString platform affords the
opportunity to perform highly multiplexed and targeted gene expression with a relatively
lower resource investment compared to RNA-Seq. Moreover, assays can be performed
using crude RNA samples and do not require any library preparation, significantly de-
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creasing the technical burden. Experience also suggests that NanoString assays are robust
under conditions of low RNA quality, suggesting that this approach may allow analysis of
samples collected in less than ideal conditions. Notably, USAMRIID has successfully im-
plemented the NanoString workflow in a BSL-3 laboratory, and this could conceivably be
accomplished in BSL-4 as well, thereby enabling transcriptomic studies of Select Agents
such as EBOV without having to develop validated sample inactivation protocols.
This data highlighted that transcriptomic analyses of whole blood and purified im-
mune cell subsets resulted in similar gene expression profiles in EBOV-infected NHPs.
Previous studies have described global gene expression of peripheral blood mononuclear
cells (PBMCs) from EBOV-infected NHPs (Yen et al., 2011; Caballero et al., 2016; Bar-
renas et al., 2015) and in humans (Liu et al., 2017; Kash et al., 2017). When comparing
these admittedly disparate PBMC and whole blood transcriptomes, similar immune re-
sponses were identified (Figure 3.4, Figure 3.5). The similarity of host response to EBOV
infection includes a strong induction of ISGs and strong up-regulation of cytokines, sug-
gesting that the NHP challenge model accurately reflects many aspects of the human re-
sponse to infection and that the different EBOV variants do not evoke unique host re-
sponses.
There were important differences notable between the human and NHP responses. I
did not observe a strong induction of the acute phase response in EBOV/Mak challenged
animals, even at the very endpoint of disease. Another notable difference is the strong
evidence of neutrophil increases in both the CBC and computational predictions in the
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RNA-Seq and NanoString in the NHPs. In the human infections, there was no strong
induction of neutrophils noted in either survivors or fatal cases of infection (Chapter 2,
(Liu et al., 2017)).
In this study, the use of two transcriptomic platforms provided cross-validation and
helped to provide strong evidence that NanoString analysis can be used to provide a broad
analysis of the host response. The benefit of using RNA-Seq is the acquisition of a fairly
unbiased view of the RNA present and detection of upwards of 20,000 transcripts. How-
ever, RNA-Seq is dependent on high RNA quality and can have a low signal to noise ratio
making lowly expressed transcripts difficult to detect.
In contrast, the NanoString probeset showed good detection of RNA even in highly
degraded RNA. One example of this is the detection of the interferon beta transcript at
day 10 post-exposure in NanoString where RNA-Seq could not be performed or had low
quality results (Figure 3.10). The ability to perform gene expression assays on degraded
samples is especially important when considering samples taken from late stages of hem-
orrhagic disease or in an outbreak setting. Proper care and handling of samples is difficult
and samples often have to be transported before processing can begin, resulting in low
quality (Ruibal et al., 2016). My results suggest that NanoString assays like the one devel-
oped here can allow mRNA quantification from clinical samples collected in low-resource
environments.
I also used this dataset to test whether I can classify animals by infection status solely
based on the host response. Similar work has been used to identify host gene expression
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biomarkers to diagnose viral or bacterial acute respiratory illness in clinical cases without
detection of the causative agent (Tsalik et al., 2016). There has also been research done
showing that without the need to detect the causative agent, it is possible to identify dif-
ferent hemorrhagic fever viruses form each other (Caballero et al., 2014). Included in the
NanoString set was a set of 41 genes identified through analysis of PBMC datasets from
Lassa, Marburg, and Ebola virus-infected animals that were investigated as markers of pro-
gressive EBOV infection. I analyzed these genes using both RNA-Seq and NanoString and
found that both platforms showed strong clustering of infected animals compared to un-
infected controls. This clustering was stronger than randomly selecting genes suggesting
that these genes are an optimal set of genes to detect infection (Figure 3.11). This provides
evidence of a biomarker signature that will identify symptomatic animals through analysis
of the host response and without the need to detect the causative agent.
Genes that are present in the viral respiratory infection (Tsalik et al., 2016) and
Lassa/Marburg classifiers (Caballero et al., 2014) contain many interferon stimulated
genes similar to the EBOV classifier presented here signifying that the interferon response
is a strong early indicator of viral infection. However, the interferon response is not spe-
cific to EBOV infection and is a general response to any viral infection. To address this, in-
cluded in the probe set is 8 genes that have a unique pattern of expression in EBOV/Kikwit
when compared to Marburg and Lassa based on comparison of expression to previous stud-
ies (Caballero et al., 2014, 2016; Garamszegi et al., 2014). To determine if these genes are
truly unique to EBOV infection, further testing would need to be carried out comparing the
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response in EBOV infection compared to Marburg, Lassa, and other viral infections. Also,
within this analysis the classifiers were not able to predict infection until after the onset
of viremia. In previous datasets, there is evidence of gene expression changes present be-
fore the onset of viremia (Rubins et al., 2007; Caballero et al., 2016; Yen et al., 2011). In
this dataset, there was no evidence of any differential expression by day 3 post-exposure.
Further testing would need to be performed on sampling days between day 3 and day 6
post-exposure to determine if the signature still is present before the onset of viremia.
The ability to extend analysis beyond gene expression is especially valuable when
limited sample is available for multiple assays (e.g., RT-qPCR, blood chemistry, hema-
tology, serology). Both the nSolver Advanced Analysis Plugin (NanoString) and DCQ
(Altboum et al., 2014) (RNA-Seq) cell prediction algorithms were able to characterize rel-
ative changes in cell type abundances using mRNA expression levels. The nSolver system
was able to predict changes on an individual animal basis whereas the DCQ data was able
to predict changes over all the animals combined. The nSolver system has only a few cell
types that can be analyzed and is limited based on its prior information matrix (although
this can be modified with additional data). The DCQ approach utilizes the entire Immgen
knowledge base to look for over 200 different cell types and can be easily manipulated
to use a human background of expression data from isolated cell types. Both platforms
correlate well with traditional hematology data, which was consistent with previously re-
ported changes during EBOV infection. Neutrophilia is a well characterized component of
end stage EVD and lymphopenia is often observed (Feldmann and Geisbert, 2011). Both
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of these were detected in the hematology data as well as by DCQ and the nSolver soft-
ware. This also suggests that similar to other EBOV infections, infection with EBOV/Mak
causes similar changes in circulating immune cells.
3.6 Future Directions
This study, along with one other study (Versteeg et al., 2017), provide the first anal-
ysis of transcriptomic datasets in whole blood samples following EBOV infection in NHP.
This opens the door for a unique opportunity to compare the NHP response to the human
response to EBOV infection. This is an important step forward since the NHP model of
infection is used to determine effecificy of drugs and vaccines before they can move to
humans. Creating a better understanding of the similarities and differences in the host
response to infection will be important to better understand potential caviats in using the
NHP model. Further analysis directly comparing the humans to NHPs will important.
Also, this dataset shows for the first time the ability of the host response to directly
classify infection following EBOV exposure in an in vivo model. This is work lays the
foundation for expansion on the host classifier. Further testing of the 41 gene biomarker
in additional datasets will be important to fully address accuracy of the classifier and fine
tune parameters. Additionally, direct testing of this classifier in other viral disease such
as Marburg virus disease and Lassa virus disease will be important to directly address
specificity.
One of the main goals of this study was to create an animal model that more accu-
rately reflects the human disease. This study and others (Mire et al., 2016) have investi-
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gated mucosal routes as possible transmission routes for infection. This study showed that
despite different routes of infection, there is not a strong difference in the host response to
infection. This is an important finding because it suggests that EBOV infections are consis-
tent despite the route of exposure. Further work investigating other mucosal transmission
routes that include asymptomatic animals will be important to expand on the animal model
and make it more like the human disease. In the next chapter, I describe a different mu-
cosal route of transmission, intranasal exposure, where the animals had variable onset of
disease.
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Chapter 4
INTRANASAL EXPOSURE OF CYNOMOLGUS MACAQUES TO EBOLA
VIRUS MAKONA RESULTS IN A CONSERVED TRANSCRIPTOMIC
RESPONSE DESPITE VARYING TIME TO DISEASE ONSET
4.1 Preamble
As was show in Chapter 3, mucosal routes of transmission in a non-human primate
(NHP) model of disease leads to a conserved host response to infection. The routes of in-
fection that were tested included the standard of intramuscular injection, but also included
two different mucosal routes of transmission, oral and conjuncitval. A mucosal route of
transmission that was not investigated in the previous work is the potential for intranasal
exposure. In this chapter, I investigate an intranasal exposure route of EBOV Makona
infections in NHPs.
To determine if a low dose infection through nasal surfaces results in a different
host response, 12 cynomolgus macaques were infected with 100 PFU of EBOV/Makona
(EBOV/Mak). To follow the host response, I utilized RNA-Sequencing and a newly de-
veloped NanoString codeset (characterized in Chapter 3) to monitor changes in RNA tran-
scripts. I found that despite different onsets of disease and some animals presenting with
delayed time to death, there was a highly conserved and predictable host response to in-
fection. When individual animal data were phased based on onset of fever, the first clinical
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sign of severe disease, the host response to infection was able to be modeled showing a
predictable pattern of gene expression with interferon stimulated genes (ISGs) appearing
as early as 4 days before fever onset. Together, this shows that lethal EVD has a uniform
and predictable response to infection and that expression of a subset of genes is present
before the onset of fever.
The work described in the chapter has been prepared for publication under Sper-
anza E*, Bixler SL*, Altamura LA, Arnold CE, Pratt WD, Taylor-Howell C, Burrows C,
Aguilar W, Rossi F, Shamblin JD, Wollen SE, Zelko JM, Minogue T, Nagle E, Palacios
G, Goff AJ, Connor JH. “Intranasal Exposure of Cynomolgus Macaques to Ebola Virus
Makona Results in a Conserved Transcriptomic Response Despite Varying Time to Dis-
ease Onset”.
SB and AG designed and executed the NHP study and all associated in-line analy-
ses. WP and FR performed the telemetry data collection and analysis. JS, SW, and JZ
performed the NHP study. CTH, CB, and WA collected NHP samples and/or performed
transcriptomic assays. EN and GP performed RNA Sequencing. CEA and GP performed
pathway analysis. Myself, JHC, and LA wrote the manuscript. SB and TM provided crit-
ical review of the manuscript. I preformed all the RNA-Seq and NanoString analysis. I
also developed the models for gene expression, analyzed pathway analysis, and wrote the
manuscript. In the following analysis, 26 of the 28 figure spanels directly reflect my work.
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4.2 Introduction
Ebola virus disease (EVD) is a serious illness that can cause up to 90% case fatal-
ities in humans and non-human primates (Feldmann and Geisbert, 2011). The causative
agent, Ebola virus (EBOV), spills over into human and non-human primate populations
on a sporadic basis and causes limited outbreaks with at most a few hundred cases. A no-
table exception was the 2013-2016 outbreak in West Africa, which caused approximately
28,000 cases (Center for Disease Control (CDC), 2017). Although long apparent, this
event highlights the need to better understand the pathogenesis and host response to EVD
as a means to create better therapeutics, vaccines, and diagnostics.
The study of EVD is difficult since human in vivo samples available for research
purposes are rare, and priority is not usually placed on preserving samples for subsequent
experimentation. To fill this gap, several animal models have been developed to study EVD
in vivo. The current model most widely used for understanding pathogenesis and testing
of therapeutics and vaccines is non-human primates (NHPs), specifically cynomolgus and
rhesus macaques (Nakayama and Saijo, 2013). NHPs, upon infection with EBOV, display
many of the same symptoms as human infections including coagulopathy, lymphocytosis,
and rash (Bente et al., 2009). However, the NHP EVD model typically employs a high
infectious dose (1000 PFU) through an intramuscular injection (IM) or aerosol exposure,
resulting in 100% lethality within 6-10 days post-exposure (Johnson et al., 1995; Jaax
et al., 1996). In contrast, human EVD typically results from exposure to a lower infectious
dose via parenteral or mucosal routes, and ranges from 40-90% mortality (Rewar and
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Mirdha, 2014). Finally, the incubation period in humans ranges widely from 2-21 days
post-exposure to EBOV (Laupland and Valiquette, 2014). These differences highlight the
need for experimental NHP models that more closely recapitulate natural human exposure
and ensuing disease.
Despite their shortcomings, important data regarding the host response can still be
learned from 100% lethal NHP models (Speranza and Connor, 2017). For example, tran-
scriptomics has been used to explore early host responses to infection in time-resolved
NHP datasets (Caballero et al., 2016; Versteeg et al., 2017; Cilloniz et al., 2011). It has
also been used to understand important aspects of the host response that contribute to sur-
vival in mice (Dutta et al., 2017), NHPs (Garamszegi et al., 2014; Yen et al., 2011), and
humans (Liu et al., 2017; Kash et al., 2017). Though many advances have been made in
using transcriptomic analysis, in depth analysis of the host response following a low dose
infection with varying incubation periods has not been done in NHPs.
Through the use of telemetry devices, blood chemistry analysis, and transcriptomic
approaches of RNA-Sequencing (RNA-Seq) and NanoString, I analyzed the host response
to EVD in NHPs. This study was unique because the combination of a low infectious dose
and mucosal exposure enabled analysis of the host response in NHPs that had variable
incubation periods and times to death. Also, I could relate gene expression changes ob-
served to the exact timing of when animals began to show signs of disease. This analysis
helped to show that variable onset of disease still leads to a conserved host response, this
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host response is similar to what is observed in humans, and certain identified genes are
up-regulated before the onset of fever.
4.3 Methods
4.3.1 Virus
The virus stock was the same described in Chapter 3 and Speranza et al. (2017).
4.3.2 Animals
Twelve healthy adult cynomolgus macaques (Macaca fascicularis), equally dis-
tributed by sex, were used for this study. All macaques were surgically implanted with
T27F-1B radiotelemetry devices (Konigsberg Instruments) at least 12 months prior to the
start of the experiment, and were allowed to fully recover. Surgeries were done under
anesthesia and, if necessary, with post-operational buprenorphine analgesia to minimize
pain.
Research was conducted under an IACUC-approved animal protocol at the United
States Army Medical Research Institute of Infectious Diseases (USAMRIID). This pro-
tocol complied with the Animal Welfare Act, PHS Policy, and other Federal statutes and
regulations relating to animals and experiments involving animals. The facility where this
research was conducted is accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care, International and adheres to principles stated in the Guide for
the Care and Use of Laboratory Animals, National Research Council, 2011. All experi-
ments were conducted in the ABSL-4 laboratory at USAMRIID.
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4.3.3 Challenge
Animals were randomly assigned to receive 100 PFU EBOV/Mak by intranasal ex-
posure either by pipette (n=6, Animals 1-6) or by mucosal atomization device (MAD, n=6,
Animals 7-12). The pipette group received 250 µl of virus inoculum in each nare dropwise
by pipette. For the MAD exposure, the device (Teleflex Medical) was attached to a 1 mL
syringe containing the virus inoculum. The animals’ heads were tilted so that the nostrils
were angled upward. Each animal received 0.5 mL of virus inoculum in each nare deliv-
ered as a single puff. The head remained tilted upwards for 1-2 min following challenge to
ensure proper delivery of the challenge material. The challenge dose was determined by
neutral red plaque assay as previously described (Shurtleff et al., 2012) was 65 PFU.
4.3.4 In-life study activities
Animals were monitored at least once daily for general health and well-being. Ad-
ditional checks were performed when animals began to display signs of illness. Physi-
cal examinations and blood collection were performed under anesthesia on day 0 (pre-
challenge), 3, 6, 10, 14, 21, 28, 35, 41 (end of study), and terminally. Euthanasia was
performed via intracardiac administration of a pentobarbital-based euthanasia solution un-
der deep anesthesia when an animal was deemed moribund (Warren et al., 2014).
4.3.5 Clinical Pathology
Chemistry parameters were evaluated in serum samples using a Piccolo Point-Of-
Care Analyzer (Abaxis) and Piccolo General Chemistry 13 panel. Hematology was
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assessed on K3 EDTA-treated whole blood using an ADVIA 120 Hematology System
(Siemens).
4.3.6 Telemetry Monitoring and Pathophysiological Analysis
The implanted radiotelemetry devices allowed for the continuous monitoring of body
temperature, aortic pressure (AOP), left ventricular pressure (LVP), heart rate (HR), and
respiratory rate (RR) throughout the baseline and study periods. The telemetry data were
captured and analyzed using the Notocord-hem Evolution software platform (Version 4.3,
Notocord Inc.). Thirty-minute averages of the above listed physiologic parameters were
calculated for each subject. Telemetry data obtained during the five days prior to challenge
were used to calculate baseline values, and provided the average and standard deviation
(SD) of each 30-min time period of a 24-h day. Using the average and SD determinations
from the baseline physiologic data, values greater or less than 3 SD of the corresponding
baseline value were considered significant. Fever was defined as >1.50C above and hy-
perpyrexia was defined as >3.00C above their corresponding baseline values. The phases
of infection were defined as the incubation period (time from challenge to onset of sus-
tained fever response for more than 2 h), the clinical period (time from onset of sustained
fever until onset of sustained hypotension, significant decline in blood pressure for more
than 2 h), and terminal period (time from onset of sustained hypotension until death or
euthanasia).
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4.3.7 Viral RNA isolation and RT-qPCR
Freshly collected plasma samples (100 µl) were combined with 300 µl TRIzol LS
(ThermoFisher Scientific) and then RNA was extracted manually using either the QI-
Aamp Viral RNA Mini Kit (Qiagen) or with an EZ1 Advanced XL system using EZ1
Virus Mini Kit (Qiagen). Viral genome equivalents per mL (ge/mL) were quantified using
an EBOV-specific RT-qPCR assay and a synthetic RNA standard curve as previously de-
scribed (Trombley et al., 2010). Alternatively, PFU equivalents per mL (PFUe/mL) were
extrapolated from the data using an RNA standard curve derived from a viral stock of
known infectivity.
4.3.8 RNA isolation from whole blood
Freshly-collected whole blood samples (500 µl) were diluted with an equal volume
of molecular biology grade water (500 µl), and then combined with 3 ml TRIzol LS. For
RNA-Sequencing (RNA-Seq) analyses, RNA was isolated from whole blood in TRIzol LS
using the PureLink RNA Mini Kit (ThermoFisher Scientific) and RNA was evaluated for
quality on the Agilent 2200 TapeStation. For NanoString analyses, total RNA was isolated
using the miRNeasy Mini Kit (Qiagen) and then quantified using the Qubit RNA HS Assay
Kit (ThermoFisher Scientific).
4.3.9 RNA-Sequencing
Libraries were generated on the Sciclone G3 Liquid Handling Robot (PerkinElmer)
using the TruSeq Stranded Total RNA Library Prep Kit (Illumina). Library quality was
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evaluated on the Agilent 2200 TapeStation 2200 and quantified by qPCR using the KAPA
Complete (Universal) qPCR kit (Kapa Biosystems) for Illumina libraries. Libraries were
diluted to 12 pM and cluster generation was performed on the Illumina cBot. Libraries
were sequenced on the HiSeq 2500 using the paired end 2x100 bp, dual-index format.
4.3.10 Nanostring RNA collection and run
Total RNA samples were analyzed using a custom-designed NanoString nCounter
gene expression codeset targeting 769 NHP genes. For each gene, a single probeset was de-
signed with predicted cross-hybridization to homologous genes for cynomolgus macaque
and rhesus macaque (Macaca mulatta). Probeset-target RNA hybridization reactions were
performed according to the manufacturer’s protocol. For each hybridization reaction, 100
ng total RNA was used or any quantity that was present in a 5µl aliquot of purified RNA
if less than 100 ng. Purified probeset-target RNA complexes from each reaction were pro-
cessed and immobilized on nCounter Cartridges using an nCounter MAX Prep Station and
transcripts were quantified on the Digital Analyzer (GEN 2).
4.3.11 RNA-Seq data processing
Raw sequencing reads were trimmed on the edges for low quality reads and filtered
using the FASTX-Toolkit v0.0.14. Paired reads were then aligned to the cynomolgus
macaque genome v5.0 (Lee et al., 2014) using Bowtie2 v2.2.6 (Langmead and Salzberg,
2012) and Tophat v2.1.0 (Trapnell et al., 2009) with default alignment parameters. Finally,
count tables were generated using HTSeq Count v0.5.4 (Anders et al., 2014) and Python
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v2.7.3. Counts were generated using an alignment to a gene and parameter –stranded set
to no.
Count tables were then read into R v3.2.2. Data normalization was performed with
the rlog function of DESeq2 (Love et al., 2014). Genes were filtered to only include genes
whose median count was greater than 1. RNA-Seq samples were filtered if the number
of aligned reads was less than one million mapped reads to genes or if they were deter-
mined to be outliers by principal components analysis (PCA). In total, 6 samples were
classified as significant outliers and were not included in the analysis. Finally, differential
gene expression analysis was done through DESeq2 and statistical significance was deter-
mined if the absolute log fold-change was greater than 1 and the Benjamin-Hochberg (BH)
corrected p-value was less than 0.05.
Human datasets were collected from BioProject PRJNA352396 and processed ac-
cording to (Liu et al., 2017). The data was read into R using DESeq2 to generate a fold-
change table. Gene conversion between human Ensembl IDs and macaque gene names
was done with Ensembl Biomart (Durinck et al., 2009).
4.3.12 NanoString Data Processing
NanoString raw counts were compiled into a single counts table. Normalization of
the counts was done using a standard method. First a global background was calculated
using the mean plus 2 standard deviations of the negative controls. Then normalization
to internal positive controls was performed to adjust for system variation between lanes.
This was achieved by first calculating the positive control factor that was the mean of the
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geometric means of the positive controls of the different lanes. A normalization factor was
calculated for each lane by dividing the positive control factor by the geometric mean of
each lane. This value was used as a multiplier for each lane’s count values.
To determine genes that would perform as good input normalization factors, genes
were first filtered to include only those whose count values were above the global back-
ground in all samples. The NormFinder R package (Andersen et al., 2004) was then ap-
plied on these genes to determine which were most stable in the data set. The top 5 most
stable genes were utilized for reference gene normalization across the samples to control
for input variation of the amount of RNA. This was done similarly to the positive control
normalization.
Differential expression analysis of the NanoString data was performed using a one-
way ANOVA test on each gene for the different conditions. This was achieved through the
lm function in R. P-values were adjusted with a BH correction.
4.3.13 Statistical Analysis and Gene Set Analysis
PCA was performed using the stats package prcomp function in R. Clustering was
determined by k-means clustering with the cluster package (Maechler et al., 2017) pam
function in R. Significant blood chemistry data was determined with a one-way ANOVA
test. Significance was determined by a p-value<0.05. All p-value adjustments were done
with a BH correction using the p.adjust function in the stats package. Gene set analysis
was done using a Fisher’s exact test on a pre-defined gene set using standard cutoffs for the
differential expression analysis (p-adjusted<0.05 and absolute log fold-change>1). Path-
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way analysis was done using IPA (Ingenuity Pathways Analysis) knowledge base. Inter-
feron type determination was done using the interferome knowledge base (Rusinova et al.,
2013). Statistical significance was determined with a hypergeometric test to determine if
the overlap of interferon response type was significant.
Clustering of the samples based on time to death was determined by k-means cluster-
ing in R. To determine if clustering was significant, 10000 iterations of k-means clustering
was performed on the time-to-death data. This was compared to 10000 iterations of ran-
domly shuffling the animals’ times-to-death.
To determine a logistic model fit to the data, all the days post-infection were first
converted into a time point relative to the group mean incubation time. Thus, 0 represents
when that group ended the incubation time, which was characterized by a sustained fever
of greater than 1.50C change. For the fitting, the day 3 post-exposure time point was not
included since it exhibited early cytokine expression. Also, the non-responder animals
were not included since they did not develop disease. The R stats package was used with
the function nls and the following formula for the fit.
Expression =
a
1 + e−(b+c2∗time)
Starting parameters were determined as follows: a=log fold change at the end of the
timecourse, b=slope of a linear model fit, c=intercept of a linear model fit. A deviance
cutoff of 20 was used to determine if the data fit the model well.
Plotting of the data was done in GraphPad Prism v.5 and ggplot2.
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4.4 Results
In the context of ongoing efforts to develop NHP models that more accurately repli-
cate EVD observed in humans, 12 cynomolgus macaques were exposed to EBOV/Mak via
the intranasal route. Virus (100 PFU) was administered either via pipette or MAD (Mu-
cosal Automization Device) to each NHP. Notably, the incubation period prior to disease
onset was quite varied, but ensuing clinical presentation was consistent with typical EVD
in NHPs.
4.4.1 Description of 4 distinct response groups following exposure
The NHPs clustered into 4 distinct groups based on appearance of disease symptoms,
onset of viremia, and time to death (Figure 4.1A-B). Three animals had a normal disease
course (Group 1: NHPs 1, 2, and 12), became quantifiably RT-qPCR positive at day 6
post-exposure and had a mean time to death of 10.47 days. Four animals had a delayed
onset of disease (Group 2: NHPs 3, 5, 8, and 10) and had a mean time to death of 13.31
days. In this group, NHPs did not develop quantifiable viremia until days 10 or 12 post-
exposure, but viral RNA was qualitatively detected as early as day 3 in NHP 10 and on
day 6 in NHPs 3 and 8. Three animals had a late onset of disease (Group 3: NHPs 4,
6, and 9) and a mean time to death of 21.42 days. NHP 6 had quantifiable viremia on
day 20, but viral RNA was only qualitatively detected on days 6, 10, and 14. NHP 9
first had quantifiable viremia on day 21, but was also qualitatively positive on day 14.
NHP 4 had borderline quantitative viremia on day 10, was qualitatively positive on day
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14, and then quantitatively positive again on day 20. Finally, two animals did not become
quantitatively RT-qPCR-positive across the timecourse of the experiment (Group 4: NHPs
7 and 11) and survived out to 41 days which was the pre-defined experimental endpoint.
However, viral RNA was qualitatively positive in these animals on days 6 and 10 post-
exposure, respectively. Survival and time to death did not correlate with the method of
intranasal exposure (p = 0.1292).
To determine if there were physiological difference that were detectable prior to ex-
posure that correlated to disease outcome I analyzed blood chemistry data, hematology,
and soluble proteins collected prior to exposure (0 DPI). A one-way ANOVA was per-
formed for each of 39 different measured parameters and a regression coefficient to symp-
tom onset (R2) value calculated. From this analysis (Figure 4.2A) all but one variable,
mean corpuscular volume (MCV), did not have a significant difference between the groups.
The difference observed in MCV was driven by the delayed animals having a significantly
lower value than the normal group (Figure 4.2C) but was not significantly different from
any other group. A low MCV value can signify an internal bleed or could mean the ani-
mals were slightly anemic. However, since the values were only significant in one of the
group comparisons, we do not think it would have contributed to the differential disease
onset.
To further investigate if there was a difference observed at the day of infection I per-
formed PCA analysis (Figure 4.2B). There is no strong clustering within groups signifying
that the across groups there is not one that stands out. Also, all the groups are centered
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overview of the experiment and separation of animals. A is a table showing the different
animals (left) and the different day post infection going across. A white square means
the animal was not PCR positive at that timepoint, blue means they were PCR positive,
and greys means that the PCR results were below the limit of quantification. The number
of plus signs in the grey boxes represents the number of replicates where the PCR was
positive. For complete table of PCR data see Bixler et al (companion manuscript). B
is the comparison of the 4 groups and their survival curves. The x-axis is the DPI and
the y-axis is the percent survival. The green line is the normal group (Ani1,2,12), blue
is the delayed group (Ani3,5,8,10), red is the late group (Ani4,6,9) and black is the non-
responders (Ani7,11).
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Figure 4.2: Comparison of the pre-infection animals. Analysis of the pre-infection an-
imals to determine any significant differences. A is the results of a one way ANOVA to
determine if there were significant changes between the groups across the many physiolog-
ical/blood chemistry data taken (x-axis). The left y-axis is the fitted R2 value (black bars).
The right y-axis is the -Log10(p-value) (red points/line). The dashed line is where the p-
value is 0.05. Points above are within a significance threshold. B is a PCA plot of the same
values as is represented in A for the different groups. Each point is an individual animal
and the colors represent the different groups (green = normal, blue = delayed, red = late,
black = non responders). C is the mean corpuscular volume (MCV) measured between the
different animals at the day of infection. The only significant difference (determined by
t-test) was found between the normal and delayed animals (p = 0.02).
131
close to the point (0,0). This means that none-of the groups had large outlier values that
could have contributed to the different onset of disease. Based on this analysis, I con-
cluded that it was unlikely a difference in the animals before infection that contributed to
the different disease onsets.
The variable onset of disease in these animals presented a unique opportunity to
identify factors that might be associated with different responses to EBOV intranasal chal-
lenge. I investigated clinical, biochemical, physiological, and transcriptional data to iden-
tify markers of disease onset within this cohort. An overview of the transcriptomic data
available can be seen in Figure 4.1C.
4.4.2 Symptomatic animals developed expected clinical changes
Typical manifestations of EVD were observed in all non-survivors, including mac-
ulopapular rash, lymphadenopathy, anorexia, and fever. Indicators of coagulopathy, such
as bleeding or hemorrhage, were largely absent in these animals. Some animals displayed
respiratory signs including cough, labored breathing, and use of accessory or abdominal
muscles for breathing. Additionally, all non-survivors had alterations in hematological and
serum chemistry parameters, regardless of the time-to-death. These changes mirrored pre-
viously reported EBOV infection of NHPs, including increases in the blood urea nitrogen
(BUN), creatinine (CRE), calcium (CA), and gamma-glutamyl transferase (GGT) (Figure
4.3). Increases in liver enzymes such as alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were also noted, along with an increase in alkaline phosphatase
(ALP) (Figure 4.3). A decrease in platelets and lymphocytes, along with an increase in
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neutrophils, was noted in non-survivors. Changes in blood chemistry and hematology
profiles coincided with the development of clinical signs and appearance of viral RNA in
plasma; these changes were delayed in those animals with an extended time-to-death. The
two survivors generally did not have any changes in behavior, health, or clinical pathology
parameters associated with EVD.
4.4.3 Up-regulation of many innate immune pathways during acute EVD
The varying times to death among the study animals led me to investigate the na-
ture of the host immune response following onset of symptoms as determined by onset
of sustained fever. I performed differential gene expression in the RNA-Seq dataset and
biological pathway analysis in IPA for each group relative to pre-challenge baseline for
symptomatic time points (Figure 4.4A). All animals showed a similar host response at the
end stages of disease as evidenced by upregulation of the same top 20 signaling pathways
based on Ingenuity Pathway Analysis (IPA) results (Figure 4.4B). The highest level of
conservation across the groups was the normal and delayed groups at 10 days post expo-
sure and the late group at 21 days post exposure. Due to loss of samples for day 14 post
exposure in the delayed, only one animal was remaining at this timepoint in the delayed
group thus reducing our ability to find statistically differentially regulated genes resulting
in fewer pathways with significant enrichment.
Enriched pathways included activation of innate immune pathways (role of pattern
recognition receptors, interferon signaling, role of RIG-I in antiviral response) as well as
acute phase response signaling and pathways associated with nitric oxide (NO) and reac-
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Figure 4.3: Blood Chemistry data for animals over time. (A) Blood urea nitrogen
(BUN) (B) creatinine (CRE) (C) calcium (CA) (D) gamma-glutamyl transferase (GGT) (E)
alanine aminotransferase (ALT) (F) aspartate aminotransferase (AST) (G) alkaline phos-
phatase (ALP). Group 1 (green), Group 2 (blue), Group 3 (red), and Group 4 (black)
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Figure 4.4: Comparison of top Regulated Pathways and upstream regulators.
Overview of the most strongly differentially regulated pathways in the viremic animals.
A) Overview of the samples analyzed (large circles) which were symptomatic (red circles)
with the number of biological replicates denoted in the circles. B) Significantly differ-
entially regulated pathways. The pathways are clustered (dendogram on pathways not
shown). (Continued on Next Pages)
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Figure 4.4: (Previous Page) The darker purple means a strong up-regulation of the path-
ways (positive z-score) and the green means down-regulation of the pathways (negative
z-score). The p-values represent if there is a significant number of genes in the pathway
that are differentially expressed. * means the p-value <0.05, ** p-value is less than 10−3,
and *** means p-value is less than 10−6. C is a similar plot but for the up-stream regu-
lators. Purple means the regulation is up-regulated and green means it is down-regulated
(log fold change). D is the breakdown of the interferon response to the type of interferon
responsive genes. The x-axis is the specific types (Uniquely Type I, II, III) and overlap
between the different responses. The red bars are normal samples, green delayed, and blue
is late. The different textures are the different DPI.
tive oxygen species (ROS). These pathways were consistent within each group and also
were consistent with host gene expression seen during viremic stages of disease follow-
ing exposure to EBOV/Kikwit (Barrenas et al., 2015) and other EBOV/Mak challenges
(Versteeg et al., 2017; Speranza et al., 2017). Interestingly I identified two pathways that
were among the top 20 that were down-regulated (PPAR signaling and LXR/RXR activa-
tion) during infection. These pathways are important in lipogenesis, cell survival, and can
down-regulate the inflammatory response through inhibition of NF-κB and TLR-4 (Tall
and Yvan-Charvet, 2015; Hong and Tontonoz, 2008). The top 20 regulators of down-
stream targets were also consistent with an over-activation of the innate immune response
and show a strongly conserved host response during the symptomatic stage of disease
(Figure 4.4C).
To further characterize the interferon response during the symptomatic stage of in-
fection, the interferome database (Rusinova et al., 2013) was used to compare the type I,
II, and III interferon responses based on the number of interferon responsive genes differ-
entially regulated. Across all the symptomatic animals, there is a strong type I and type
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II interferon response but minimal type III response (Figure 4.4D). This is consistent with
the upstream regulators where interferon alpha (IFNA) and interferon gamma (IFNG) are
significantly enriched across all the groups.
4.4.4 Up-regulation of cytokine gene transcription during acute EVD
Using differentially expressed cytokine genes identified through RNAseq, I examined
whether animals that showed symptoms at different times of infection had differences in
their cytokine response during the course of disease. I identified 57 differentially expressed
cytokine mRNAs and then determined whether the animals showed similar expression
based on the groups or on the distinction between symptomatic or asymptomatic. I found
that the dominant driver of clustering in this approach was symptom onset (Figure 4.5A).
In contrast, there was little clustering based on day of disease onset, further suggesting
the symptom onset is a more important indicator of disease course than time since virus
exposure.
Of the cytokines in the RNA-Seq dataset that were differentially regulated, 11 were
common to all groups and time points (Figure 4.5B). Again, due to sampling size being
reduced to one animal in the delayed group at day 14 post exposure, fewer differentially
regulated genes were identified. Comparing only the normal group day 6 and 10 post ex-
posure, delayed group at day 10 post exposure and the late group at day 21 post exposure,
the number of conserved cytokines increases to 22. This suggests that the cytokine re-
sponse is highly similar in the symptomatic animals. To confirm the host response profiles
that were observed with NGS, I also used a NanoString codeset to profile the expression
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Figure 4.5: Late State cytokine response conservation. Analysis of the conservation of
the cytokine response. A) Correlation plot using just the cytokine genes. The rows and
columns are the same and represent a single group at a single timepoint. The dendogram is
colored based on a k-means clustering with 2 centers. The first color bar at the top shows
the groups (green = normal, blue = delayed, red = late). The second color bar is when the
groups are symptomatic with red meaning the column is symptomatic and black still in the
incubation period. B is a venn diagram of cluster 2 samples with cytokine genes that are
differentially express in any of the samples. If a spot does not have a value, the value is 0
genes.
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of 769 NHP genes (Speranza et al., 2017). This analysis confirmed the upregulation of the
cytokine genes identified by NGS.
4.4.5 Early and ephemeral transcriptional response detected in NanoString data
The NanoString NHP gene expression codeset has the potential for increased sensi-
tivity vs RNA-Seq for targeted gene expression profiling. Notably in this dataset, I iden-
tified a subset of cytokines that were upregulated at day 3 post-exposure in NHPs that
showed a delayed course of disease (NHPs 3, 5, 8, and 10).
This up-regulation was consistent across all four animals in this cohort and was not
identified as up-regulated in NGS datasets. This finding led me to broaden the analysis of
the NanoString data to see if there were other genes upregulated at this early time point.
Subsequently, I identified 178 genes that were found to be up-regulated on day 3 post-
exposure in the delayed animals, but had returned to near baseline by day 6 post-exposure
with the exception of three interferon stimulated genes (Figure 4.6A-B, and Figure 4.7). I
performed k-means clustering (k = 3) on NanoString expression data for all NHPs at all
timepoints (Figure 4.6C) using these 178 genes. In the PCA plot, the 3 clusters are shown.
Cluster 1 is made up of most samples. Cluster 2 represents the delayed animals at 3 DPI.
One animal from the normal group (NHP 2), one from the late (NHP 9), and one from
the no-response group (NHP 11) at day 3 post exposure are also included in this cluster
showing a similar up-regulation at this timepoint. Three points formed Cluster 3. All three
were end-stage samples that were close to death.
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Figure 4.6: Early and Modest Immune Response at 3 DPI in Delayed Animals. Anal-
ysis of the NanoString samples with only the genes identified as being up-regulated at an
early timepoint (3 DPI delayed). A) MA plot of the 178 identified up-regulated genes
at 3 DPI in delayed animals. Each point is a gene. The x-axis is the log2 of the base
mean counts and the y-axis is the log2 fold change relative to day 0. B) MA plot for the
same genes at 6 DPI. The only highly expressed genes at this time are three ISG (ISG15,
HERC5, RSAD2). C) PCA of the 178 up-regulated genes across all samples. K-means
clustering was performed on all principal components with k = 3 to determine the clus-
tering. The PCA plot is showing the first two principal components. The colors are the
different clusters.
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Figure 4.7: Example genes from NanoString in Delayed animals. Different days post
exposure are on the x-axis and the log2 fold change relative to pre-infection controls is
on the y-axis. All data is from delayed animals. Colored bars represent different genes
(black = HERC5, red = CCL17, green = IL22, blue = VCAM1, purple = IFNL3). HERC5
has consistent increasing expression across the different days and holds steady at 14 DPI.
CCL17 and IL22 are high at day 3 post exposure but do not come back up in expression.
VCAM1 and IFNL3 are high at day 3 post exposure, turned off at day 6 post exposure,
and reach higher levels of expression at day 10 and 14 post exposure.
I utilized PANTHER (Thomas et al., 2003) to determine if any one set of genes was
significantly enriched in this subset. As a reference, I used only those genes included in
the NanoString codeset to account for potential bias of the genes included in the codeset.
I found that GO terms associated with cytokines, cytokine response (GO:0005125) and
cytokine receptor binding (GO:0005126), were significantly enriched (adjusted p-value
= 8.91 ∗ 10−5 and 6.05 ∗ 10−3 respectively). Cytokine response genes that were up-
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regulated at day 3 post-exposure in delayed animals included interferons (e.g. IFNB1,
IFNL2, IFNL3), pro-inflammatory cytokines (e.g. IL17F, IL6, IL-10) and many T-cell
recruitment/activation genes (e.g. CCL18, IL2, CCL17). Though there was detection of
interferon, there was no significant up-regulation of interferon-stimulated genes at this
point. This may suggest a modest immune response to the infection in the nasal cavity and
that the time point was optimal for detection with the delayed animals. Transcriptional
analysis of early events in the nasal cavity would be needed to support this hypothesis.
4.4.6 Interferon Simulated Gene activation immediately prior to onset of EVD
symptoms
As the response to infection in the symptomatic stage offered few differences to ex-
plain disease onset, I moved to studying events after infection at the time point directly
preceding the symptomatic stage (Figure 4.8A). Previous studies have suggested that tran-
scriptional analysis of host innate immune response genes are induced following hemor-
rhagic fever virus infection and that some of these genes can be detected prior to the onset
of symptoms (Caballero et al., 2016, 2014; Malhotra et al., 2013; Connor et al., 2015). To
determine whether there was any evidence of host-response gene expression changes at
early times post infection, I examined the RNA-Seq data for evidence of transcripts that
were induced prior to the display of overt symptoms (fever as determined by telemetry) or
quantifiable viremia (determined by RT-qPCR) and that were then sustained through the
end of infection. This analysis identified a number of genes that were induced at or prior
to induction of fever. In challenged animals that did not develop disease I did not find
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these genes to be significantly differentially regulated. Many of these “sentinel” genes are
classified as interferon stimulated genes, or ISGs.
The transcriptome from animals that developed disease on a “normal” timecourse
showed increased accumulation of approximately 100 ISGs concurrent with the onset of
quantifiable viremia and symptoms (Figure 4.8B). In animals showing a delayed onset
of symptoms, 14 ISG transcripts were significantly up-regulated (log2(fold change) > 1,
adjusted p-value< 0.05) by day 6 post-exposure. This represented a gene expression spike
that occurred 4 days before the onset of quantifiable viremia and fever (Figure 4.8C). The
pre-symptomatic expression of host innate immune genes was even more remarkable in
animals that showed a late onset of disease. ISGs transcripts were upregulated at 14 days
post-exposure, which was 7 days before the onset of quantifiable viremia and 5 days before
the onset of fever (Figure 4.8D, Table 4.1).
Together, this showed that ISG mRNA up-regulation is a pre-symptomatic indicator
of the development of EVD. This is summarized in Table 4.1, which shows that the ISG
markers are highly expressed by day 6 in the normal course of disease, coincident with
fever and quantifiable viremia, but appear markedly in advance of both fever and quantita-
tive viremia in cases of delayed disease onset. In the delayed and late groups, the interferon
response preceded a sustained fever by 4 and 5 days respectively. This pre-symptomatic
response was a conserved response. Of the 4 ISGs upregulated at day 14 post exposure in
the late-onset animals (NHPs 4, 6, and 9), 3 of the 4 were identical to ISGs upregulated
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Figure 4.8: Analysis of the pre-viremic ISG response. Analysis of the onset of the
ISG response and the conservation. A) Samples that were the focus of this analysis. Large
circles represent samples that were used in the analysis. Red circles represent symptomatic
samples. The numbers tell how many samples were used. B) Comparison of the onset of
viremia to induction of the group of ISGs. The DPI are on the x-axis. The left y-axis is
the PCR values (black line) and the right is the number of genes that are annotated as ISGs
that are up-regulated (blue line). C is a similar plot the delayed animals, D for the late, and
E for the non-responders.
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Group ISG+ PCR+ Fever (DPI)
Normal 6 DPI 6 DPI 7.1± 0.99
Delayed 6 DPI 10 DPI 9.46± 0.06
Late 14 DPI 21 DPI 19± 0.74
No Response NA NA NA
Table 4.1: ISG Response Table
at day 6 post exposure in the delayed-onset animals. All were upregulated in animals that
showed the expected timing of symptom development.
The early upregulation of these ISGs was also seen using the NanoString codeset,
which contained 80 ISGs. Differential expression analysis of genes in the NanoString
codeset showed that all symptomatic animals had upregulated ISGs while asymptomatic
animals (Group 4, no response) did not (Figure 4.9). As was seen in our NGS datasets, at
day 6 post exposure in the delayed group and day 14 post exposure in the late group, there
was up-regulation of IFIT2/3/5, OASL, ISG15 and DDX58. Expression of these genes
persisted through to the late stage of disease and was conserved between animals in each
group (Figure 4.9).
4.4.7 The ISG response is conserved to Humans
The ISG response during the acute phase of EVD in NHPs was highly conserved
among the groups. Figure 4.10A shows the fold change of ISGs in normal-onset animals
at day 10 post-exposure (x-axis) compared to the delayed-onset animals at day 10 post
exposure and the late-onset animals on day 21 post exposure (y-axis). The lines represent
linear model fits. As can be seen, the ISGs are highly similar in their expression values
across the different groups suggesting that mRNAs that make up the response were highly
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Figure 4.9: Interferon Response in NanoString Codeset. Overview of the top ISG de-
tected in the NanoString codeset. The top color bar represents the different DPI with the
darker purple colors representing later days. The second color bar represents the different
groups (normal = green, delayed = blue, late = red, no response = black). The heatmap
shows the fold change compared to day 0 with red meaning up-regulated, blue down-
regulated, and white is no change.
conserved despite different times to the onset of disease. The conservation of the late stage
animals and the early response suggests that the ISG response is up-regulated at similar
times and in similar orders. Notably, there is no significant difference in the linear model
fits of the delayed and late groups compared to the normal group (p-value=0.6) further
suggesting a high conservation of ISG expression and both the linear fit of the normal
group to the delayed group and the normal group the late group have a slope that is not
significantly different from 1.
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Figure 4.10: Correlation of ISG to human expression. Looking at the fold induction
correlation with regard to the ISG response in NHPs to Human fatalities. A is a correlation
plot of all ISG that are identified as being differentially regulated at any timepoint in the
NHP dataset. The x-axis is the log2 fold change for the normal animals at 6 DPI and the
y axis is the log to fold change for the delayed animals at 10 DPI (red points and line) or
the late animals at 21 DPI (blue points and line). The lines are linear model fits. B is a
correlation of the human fatal cases (log2 fold change compared to controls) on the x-axis
and the fold change of the late group (log2 fold change compared to controls) at 21 DPI.
The line represents a linear model fit of the data. C is a correlation plot similar to B but
with only the early ISGs shown. D is a table of the genes in C with their comparison of
the log2 fold change in Humans and NHPs.
147
To determine whether the ISGs up-regulated in NHPs were also up-regulated in clin-
ical patients with EBOV/Mak, I compared the fold induction of the ISGs that were identi-
fied in this study to ISGs that showed increased expression in a transcriptional analysis of
EBOV-infected patients in Guinea (Liu et al., 2017) that succumb to disease. A correlation
plot shows that many of the same ISGs were up-regulated in both NHPs and in human host
responses to EBOV infection (Figure 4.10B). From this analysis I identified a small subset
of ISGs that could act as early indicators of disease in NHPs and humans: IFI44, IFI44L,
IFIT2, IFIT3, IFIT5, ISG15, MX1, and OASL. Based on their profile of expression in the
NHPs and their conservation into the human dataset, I suggest that at a pre-symptomatic
timepoint, these genes could act as early indicators of viral infection.
4.4.8 Modeling Host Dynamics of Infection
This dataset provided a chance to look at modeling the host response relative to the
end of the incubation period to determine if 1) there is a way to align the samples to gener-
ally analyze the host response across the three symptomatic groups, and 2) to see if I could
model the different gene groups to more robustly determine which will be up-regulated first
and how I expect these genes to be up-regulated. The gene expression changes across the
four groups did not align well when comparing the fold changes observed in the NanoS-
tring codeset to the days post exposure (Figure 4.11A). However, using the telemetry data,
I was able to determine a mean time to onset of fever for each of the days post exposure.
I assigned 0 to be the mean day of onset of sustained fever (>1.50C above mean tempera-
ture). All the sampling days were then either negative (meaning they happened before the
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onset of a fever) or positive (meaning they happened after the onset of a fever). When I
looked at the gene expression data using time relative to onset of sustained fever, I found
that the samples aligned well to each other (Figure 4.11B). I concluded that despite differ-
ential onset of symptoms and gene expression, the pattern of gene expression relative to
fever onset is conserved.
Next, I used a logistic model to fit the data to curves. This type of model does limit
the analysis to genes that show a pattern of expression consistent with a logistic curve. I fit
a single model to a single gene at a time (Figure 4.11C). I did not include the time point of
day 3 post exposure since I wanted to look at gene expression relative to acute disease and
the day 3 post exposure spike of cytokines is eliminated by day 6 post exposure. I found
that the ISGs identified as early up-regulators preceded expression of cytokine genes in
all cases (Figure 4.11D). Also, their predicted mean time to detectable expression (log2
fold change > 2) was found to be 4.6 days before the onset of fever (± 0.46 days). This
means that the early interferon genes are strongly up-regulated 4.5 days before the onset
of symptoms. Finally, this response is followed by the cytokine response which reached
higher levels of expression overall than the interferon response (Figure 4.11D) but was not
significantly expressed earlier than the end of the incubation period. This shows that the
cytokine response is concurrent with the onset of fever.
4.5 Discussion
In this study, I used a combination of RNA-Seq and NanoString in conjunction with
blood chemistry and telemetry data to analyze the host response to EVD in a NHP model
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Figure 4.11: Host Response to Infection Modeled Relative to Fever Onset. Alignment
and modeling of gene expression across the four groups. A) Example gene (ISG15) ex-
pression (log2 fold change, y-axis) in the NanoString dataset relative to days post-exposure
(x-axis). B) Expression of the same example gene (log2 fold change, y-axis) relative to
the onset of a fever (0) on the y-axis. Green line is the normal animals, blue is the delayed
animals, and red is the late animals. C) Logistic model fit for the expression of ISG15
relative to the onset of a fever. The points are the mean log2 fold change for a group at
its time relative to fever onset and the solid line is the model fit for the fold change. D)
Comparison of the early ISG expression (black lines) logistic model fit relative to the onset
of a fever (x-axis) to many cytokine genes (red lines). The dashed line is for a reference of
when the genes expression crosses the threshold of a log2 fold change > 2.
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that had variable incubation periods. Following low dose (100 PFU) intranasal exposure,
the animals separated into 4 distinct groups based on time to death with 2 of the animals
surviving to the end of the study (Group 4, no-response). Because of the delayed onset
of disease, I was able to look at gene expression patterns that were up-regulated either
concurrently with the onset of fever or earlier. This allowed for the development of a
model for the gene expression patterns seen in NHPs in response to EVD.
Despite the different times to onset of disease, the transcriptional response was sim-
ilar across the three symptomatic groups (Group 1 (normal), 2 (delayed), 3 (late)). In the
delayed and late groups, each of which had a longer mean time to death than the standard
6-10 days, detection of interferon-stimulated genes was demonstrated as early as 4-5 days
before the onset of symptoms. In the later stages of infection, the interferon response was
highly conserved regardless of mean time to death. This is similar to what was observed in
a lethal model of infection in PBMCs where the onset of symptoms was preceded by the
induction of many interferon stimulated genes (Caballero et al., 2016). At this timepoint,
there were very few cytokine genes that were up-regulated. The normal animals have no
evidence of an interferon response early in infection. This could be an effect of low dose
mucosal infections. In the normal animals, either the timepoint at which the interferon re-
sponse would have been detectable was missed, or the disease progresses too quickly from
asymptomatic to sustained, resulting in this event not being detectable. The normal course
of disease is similar to a previous study of mucosal infection with EBOV/Mak (Speranza
et al., 2017).
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The conserved interferon response was followed closely by a cytokine response that
was more concurrent with the onset of a fever. This cytokine response was similar to what
has been seen previously in NHP infections with a 100% lethal model of infection with
many expected cytokines such as IL-6, CCL8, and CXCL10 up-regulated to very high lev-
els (Caballero et al., 2016). This cytokine response started just after the interferon response
and reached higher end-point levels for many of the genes (Figure 4.11). The cytokines
found to be up-regulated late in infection are consistent with the cytokine storm that is
characteristic of dysregulation of the immune system (Bixler and Goff, 2015). This is also
consistent with a strong pro-inflammatory response in innate immune cells circulating in
the blood.
Due to the nature of NanoString and its sensitivity, smaller changes than can be seen
with RNA-Seq were detected allowing for the characterization of a modest immune re-
sponse very early in infection. This response mostly contained pro-inflammatory cytokines
and well as general immune response genes. This response could be the animals respond-
ing to the infection in the nasal cavity, which was the site of initial exposure. The presence
of interferon lambda (IFNL) may suggest an immune response in epithelial cells consistent
with a modest immune response occurring in the nasal cavity. IFNL has been previously
shown to be an important factor in protection of respiratory epithelial cells against viral
infections (Mordstein et al., 2010).
The early response was present in all the delayed animals, one late animal, one nor-
mal animal, and one of the non-responders. The non-responder that had a detectable early
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response at day 3 post exposure did have more instances of elevated body temperature
than the other non-responder as determined by implanted telemetry devices. Also, the an-
imal that did not have the early response presented upon necropsy with viral antigen in
the hypothalamus suggesting that viral antigen many have quickly entered the olfactory
bulb into the hypothalamus as the olfactory bulb is a common site for viral entry in the
central nervous system (Munster et al., 2012). This would have allowed the virus to evade
the immune response preventing an early response to be present. This early host response
was no longer detectable by day 6 post exposure in all the animals except the one normal
animal as that animal was viremic with a fever by day 6 post exposure. During this initial
immune response it is likely that myeloid cells such as dendritic cells and macrophages
become infected as they are suggested as initial targets for EBOV (Lu¨dtke et al., 2017) and
found to be major contributors to the host response (Bray and Geisbert, 2005). This would
contribute to viral dissemination and later transcriptional changes.
The response observed in the symptomatic phase of the animals is consistent with
what has been seen transcriptionally in human infections. In a patient treated at the NIH
clinical center, the earliest response to viral infection involved many interferon stimu-
lated genes and cytokine expression (Kash et al., 2017). Since this patient went on to
survive, these responses eventually subsided. In a Guinea cohort of patients from the
2013-2016 EBOV outbreak in West Africa, a gene set strongly enriched in the fatal cases
was interferon-stimulated genes (Liu et al., 2017). Interestingly, when I compare the ex-
pression of the early genes to the human fatal cases, there was a strong correlation between
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the genes during the acute phases in both the humans and NHPs (Figure 4.10). This strong
correlation and the conservation of interferon genes at the earliest stages of disease suggest
that these genes may be up-regulated early in infection in humans. This opens the door
for using the host response as an early diagnostic, and preliminary work to do so has been
performed (Navalkar et al., 2013). Though the interferon response is not unique to EBOV,
finding other genes with a similar expression pattern may help to isolate potential early
markers.
The gene expression data coupled with telemetry devices allowed for a unique oppor-
tunity to look at gene expression relative to onset of fever. I found through modeling the
gene data relative to the onset of a fever, the interferon response was detectable as early
as 4 days prior. Correcting for sampling times (which are only reported as the day, not
the exact time), ISG are still detectable up to 3 days before the onset of fever. When I
examined the cytokine gene set, I found that these genes were centered around the onset
of a fever suggesting again that they are concurrent with the onset of disease. This data
also shows that animals can be aligned to study the host response based on when they first
spike a fever. This is an important turning point for the host response to the virus and has
predictable patterns just before and after the onset of a sustained fever. This also highlights
the usefulness of telemetry devices in the study of disease progression.
Though there was a separation of animals to different groups based on incubation
time, I cannot rule out that the normal or delayed groups caused a secondary infection in
the late animals that eventually caused them to spike a fever. Despite the potential for cross
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infection, the host response to infection, once present, is highly conserved and follows a
predictable pattern.
Overall, this animal model provided a unique opportunity to study the host response
to infection with differential onsets of disease and time to death. Also, the combination
of telemetry, blood chemistry data, and gene expression allowed for an in-depth analy-
sis of the exact timings of the host response relative to clinical presentation. This study
highlighted that once the disease has started, it follows a predictable pattern over time
with interferon genes being up-regulated early, followed by fever and cytokines, and the
end stage of disease have excessive immune dysregulation. Despite the different onset of
symptoms between the animals, the host response, once started, occurred in approximately
the same time frame.
4.6 Future Directions
This study lays the groundwork for further studies that create a model of EVD in
NHPs that more accurately reflects the human disease. Future studies that use a similar
model can help to determine many important factors in the host response to EVD including
why some individuals are better at controlling the virus than other. This study did not have
the power in numbers to preform an in-depth comparison of the animals at the pre-infection
timepoint. Also, more studies with a combined analysis of implanted telemetry, cytokine
panels, blood chemistry, and transcriptomics can further help to determine the dynamics
of the host response relative to the onset of symptoms and not strictly days post infection.
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One area that this study is lacking on is expansion of the gene expression models. In
this initial study, I limited the model fits to a logistic growth curve meaning only genes that
are turned on and sustained throughout the course of infection would have a sufficient fit to
the model. There are many more models of gene expression that could be explored to cre-
ate an even more complete picture of the dynamics of the host response to infection. Also,
additional studies would help to fine-tune these models to determine with more confidence
how early the gene expression changes are likely to be starting.
This study also provides evidence of an early immune response likely associated
with a response at the site of infection. Directly studying the actual site of infection,
especially with mucosal transmission studies, at early times can help to better understand
the very early events. No study has looked transcriptionally at the site of infection and
all transcriptomic studies in NHPs have been focused on PBMCs or the peripherial blood.
Nasal swab data was collected with these animals at 3 days post-exposure and further
analysis of this data could help to answer what happens at the site of infection that may
lead to progressive disease.
Finally, this study and the ones previous (chapters 2 and 3) have identified many
genes that are consistently changed in response to EBOV infection from uninfected in-
dividuals. This information lays the groundwork for the development of a host-based
classifier for infection. The utility of such a classifier is of importance to better moni-
tor potentially exposed individuals to determine infection before the onset of symptoms.
Further development of a pre-symptomatic classifier is described in the next chapter.
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Chapter 5
PRE-SYMPTOMATIC BIOMARKER FOR EARLY AND SPECIFIC
DETECTION OF EBOLA VIRUS DISEASE
5.1 Preamble
In the previous chapters (2-4), I have consistently identified genes that are changed
in response to Ebola virus (EBOV) infections in both humans and non-human primates
(NHPs). These genes also showed a high degree of conservation from NHPs to humans
and were shown to precede symptom onset. This lead me to investigate if this information
could be utilized as a diagnostic assay to identify an infected individual earlier than the
current diagnostic for EBOV which relies on detection of virus in the circulating blood
and which is concurrent with onset of symptoms.
Diagnostic assay development is a constantly evolving field of research focused on
producing more sensitive means to identify the causative agent of an infection. One impor-
tant component of this work is to identify infections at earlier times after exposure to more
readily isolate and treat individuals. This is especially important for infections that have
high morbidity and mortality, as earlier treatment has been shown to improve outcome.
One avenue to develop a diagnostic assay for infectious diseases, independent of the need
to directly identify the infectious agent, is through analysis of the host response to infec-
tion. To this end, we developed a novel approach to host response diagnostics assays with
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regards to Ebola virus disease (EVD) and Marburg virus disease (MVD) that combines the
use of the host response and detection of the causative agent to identify infection at pre and
post symptom onset. We have developed an assay, through the use of the nCount NanoS-
tring method of RNA quantification that can identify infection at a time that precedes the
infectious agent being present in the blood. Furthermore, this assay can distinguish EVD
from MVD through a combination approach of host response and detection of viral parti-
cles (if present). Together, this work shows the utility of a multiplexed assay that uses both
the host response to infection and the infectious agent to better identify individuals during
an outbreak before they show symptoms.
This work has been perfromed in collaboration with Anna Honko, Richard Bennett,
and Josh Johnson at the Integrated Research Facility (IRF) in Fredrick, MD. Anna, Rich,
and Josh carried out the infections of animals, preformed plaque assays, and determined
changes in blood chemistry data. I preformed all processing of RNA samples, development
of the NanoString codeset and identification of important genes, testing of the NanoString
codeset, qRT-PCR for viral genomes, and computational work.
5.2 Introduction
Diagnostic assays for infectious disease is an ever-evolving area of work to constantly
improve diagnostic capability. A constant goal is to drive diagnostic paradigms to identify
infection at the earliest time possible. Some of the most powerful diagnostics identify the
causative agent directly through identification of nucleic acids from the infectious agent
using real time polymerase chain reactions (RT-PCR) (Grolla et al., 2005). Though these
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methods can have high levels of specificity, they are usually not successful until the symp-
tomatic stage of infection as they rely the infectious agent being present in the circulating
blood.
While this approach can be satisfactory for many diseases, early diagnosis of disease
is a particular need in viral infections associated with high morbidity and mortality such
as Ebola virus disease (EVD) and Marburg virus disease (MVD). In the recent Ebola virus
(EBOV) outbreak in West Africa, qRT-PCR for the virus genome was shown to have vari-
able ability to determine infection up to 72 hours after the onset of symptoms (Broadhurst
et al., 2016). This may be due to the specifics of EBOV replication, as the virus will first
replicate in the liver and spleen after exposure (Martines et al., 2015) and is not present
at significant levels in the peripheral blood (where samples are taken for diagnosis) un-
til later stages of disease that can be antecedent to onset of symptoms. The potential for
rtPCR-based diagnosis to act as a late-stage diagnostic combined with the finding that in
EBOV infections the earlier palliative care is provided to someone the better the prognosis
(Ji et al., 2016; Nguyen and Hernandez-Vargas, 2017) argue strongly for incorporating ad-
ditional factors into the diagnosis process for diseases such as EVD and the related MVD.
Furthermore, recent work has shown that detection of pre-symptomatic individuals during
an outbreak, such as an EBOV outbreak, can signficantly help control spread of the disease
and forecast likely spread (Thompson et al., 2016).
One potential approach that could be used to identify infection and the potential
causative agent without needing to isolate the causative agent is through the analysis of the
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host response to infection. Meta-analysis studies have shown that expression changes in a
small number of host RNAs in peripheral blood can be used to differentiate viral disease
from other inflammatory diseases (Sampson et al., 2017). This concept has been clinically
applied using host RNA analysis of the peripheral blood of patients with upper respiratory
infections to correctly differentiate viral from bacterial infections, establishing that analy-
sis of the host response alone can be an effective diagnostic approach (Tsalik et al., 2016;
Zaas et al., 2013). In controlled human infections of influenza virus, some patients could
be identified as successfully infected prior the onset of symptoms (Woods et al., 2013;
Zaas et al., 2009), suggesting that diagnosis of viral infection can be accomplished earlier
than would be possible by looking for viral genetic material directly.
In emerging viral disease, a similar information dataset has emerged. Differential
regulation of host RNAs in the circulating immune system can be identified as early as 1 or
3 days post-exposure (respectively) (Caballero et al., 2014) in non-human primate (NHP)
models of infection with Lassa virus (LASV) or MARV. Similarly, pre-symptomatic gene
expression changes are present in response to EBOV infections in NHP disease (Ca-
ballero et al., 2016; Versteeg et al., 2017; Speranza and Connor, 2017; Rubins et al., 2007;
Navalkar et al., 2013). These findings suggest that tracking the host response to viral infec-
tions such as EBOV and MARV could be an effective path towards identifying infection
before the appearance of symptoms.
I have sought to identify a set of RNAs that could serve as diagnostic markers for
detecting infection with EBOV or MARV that would function in pre-symptomatic and
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symptomatic patients. To do so, I established a single-tube assay that combines probes
targeting mRNA of the peripheral blood host response that predict general viral infection,
probes of the host response that distinguish EBOV infection from MARV infection, and
probes that identify EBOV and MARV genomes directly. I validated the performance
of this approach using blood samples from four different independent animal models of
EBOV or MARV infection. These results suggest that an iterative algorithm to determine
viral infection and the causative agent is possible in the context of severe emerging viral
diseases.
5.3 Methods
5.3.1 Infections with EBOV/Makona
The CO5 isolate of Ebola virus isolate Makona (full designation: Ebola
virus/H.sapiens-tc/GIN/2014/Makona-CO5, abbreviated name: EBOV/Mak-CO5, Gen-
Bank accession number KP096420.1, BioSample number SAMN03611815) was gener-
ously provided by Dr. Kobinger of Public Health Agency Canada and propagated as pre-
viously described (lot number IRF0137) (Honko et al., 2017), Animals were challenged
intramuscularly or via aerosol exposure with a target dose of 1000 PFU. Aerosol chal-
lenges (target dose 1000 PFU) were generated using a 3-jet Collison nebulizer and inhaled
volume measured in real-time using plethysmography. Challenge doses were confirmed by
back-challenge. Animals were observed daily for clinical signs of infection and humanely
euthanized when they met pre-established euthanasia parameters allowing morbidity as a
surrogate for lethality.
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5.3.2 Infection with MARV
The Angola isolate of Marburg virus (full designation: Marburg virus/H.sapiens-
tc/AGO/2005/Ang-1379v, abbreviated name: MARV/Ang) was used. This stock (lot num-
ber IRF0202) was isolated from a fatal human case (collected by the CDC) and was prop-
agated in VERO C1008 (E6) cells, Kidney (African green monkey), Working Cell Bank,
NR-596 were obtained through BEI Resources (National Institute of Allergy and Infec-
tious diseases [NIAID], National Institutes of Health [NIH], Manassas, VA) using Mini-
mum Essential Medium-alpha, GlutaMAX, no nucleosides (Gibco, ThermoFisher Scien-
tific) supplemented with 2% US-origin, certified, heat-inactivated fetal bovine serum (HI-
FBS, Gibco, ThermoFisher Scientific). This virus stock has a passage history of VERO E6
passage 4. Following harvest, HI-FBS was QS’d to 10% final concentration prior to cry-
opreservation. Animals were challenged intramuscularly with a target dose of 1000 PFU
and challenge dose confirmed by back-titration. Animals were observed daily for clini-
cal signs of infection and humanely euthanized when they met pre-established euthanasia
parameters allowing morbidity as a surrogate for lethality.
5.3.3 RNA-Extractions and Quality Control
Whole blood samples from infected macaques (either Ebola or Marburg) were com-
bined with 3 volumes of TRIzol LS reagent. Samples were mixed thoroughly and left to
incubate for 10 minutes to inactivate virus. Samples were then transferred to a new tube
and surface sterilized by soaking tubes in microchem for a minimum of 10 minutes.
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RNA was extracted using the standard TRIzol protocol. 200 µl of chloroform was
added per 1µl of sample and shaken by hand. They were then spun for 15 minutes at
12000xg. The aqueous layer was removed. To further clean up samples, a second chlo-
roform addition and spin was performed. After the second aqueous phase was transfered
into a fresh tube, an equal volume of isopropanol was added to the samples and they were
incubated at 40C for 3 hours. RNA was precipitated by spinning samples at 12000xg for
10 minutes and the supernatant was removed. 75% ethanol was added to the pellet to
wash the RNA, vortexed, and spun for 5 minutes at 7600xg. The ethanol was removed and
30µl of RNase free water was added. RNA quality and concentration was determined by
Bioanalyzer analysis using a Agilent Bioanalyzer 2100 and RNA Nano 6000 chips.
5.3.4 NanoString Analysis
A NanoString Elements codeset was developed to target 12, 36 ,or 48 genes. Oligos
were generated through IDT. 100ng of RNA in a maximum of 13µl volume was added
to the NanoString reaction. Samples were incubated at 670C for 12 hours and then held
at 40C. Samples were prepped on a NanoString Max Prep Station. After sample prep,
cartridges were kept at 40C until reading. Count tables were generated on the NanoString
Max Digital Analyzer station.
5.3.5 NanoString Data Normalization
Raw counts files (.RCC) were read into the nSolver Advanced Analysis Software 3.0
to perform quality control checks and generate counts tables. Quality control included
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filtering for too few field of view (FOV) counts (expected 270), filtering for binding densi-
ties outside of expected range (0.5-2.5), checking for positive control linearity to spike-in
RNA, and determining in the lowest positive control (5pm) was at least greater than 2 SD
above the mean of the background.
Counts files were then read into R. Normalization of the counts was performed as
follows. First, the positive control normalization was performed to account for variance
across lanes. The geometric mean of the positive control values for each lane was de-
termined. Then an average value for these geometric means was calculated. A positive
control normalization value was calculated for each lane by dividing the average across
the lanes by the geometric mean for each lane. This was then used as a multiplier for the
gene counts in the lanes. Next, normalization for the input amount of RNA for the dif-
ferent samples was determined. A housekeeping was included in the codeset, RPL37A,
which has been shown to have low variance across EBOV infections and high counts val-
ues (Lo et al., 2017). For the normalization, a similar process was used as with the positive
controls. A mean of the counts across the lanes was determined for RPL37A and a scal-
ing factor was calculated by dividing the mean across the lanes by the counts of RPL37A
within the sample. Then the positive control normalized counts were multiplied by this
value to account for input control.
5.3.6 RNA-Sequencing of Samples
RNA-Sequencing was carried out at the BU Microarray core. Library preparation
was performed using the TruSeq stranded total RNA with RiboZero Gold. Initial input of
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RNA was 0.5µl across all samples. Libraries were quantified on a qubit to create pooled
libraries. Samples were run on a Illumina NextSeq with 75bp paired reads outputs.
5.3.7 RNA-Seq Data Processing
Raw sequencing reads were demultiplexed using the Illumina Basespace application.
Demultiplexed reads were then downloaded and processed as follows. Filtering of reads
for poor quality of the ends of reads, read length, and poor quality reads was done us-
ing the fastx-toolkit. After filtering, reads were mapped to the Rhesus Macaque genome
(Zimin et al., 2014) using TopHatv2.1 (Kim et al., 2013) which calls the aligner Bowtie2
(Langmead and Salzberg, 2012). After mapping of the reads was completed, count tables
were generated with HT-Seq count (Anders et al., 2014).
Raw counts files were read into R. Reads were normalized using the DESeq2 (Love
et al., 2014) rlog function and principal component analysis was carried out to determine
significant outliers. Finally, differential gene expression analysis was performed in DE-
Seq2 to determine significantly differentially expressed genes using standard cutoffs (ab-
solute log fold change > 1 and adjusted p-value < 0.05). Differential expression results
were read into Ingenuity Pathways Analysis (IPA) to find pathways that are enriched at
different days.
5.3.8 General infection classification of samples
Two different approaches were taken to identify general infection using the NanoS-
tring codeset. The first method was dependent on the pre-infection samples for each an-
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imal. A fold cutoff of 4 for a minimum of 3 selected genes determined if a sample is
positive for infection or a change in the EBOV genome 3 counts about the pre-infection
levels.
The second method used in the NanoString is the profile correlation. To determine
which genes from a larger NanoString codeset would still separate samples, a filtering step
was first performed. Genes that did not show good expression (log2(mean(normalized
counts)) > 0) were filtered out to only include genes that are strongly expressed. A sub-
stitution method was further used to determine genes that create a profile of expression
the greatly separates the different days from each other. To achieve this, a set of genes is
randomly selected to start. Then the profiles are generated using the median counts of the
samples within a given group for each gene. The profiles are then correlated to each other
to determine how similar or different they are. Then, iteratively genes are substituted into
the model to determine if they create lower correlation values. This is run until conver-
gence is reach. This was then run 100 times for a starting number of genes being 5-20.
An optimal set was chosen based on end correlation values of 15 genes. To then perform
leave-one-out cross validation using these selected genes, one at a time a sample was re-
moved. Then the profiles, using the 15 genes, for the different categories were generated.
Then the correlation of the left out sample to the profiles was determined and the highest
match determined the sample category. A similar process was done for the viral specific
classifier.
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5.3.9 Statistical Methods
To determine if the correlation of the profiles were different from each other in the
general-infection classifier, a Kruskal-Wallis test was performed across the three groups.
To determine if one group was significantly different from another, a Mann Whitney test
was performed on the two groups. For the virus specific classifiers, to determine if the
difference between the expected profile and the other profile was significantly different
from zero, a standard T-test was performed. Statistical calculations were carried out in
GraphPad Prism 5 or in R.
5.3.10 Collection of previous RNA-Seq datasets
Previous RNA-seq datasets for EBOV, LASV, and MARV were analyzed using the
HoTResDB (Lo et al., 2017). Genes of interest where put into the search function and
EBOV Kikwit (without survivors), LASV Josiah, and MARV Angola were selected. Fold
calculations were downloaded and put into Prism for visualization.
5.4 Results
5.4.1 Initial EBOV/Mak studies for identification of pre-infection markers
I analyzed whole blood samples from non-human primates (NHP) that had been in-
fected with the C05 Makona strain of EBOV (EBOV/Mak). Animals were infected with
1000 PFU of EBOV/Mak through intramuscular (IM) injection.
Viremia levels determined from serum samples (Figure 5.1E) showed little evidence
of infectious virus in the peripheral blood at day 3 post-exposure with only 1 animal being
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positive. By day 5 post-exposure, all animals had infectious virus in the blood. Virus titers
reached a peak between 107 and 108 PFU per ml of plasma by day 7. Animals showed ex-
pected increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
at day 7, increases in neutrophils at day 5, and showed decreases in lymphocytes (Figure
5.1). These results are consistent with other recent studies of NHP response following
EBOV/Mak infection (Speranza et al., 2017; Versteeg et al., 2017; Menicucci et al., 2017;
Mire et al., 2016; Marzi et al., 2015).
5.4.2 RNA-Sequencing for early markers of infection
To broadly search for early markers of infection to EBOV/Mak, RNA-sequencing
on RNA extracted from whole blood from a set of animals was preformed (Figure 5.2A).
Whole blood samples were collected in a serial manner from animals at pre-infection (2
time points), day 3 post-exposure (pre-symptomatic), day 5 and 7 post-exposure (symp-
tomatic), and upon necropsy (Figure 5.2B). In total, RNA from 12 animals with serial sam-
pling was sequenced. RNA sample quality led to the elimination of 8 of 67 total samples.
To determine early gene expression changes, I performed differential gene expression on
the animals at day 3 post-exposure (pre-symptomatic time) compared to the pre-infection
samples (day -13 and day 0) similar to previous work (Rubins et al., 2007; Caballero et al.,
2014). 172 transcripts were identified as differentially expressed by day 3 post-exposure
(Figure 5.2C). Many of these genes maintained their differential expression at day 5 and 7
post-exposure.
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Figure 5.1: Changes in Blood analytes and cell populations in EBOV/Mak infections.
A is the change in ALT over time. The x-axis is the days post-exposure and the y-axis is
the ALT measurement in U/l. The different lines are the different animals. B is a similar
plot for AST levels. C is a similar plot showing the change in neutrophils and D is the
change in lymphocytes. E is the PFU/ml of serum for the same animals.
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Figure 5.2: Isolation of Early response genes in EBOV infection through RNA-Seq.
A is an overview of the experiment. The timeline represents the different days following
exposure to EBOV/Mak. The large circles show the days that blood was taken from ani-
mals and the number inside shows the number of blood samples. B is an overview of the
RNA samples that were sequenced with RNA-Seq. The x-axis is the days post-exposure
and the y-axis is the different animals. Red points signify samples taken upon necropsy
and black points are live animals. Connected points (grey lines) are serial samples from
the same animals. C is an MA-plot for the earliest timepoint post-exposure (3DPI) com-
pared to the pre-exposure controls (-13 and 0 DPI). Each point is a gene and black points
are not significantly differentially expressed and red points are significantly differentially
expressed. The x-axis is the base mean of the point across all samples and the y-axis is the
log2 fold change. (Next page)
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Figure 5.2: (Previous Page) D is IPA results from the DE genes identified at day 3 DPI. The
three pathways identified as significantly enriched at day 3 post-exposure are on the x-axis.
The y-axis is their activation score (z-score). The black bars are at day 3 post-exposure,
red are day 5 post-exposure, blue are day 7 post-exposure, and striped is at NEC. E are
example ISGs that are up-regulated by day 3 post-exposure. The x-axis is the DPI, the
y-axis is the log2 fold change and the lines represent individual genes.
IPA analysis identified three pathways of interest that were associated with the upreg-
ulated transcripts (Figure 5.2D). Two of the pathways, interferon signaling and activation
of IRF by cystolic PRR, share many of the same downstream genes, mainly interferon
stimulated genes (ISGs). A third pathway, p38 MAPK signaling, was also found to be
increased at day 3 post-exposure and showed increase activation through to day 5 and 7
post-exposure. A subset of ISGs were found to be consistently up-regulated in all the ani-
mals in the RNA-Seq dataset. ISGs were selected based on being significantly up-regulated
(log2(fold change) > 1.5, FDR < 0.05) in this datasets and in previously analyzed RNA-
Seq datasets from an EBOV/Kikwit infection (Caballero et al., 2016) and an EBOV/Mak
infection (Speranza et al. (2017) and Chapter 4), and persistence of expression through to
later stages of disease. This lead to the selection of 6 ISGs (Figure 5.2E). Using these mR-
NAs and a simple fold change cutoff within an individual animal as a classifier (fold of 3
DPE to pre-exposure for the genes > 1), all animals except one showed significant expres-
sion of these ISG by day 3 suggesting that they can act as early markers for infection. The
ISGs used in this analysis are not specific to EBOV infection as they are up-regulated fol-
lowing many viral infections. For this reason, this classification step is to identify general
viral infection.
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5.4.3 Development of a targeted NanoString codeset to identify EBOV infections
The RNA-seq data provides a good point for general discovery of genes, but is not an
ideal platform for a diagnostic assay since it takes a long time to run and has a requirement
of high quality input RNA. To further develop a means to measure mRNA accumulation in
samples, I developed an nCounter NanoString codeset. The nCounter NanoString platform
was chosen as a test-system for the host classifier since this approach offers simultaneous
detection of different RNAs, can be performed on blood samples or purified RNA, and
has been used in clinical settings as a diagnostic platform. I incorporated three major
components into our assay: 1) a probe to recognize the EBOV genome within the NP gene
sequence, 2) probes to recognize early host transcripts associated with viral infection (ISGs
from Figure 5.2), and 3) markers that should have specific expression to EBOV compared
to Lassa Virus (LASV) and Marburg Virus (MARV) (Figure 5.3A).
The markers that are designed to be EBOV specific were derived from analysis of
RNA-seq data in peripheral blood mononuclear cells (PBMC) of infected NHPs across
LASV and MARV infection (Caballero et al., 2014) and EBOV/Kikwit infection (Ca-
ballero et al., 2016). Genes were selected that showed the strongest difference in expres-
sion in the EBOV data compared to the MARV and LASV data (Figure 5.4). Through this
analysis, 4 genes up-regulated in EBOV and not in MARV or LASV were identified and 4
genes down-regulated in EBOV but not in MARV or LASV were identified. These genes
provide a starting point for the search for specific markers of EBOV infection.
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Figure 5.3: Testing of NanoString on a minimal set of animals. A is an overview of the
NanoString Codeset. B is the counts to the EBOV genome. The x-axis is the DPI, and the
y-axis is the log2(EBOV counts) above background. The different colored bars are for the
different animals. C is a graph of the early ISG expression. The x-axis is the DPI and the
y-axis is the log2(fold change). The black line is the fold change for EBOV counts (with a
pseudo count of 1) for the EBOV genome. The red lines are the ISGs. D is a similar graph
for just STK38L, E for ZFYVE16, and F for MMP8.
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Figure 5.4: Ebola specific genes expression. In all graphs, the x-axis is days post-
exposure and the y-axis is the log2(fold change) based on pre-infection samples. The
black line is the expression in EBOV, blue is for LASV, and red for MARV. The top 4
genes are up-regulated and the bottom 4 are down-regulated.
I tested samples from 4 NHPs using our 12-RNA recognizing codeset. In this set,
the NanoString probe for EBOV genome did not show signal above background until day
5 post-exposure consistent with PFU data from these same animals (Figure 5.3B). In con-
trast, the ISG were up-regulated at day 3 post-exposure and continued to increase through
to day 5 post-exposure (Figure 5.3C). Only one of the EBOV specific genes still showed
increased expression at day 3 post-exposure (Figure 5.3D) and two other showed increased
expression at day 5 post-exposure (Figure 5.3E and F). These results were consistent with
the identification of these genes as early markers using RNAseq and suggested that the
NanoString assays targeting host RNAs are capable of identifying infection signals prior
to the appearance of viral RNA in the blood.
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5.4.4 Expanded testing of early biomarkers
I tested the performance of the NanoString assays using blood samples obtained from
an additional set of NHPs that had been challenged with EBOV/Mak C07 variant through
two different routes of infection; IM injection and aerosol exposure across two indepen-
dent experiments. NHPs in these new studies showed similar kinetics of fever and viremia
to that seen in the animals analyzed in the earlier set. 98 samples across 23 NHPs were an-
alyzed at pre-infection (2 time points), day 3 post-exposure (pre-symptomatic), day 5 post-
exposure (symptomatic), day 7 post-exposure (symptomatic), and upon necropsy (Figure
5.5). The EBOV-specific probe showed no significant levels of the EBOV genome at day
0 or day 3 post-exposure. By day 5 post-exposure (viremia detectable by plaque assay),
there was variable levels of EBOV genome detected and by day 7 all animals showed de-
tectable levels of EBOV RNA (Figure 5.6A) with very little variation. EBOV genome
detection in blood from aerosol challenged animals was generally lower than that seen in
IM challenged animals, consistent with other studies showing a delay in infection in the
aerosol model. These results show that the NanoString assay for viral RNA is a reasonable
proxy for viremia.
In contrast to the appearance of viral RNA in the blood at day 5 post-exposure, all
“early marker” probes showed increased accumulation at day 3 post-exposure. By day
5 post-exposure, the ISG genes had increased their expression which was maintained
through to day 7 post-exposure (Figure 5.6B and see ISG15, OASL, and IFI6 in Figure
5.6D-F). In all of these genes, at day 3 post-exposure, there was variation in the counts val-
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Figure 5.5: General Overview of the EBOV/Mak Experiments Performed at IRF-
Fredrick. The x-axis is the DPI and the y-axis is individual animals. The points represent
a single sample from a single animal and black points represent alive animals and red
points are necropsy samples. Horizontal lines represent serial sampling from the same
animal represented by grey lines.
ues suggesting variation in the response across the animals similar to the EBOV genome
at day 5 post-exposure. Despite this, there is a significant (p < 0.05) increase in the gene
expression changes at this time point. At day 5 post-exposure, signal from all infected
monkeys had reached a maximum in the assay with the exception of the aerosol exposure.
5.4.5 ISG fold change precedes viremia
The NanoString ISG data could be used to construct a disease predictor for infection
for individual animals. By setting a cutoff of 1) the EBOV genome counts were increased
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Figure 5.6: Performance of targeted NanoString Codeset for general infection genes.
A is an overview of the EBOV NP probe in the EBOV samples. The DPI are on the x-
axis and the log2(normalized count) value is on the y-axis. Each point is an individual
sample. The dashed line is the background threshold (as determined by the pre-infection
timepoints) for the probe. The red points represent animals from an aerosol model of
infection. B is a log2 fold change graph for the early ISG (black bars) compared to the
EBOV NP probe (red bar). nd means the EBOV genome was not detected at day 3 post-
exposure. C) Demonstration of counts for ISG15. Each point is a sample (black from IM
exposure, red from aerosol). The x-axis is the DPI and the y-axis is the log2 of normalized
counts. D is a similar plot for OASL and E for IFI6. For all counts graphs, bars show
significance level of the sample to pre-infection (* means p < 0.05, ** means p < 0.001,
*** means p < 0.0001)
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more than 3 counts above the pre-infection time points or 2) a minimum of 3 ISG increased
above baseline by more than 4 fold, I tested to see if I could identify infection before the
onset of viremia. Of the 15 animals tested, 13 had a timepoint of infection that preceded
the EBOV genome levels (Table 5.1 animals AA-NN and FF). Of these animals, 12 could
be correctly identified before the onset of viremia (Table able 5.1, animals AA-NN). The
one animal that was not identified, animal FF, did not have enough ISGs expressed at day
3 to be considered positive. Two of the animals were not able to identify due to sampling
days. One animal, animal OO, was already viremic by day 3 post-exposure which was
the earliest time point after exposure collected. At this time point, animal OO was also
positive by ISG expression. Finally, animal KK could not be detected in either platform by
day 5 post-exposure. This data shows that a host-based classifier could identify infection
prior to viremia when pre-infection data is known.
5.4.6 Development of a baseline independent method for early identification of
EBOV
Based on the success of the classifier in situations where a pre-infection value for each
gene was known, I was interested in understanding its’ potential to act as a predictor when
pre-infection samples are not available. Stated another way, I was interested in whether I
could a priori predict infection and disease progression in an unknown sample. To achieve
this, I used a profile-based method of classification. This is a simple method that develops
a profile of gene expression for pre-infection samples, early infection (pre-symptomatic)
and late infection samples (viremic) using a subset of genes. These profiles are then used
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Animal ISG+ EBOV+ Early?
AA 3 5 X
BB 3 5 X
CC 3 5 X
DD 3 5 X
EE 3 5 X
GG 3 5 X
HH 3 5 X
II 3 5 X
JJ 3 5 X
LL 3 5 X
MM 3 5 X
NN 3 5 X
OO 3 3 No
FF 5 5 No
KK N/A N/A No
Table 5.1: EBOV NP gene in the NanoString codeset vs. IFN response in individual
animals
to correlate a new samples gene expression to the three possible profiles, and the highest
correlation value determines the sample classification.
To develop the profile, I expanded the NanoString testing codeset to include 15
RNAs. These RNAs stringently separated the three time points from each other: unin-
fected, pre-symptomatic, and symptomatic (Figure 5.7A). The final profiles were deter-
mined by the median value of expression for each gene across the samples within a given
group. When these values were plotted for each RNA probe, they generated a pattern of
expression levels over a set of genes for the different stages of disease (Figure 5.7A).
To assess how well each sample fit its expected profile, I plotted the expected expres-
sion over the genes (Figure 5.7B-D black line) with the samples from that group (Figure
5.7B-D, grey lines). The pre-infection match to the profiles is fairly tight with pre-infection
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Figure 5.7: Infection profiles determine with NanoString. A is the infection profiles
determined across the NanoString dataset for the pre-infection samples (black), early sam-
ples (blue), and late samples (red). B is the pre-infection profile (black line) plotted with
the pre-infection samples (grey lines). C is a similar plot for the early profile and D for the
late profile.
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samples showing a similar expression value across the selected genes. The early profile
matches are more spread which is expected since these samples will have the most vari-
ation in point of disease. The late profiles have the tightest expression signifying that
the genes selected will trend towards stronger match to symptomatic infection as disease
progresses. Together this sets the expectation that the late stage of infection should have
the highest degree of correlation, the pre-infection should have the next highest degree of
correlation, and the early infection samples are likely to be variable in ability to predict
infection due to the wide spread and variability in response.
5.4.7 Testing of profile method in the NanoString acquired samples
I then tested the ability of these profiles to accurately classify samples into their
correct category using leave-one out cross validation. For each sample I determined how
well the sample profile correlated with the pre, early, and late infection profiles. For the
pre-infection samples 28 of the 40 samples showed the strongest correlation match to the
pre-infection profile (Figure 5.8A). Of the 12 samples that did not match to pre-infection
the best, 10 matched to early infection and two matched to the late infection profiles. To
determine if the overall correlation of pre-infection samples to the pre-infection profile
was significant, an ANOVA test was performed on the correlations of the samples to the
different profiles. For the pre-infection samples, the correlation matches were significantly
different from each other (p < 0.0001), and the pre-infection matches were significantly
higher than the early profile correlations and late profile correlations (p< 0.0001 for both).
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Figure 5.8: Correlation matches of samples to different profiles. A) Left: Profile match-
ing of pre-infection samples to pre-infection profile (black points), early infection profile
(blue points) or late infection profile (red points). The x-axis is individual samples and
the y-axis is the correlation match to the different profiles of expression. Each sample has
three points. (Next page)
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Figure 5.8: (Previous Page) The highest match (top point) identifies what the sample would
be classified as. The left graph shows the spread of the correlations to the different profiles
for the pre-infection samples (pre = black, early = blue, late = red). Brackets represent if
the correlations across the groups are the same or not (* is p < 0.05, ** is p < 0.001, ***
is p < 0.0001) as determined by a Mann-Whitney test. The p-value printed on the graph
is the results of a Kruskal-Wallis test for all the samples. B is a similar plot for the early
infection samples and C is for the late infection samples.
In samples from animals at early time point of infection, 18 of the 22 samples were
identified as infected with either the early-profile or late-profile having the highest match
(Figure 5.8B). The correlations to the different profiles were significantly different from
each other (p = 0.0009) and the early profile correlations were significantly higher than
the pre-infection profile correlations (p = 0.0011) and late infection profile correlations
(p = 0.0019). Of the samples misidentified, two were from an aerosol infection that had
delay in disease progression. For the late-infection profiles, all the samples were correctly
identified as infected with 39 of the 41 samples matching to the late profile (Figure 5.8C).
The correlations to the different profiles were significantly different from each other (p
< 0.0001) and the late correlations were significantly higher than the pre-infection profile
correlations and the early infection profile correlations (p < 0.0001 for both). Together,
this shows how using the profile match method, the samples trend towards matching to the
late infection profile as disease progresses.
5.4.8 Testing of general infection classifier on MARV samples
The success in classifying infection and disease progression in EBOV infected an-
imals led me to investigate whether these approaches also indicated infection in samples
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from animals infected with other hemorrhagic fever viruses. I used samples from NHPs
exposed to MARV, a hemorrhagic fever virus in the same family as EBOV, to investigate
this possibility. Blood samples were obtained from individual animals at pre-infection,
day 3 post-exposure, day 6 post-exposure, and upon necropsy (Figure 5.9A). I first in-
vestigated the pre-infection samples using the profile based expression method. 5 of the 6
pre-infection samples matched to the pre-infection profile the best and one of the 6 samples
matched to the early profile. When I looked at the infected samples, for both early and late
samples, all samples were correctly identified as infected. Early sample identification in
this model preceded viremia by 3 days. This data suggests that the pre-viremic classifier is
effective at identifying infection at early times in multiple examples of viral hemorrhagic
fever.
5.4.9 Generation of a virus specific profile of expression against MARV
These results led me to investigate whether I could broaden the NanoString assay to
enable early detection and classification that would distinguish EBOV from MARV infec-
tion both prior to fever/viremia and after the appearance of viral RNA in the blood. Accord-
ingly, I constructed a 48 gene NanoString assay that has host RNAs that showed specific
expression following EBOV or MARV infection, has a probe for the EBOV genome, and
a probe for the MARV genome. Based on the NanoString probes to the viral genomes,
one of the MARV samples appeared to have high levels of EBOV genome and no MARV
genome (Figure 5.10). To further test this, I performed qRT-PCR using primers to the
EBOV NP region and the MARV NP region (Figure 5.11). Based on these validation re-
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Figure 5.9: Marburg samples and infection classifier. A is an overview of the Marburg
whole blood RNA samples. The x-axis is the days post-exposure and the y-axis is indi-
vidual animals. Serial sampling from the same animal is connected by a grey line. Black
points are samples that are currently alive and red points are samples taken at Necropsy. B
is the profile match for the MARV samples using the EBOV general infection classifier.
sults, it was further determined that the sample in question was positive for EBOV and not
for MARV. For this reason, it was excluded from further analysis.
To determine profiles of expression, I generate profiles for pre-infection, early infec-
tion (day 3 post-exposure, pre-viremic), and late infection (day 5 post-exposure for EBOV
and day 6 post-exposure for MARV, viremic). These profiles were generated in a similar
manner as the general infection profiles where gene selection was done based on genes
that created the most similar profile of expression for pre-infection, had a different pat-
tern of expression for early infection (greater than a log difference) and different pattern
of expression for late infection (greater than a log difference). The pre-infection profile
included almost all genes, and the profiles for EBOV and MARV had a high correlation to
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Figure 5.10: Specificity of the EBOV and MARV NanoString Probes in EBOV and
MARV samples. A is the EBOV probe in EBOV samples (black points) and MARV
samples (red points). The different viral infections at the different days are on the x-axis
and the log2 of the normalized counts to the genomes are on the y-axis. The dashed line
represents the threshold for the EBOV probe. B is a similar plot for the MARV probe in
EBOV samples (black) and MARV samples (red).
each other (pearson R = 0.98, p-value < 0.0001). The early profiles had a lower correla-
tion to each other though it was still significant (pearson R = 0.77, p-value< 0.0001). The
late profile utilized only a few genes and included the probes for the EBOV and MARV
genomes. These profiles had very low correlation to each other (pearson R = 0.12, p
= 0.73).
I again tested these profiles using leave-one out cross validation on the samples at
the different time points. For the pre-infection samples, the samples matched very close
to both profiles of expression, which was expected (Figure 5.12A). To get an idea of how
close the samples were to being miss-classified, I calculated the difference from the ex-
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Figure 5.11: qRT-PCR for EBOV and MARV detection on unknown sample The x-
axis is the different samples tested against primes for the EBOV NP region of the genome
(first 4, left of the vertical line) or the MARV NP genome (last 2, right of the vertical line).
The y-axis is the Cq values. The horizontal dashed line is the limit of detection for the
assay where samples above are negative and samples below are positive.
pected profile (ex. EBOV sample to EBOV profile) to the other profile (ex. EBOV sample
to MARV profile). I then determined if the differences were significantly greater or less
than 0. For pre-infection profiles, it was determined that the match for the EBOV samples
was significantly greater than 0 (p = 0.036) but the MARV samples were not significant
(Figure 5.12A).
Similar analysis was done on the early samples to their early and specific profiles of
expression (Figure 5.12B). All but one EBOV sample was miss-identified as MARV and all
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Figure 5.12: Prediction ability of specific markers for EBOV and MARV. (Next Page)
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Figure 5.12: (Previous Page) A is the correlation of the pre-infection samples to the EBOV
profile (red points) or the MARV profiles (blue points). The bar plot on the right of A is the
difference between the expected profile and the other profile for the pre-infection samples.
The value above the bar represents significance (n.s means not significant, * means p
< 0.05, ** means p < 0.001, *** means p < 0.0001) of if the difference is significantly
different from zero. B is a similar plot at day 3 for both datasets and C is for day 5 of
EBOV and day 6 of MARV (representative of the symptomatic stage)
MARV samples were correctly identified. Also, the difference between the correlation to
the expected prediction and other prediction was significantly greater than zero for EBOV
(p = 0.0031) and MARV (p = 0.0095) signifying a significant difference in the correlation
matches. Finally, I looked at the late specific profiles. One MARV samples was miss-
identified as an EBOV likely due to having generally low counts to the MARV genome
since genome identification is the main driver of classification at this point. The difference
in the correlation values of the expected profile to the other profile was significant for the
EBOV samples (p < 0.0001) and for the MARV samples (p = 0.018) (Figure 5.12C).
5.5 Discussion
This work builds on earlier efforts to identify pre-viremic and pre-symptomatic mark-
ers of infection following exposure to high consequence viruses that are associated with
hemorrhagic fever. I was able to identify general markers of infection as well as specific
markers of EBOV or MARV infection. I was further able to incorporate these markers
into an RNA abundance assay and use the results from this assay to develop an algorithm
that will identify pre-symptomatic samples and identify if they likely came from an EBOV
infection or MARV infection.
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Figure 5.13: Flow chart for host classifier for infection. To start, an unidentified sample
is run through the infection classifier to determine if the individual is likely uninfected or
positive for infection. If the sample is positive for infection, next the presence of the virus
is tested for. If the sample has ample causative agent, then the classifier stops. If the agent
can’t be identified, then the virus specific classifier is run. From this, the output is if the
causative agent is EBOV or MARV.
How this approach might be used is depicted in Figure 5.13. In this use scenario
an unidentified blood sample would be analyzed using the designed codeset described
in Figure 5.7, and RNA abundance levels would be analyzed through the “general viral
infection” classifier. This analysis would predict if the sample came from an uninfected
(or very early stage infection) individual or from an individual who was likely infected
with a virus.
If the sample is positive for infection, the algorithm would then suggest the potential
infectious agent using a combined analysis of host RNA changes and the presence of viral
genomes. This represents a hybrid approach that combines looking at the host response
while at the same time seeking confirmation of viral RNA within the same assay system.
If the sample comes from a viremic individual, detection of viral RNA will drive the algo-
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rithm decision. If the sample is not viremic and the infectious agent cannot be identified,
then the host gene expression pattern is used to infer viral infection, leading to the sugges-
tion of one virus as the likely infectious agent. After this point, the likely causative agent
can be identified as either EBOV or MARV.
I see this hybrid approach of following both host response gene signatures and unique
viral gene signatures as an important point of investigation for improving the quality and
applicability of diagnostics for high consequence pathogens. While the identification of
infected individuals before the onset of symptoms is not necessarily a concern for viruses
associated with low levels of individual mortality or morbidity, it would be a large bene-
fit for diseases associated with high mortality and morbidity. During the EBOV outbreak
in Western Africa, health care workers and primary contacts of symptomatic individuals
were at significant risk of acquiring the disease. The earliest diagnostic criterion available
was appearance of fever, a non-specific indicator with a high false-positive rate in an en-
vironment where the burden of other diseases such as malaria, Dengue, and Typhoid is
high.
A means of monitoring high risk individuals for signs of infection and predicting
likely infection source before the onset of symptoms or viremia would help to further stop
the spread and increase chances of survival. Here, I directly tested EBOV infected NHPs
against MARV infected NHPs to show that two related viruses that share a demographic
distribution of outbreaks can be distinguished form each other before the onset of symp-
toms. This is an encouraging finding and suggests a need to further investigate how broadly
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applicable such an approach might be and ability to include other diseases and possibility
of co-infections.
Investigating whether the host RNA changes seen in NHPs are also present in humans
exposed to these infections is an interesting next step. The general infection genes (ISGs)
have been shown to be increased in human symptomatic EBOV infections, and further
increased to a greater extent in fatal cases compared to survivors (Liu et al. (2017), Chapter
4). Due to the high similarity of host RNA accumulation changes between humans and
NHPs (Speranza and Connor, 2017), I am optimistic that a substantial majority of these
genes will be conserved across to human infections. These responses are also likely to be
conserved between different species/variants of EBOV (Caballero et al., 2016; Barrenas
et al., 2015; Rubins et al., 2007; Yen et al., 2011; Speranza et al., 2017).
The enthusiasm about a hybrid host/viral classifier system is tempered by the recogni-
tion that additional work remains to be done to further define the strengths and weaknesses
of this approach. The current approach would benefit from testing on a large validation
dataset as all testing and training were preformed internally. The requirement for high
containment to perform these studies as well as the limited numbers of studies makes this
a significant challenge. As more studies are performed, better validation of the general
infection classifier and the EBOV specific gene set can be undertaken.
As an indication of how broadly applicable this approach might be, genes that were
utilize in the “viral infection classifier” are also incorporated as a component of other
host based diagnostic assays for upper-respiratory viral infection (Zaas et al., 2013, 2009).
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These studies and others (Woods et al., 2013) found that ISGs are differentially regulated
early in viral infection (i.e. OAS, DDX58, MX1). These genes can act as differentiating
viral infections against other infectious agents, such as bacterial or parasitic infections
or other causes of inflammatory disease in humans (Sampson et al., 2017; Woods et al.,
2013). This gives confidence that the general infection classifier will not only perform
across a broad range of viral infections, but also likely help to distinguish viral infection
from parasitic and bacterial diseases.
The analysis of the RNA-Seq data lead to insights about disease progression of
EBOV/Mak in NHPs. Consistent with many previous studies of infection, the innate im-
mune response relating to the type I interferon response showed increased expression very
early in infection (Caballero et al., 2016; Garamszegi et al., 2014; Rubins et al., 2007).
Another pathway that was identified early in infection as being induced is the p38 MAP
kinase pathways. It has been suggested that the p38 pathway activation is important for
entry of the EBOV virus into various cell types. Furthermore, reports have suggested the
use of p38 inhibitors as a means for treatment of EBOV infections and have shown re-
duced entry and cytokine production in human dendritic cells (Johnson et al., 2014). The
early activation of this pathway in the peripheral blood suggests that up-regulation of this
pathways is important in productive infections.
Together, this work highlights that not only is a pre-symptomatic EBOV diagnostic
possible using a select few host response genes, but I further developed a testable assay
using the NanoString system. This NanoString system could be used to continue to test
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EBOV infected NHPs as studies are performed and could be run on human RNA collected
during the West Africa outbreak. Finally, I directly compared the EBOV specific classifier
to a related virus, MARV, and showed a strong ability to specifically identify EBOV infec-
tion using the NanoString developed assay. The developed assay can now easily be tested
across more datasets.
5.6 Future Directions
This work highlights an important first step in improving diagnostic capabilities for
EBOV infections. An important step that this approach takes compared other approaches
is the utilization of a single assay to test for host markers of infection and for presence of
the viral genome. Further testing of this approach will be important to preform validation
of the classifier and more accurately determine sensitivity and specificity.
Additionally, this study shows that a multiplexed format can be used when analyzing
if a sample is positive for a variety of viral genomes and specific host responses. Though
only two types of infections have currently been tested with this method, expanding this
method beyond EBOV and MARV to other diseases present in the same area will be of im-
portance. Other disease present in the same demographic reach of EBOV include Malaria,
HIV, Influenza, Dengue, Yellow Fever, Lassa Fever, and Typhoid Fever. Building on this
idea of distinguishing two pathogens from each other to three and then four and so on
within a single assay and algorithm could help with patient isolation and help prevent
miss-identified patients from being exposed to an additional disease. Based on the re-
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sults of the two infection classifier and previous groups having success in telling different
diseases from each other, I have confidence that this approach will be useful.
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Appendix A
Appendices
In the this section, I outline a related project to develop a database for the sequencing
data accquiried in the Connor Lab over the years for our colloborators and the general
public to have better access to the data. This project was concieved by myself and Dr.
Connor. I was responsible for the direct mentoring of three bioinformatics masters stu-
dents who worked to impliment the database as a part of the database course. I further
directly mentored two of the three students through a masters internship where they car-
ried this project through to publication. The publication for the database can be found at
Lo J*, Zhang D*, Speranza E, Negron JA, and Connor JH. “HoTResDB: host transcrip-
tional response database for viral hemorrhagic fevers”, 22 September 2017, Bioinformat-
ics, btx599, https://doi.org/10.1093/bioinformatics/btx599.
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A.1 HOTRESDB: HOST TRANSCRIPTONAL RESPONSE DATABASE FOR VI-
RAL HEMORRHAGIC FEVERS
High-throughput screening of the host transcriptional response to various viral in-
fections provides a wealth of data, but utilization of microarray and next generation se-
quencing (NGS) data for analysis can be difficult. The Host Transcriptional Response
DataBase (HoTResDB), allows visitors to access already processed microarray and NGS
data from non-human primate models of viral hemorrhagic fever to better understand the
host transcriptional response. The database can be accessed through hotresdb.bu.edu.
A.1.1 Introduction
The host response to viral infection is an important aspect of viral pathogenesis. In
hemorrhagic fevers such as Ebolavirus (EBOV), Marburg virus (MARV) and Lassa virus
(LASV) their high levels of pathogenicity can in part be attributed to a hyperactive immune
response. High-throughput screening techniques allow for full analysis of the host tran-
scriptional response to various viral infections and provide a wealth of data to researchers
to help generate hypotheses. However, utilization of microarray and next generation se-
quencing (NGS) data for analysis can be difficult. Extrapolation of useful information
from raw data requires knowledge of programming and high-level statistics. To help re-
searchers without a background in programming or statistics explore viral hemorrhagic
fever data sets, we established a database, the Host Transcriptional Response DataBase
(HoTResDB), that allows visitors to access processed microarray and NGS data from non-
human primates models of viral hemorrhagic fever to better understand the host transcrip-
197
tional response. Users with gene IDs or Ensembl identifiers of interest can view the data
in several graphical formats and download raw data. Additionally, a keyword search is
available to facilitate the general search.
A.1.2 Description
Using HoTResDB, visitors can explore relationships and trends in data sets of spe-
cific genes of interest or browse through the database to find genes of interest. The database
was desigend to be a resource for the study of the host transcriptional response to viral
hemorrhagic fever by giving researchers an easy-to-use interface to explore this data and
aid in generating hypotheses.
A.1.3 Data Processing
All currently available data sets are accessible through NCBI. The raw counts tables
for the data sets were processed as follows. The Lassa and Marburg RNA-Seq data were
processed according to Caballero et al. (2014). The two Ebola RNA-Seq studies were
processed according to Caballero et al. (2016). Finally, the Ebola microarray study was
collected from Yen et al. (2011) and the data were downloaded from GSE24943. The raw
values were normalized in R (http://www.R-project.org/) using the limma package (Ritchie
et al., 2015) to determine the normalized fluorescence for each probe. The RNA-Seq data
was compiled into a single-large table for all studies. The table was read into R and using
the edgeR package (Robinson et al., 2010), the data was normalized and the counts per
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million (CPM) calculated. This was then imported into the database in a counts table
format.
A.1.4 Database Design
Due to the nature of the data being stored, HoTResDB is built as a MySQL relational
database. This offers the advantage of easy extensibility and the ability to perform com-
plex, multi-row transactions. The use of a relational database management system also
reduces the need for data duplication, which is valuable given the size of gene expression
data sets. It runs on a Linux server and is currently hosted using Apache 2.4. For the user
interface, HoTResDB uses HTML and PHP files with CGI Python scripts for data inter-
action and retrieval. The Python scripts were developed with version 2.7 or above. The
database is currently separated into seven tables due to the range of data available.
The general search form submits user input to the CGI Python files that handle
MySQL database queries. The Python scripts then calculate mean and standard error of
the expression values at the various days post-infection as well as the log 2 expression ratio
of the data relative to the pre-infection controls. Clustering of heat map data is also done
by the Python scripts. The data are then converted into JSON format upon return to the
user interface as this data structure is most compatible with the HighCharts API.
All output graphs are downloadable in several formats: PNG, JPEG, PDF and SVG,
as a built-in function of the HighCharts API. This helps the user find a compatible format
for their intended use of the graphs (i.e. PowerPoints or a printed image). In the current
199
version, the graphs generated by the database are not recommended to be used as a rigorous
analytical tool, but are meant to be a visualization tool for existing data sets.
A.1.5 Using HoTResDB
To initiate a search on HoTResDB, the user must select one or more viruses, strains
and data types from the available options. The search form requires the user to input gene
identifiers in the appropriate box. An option to upload a plain text file containing a list of
genes separated by whitespace is available for user convenience. By default, the search
only includes fatal outcomes from infection. However, the user can choose to include
survivor data if available in data sets of interest. Additionally, for first time users, the
sidebar provides an example search, which automatically performs a basic search of one
gene in a single data set
A.1.6 Viewing Search Results
Once collected, the data can be viewed in various different formats. Data, if any
are found matching the query, are organized into several tabs on the search page: ‘Search
Results’, ‘Expression Data’, ‘Counts Graphs’, ‘Fold Change Graphs’, and ‘Heat Maps’.
These sub-tabs are organized in such a way that each successive tab is an increased level
of processing from the one previous. For example, ‘Search Results’ shows the genes
that matched the search parameters, ‘Expression Data’ shows the count values from those
genes, ‘Counts Graphs’ show line graphs of those counts, ‘Fold Change Graphs’ show the
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log fold change of the counts relative to pre-infection and ‘Heat Maps’ shows the clustered
fold changes.
A.1.7 Browsing the Database
Users can also browse genes in the database using the browse database function.
Using this feature, users are able to look for any human gene ID, macaque gene ID, gene
description or gene ontology (GO) term that contains their term of interest. In addition, the
browse function offers the ability to further narrow search parameters using Boolean search
operators, which allow users to search multiple parameters simultaneously or concurrently.
A.1.8 Conclusions
Investigators with specific gene sets or gene categories of interest looking for a con-
venient method for visualizing translational data in NHPs infected with hemorrhagic fever
viruses will be able find use in HoTResDB. The database is useful for exploring questions
regarding the effect hemorrhagic fever virus infection has on the expression of certain
groups of genes. For example, the following question could be addressed: ‘How does tran-
scription of interferon-stimulated genes differ in response to infection by different strains
or species of filoviruses?’ Through using HoTResDB, investigators will be able to find an
expression pattern of interest that may lead to new hypotheses.
The database will aid in generating hypotheses on the elucidation of hemorrhagic
fever virus host transcriptional response mechanisms. Users would be able to gain insight
into potential virus-host interactions through visualizing gene expression data in specific
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gene sets. This can help to drive hypotheses about how the virus and host interact during
infection and how the host responds to highly pathogenic viruses.
HoTResDB is also unique in that it provides a look at the temporal progression of
the host transcriptional response to infection. This type of data is typically difficult to
obtain due to the challenge of repeatedly sampling infected subjects to measure their gene
expression over time, especially in individuals infected with VHFs.
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